Hematology/ Oncology

DIVISION OF HEMATOLOGY/ ONCOLOGY

DEPARTMENT OF MEDICINE ANNUAL REPORT FY20

DIVISION OF HEMATOLOGY/ONCOLOGY ANNUAL REPORT

TABLE OF CONTENTS

Message from the Chief 3 Faculty Listing 4 Clinical Activities 7 Quality Improvement Initiatives 13 Clinical Locations 14 Research Activities 16 Grants and Contracts Awarded 65 Teaching Activities 74 One-Year Bibliography 83 Acknowledgments 96

DIVISION OF HEMATOLOGY/ONCOLOGY

he major priorities within the Division continue Tto focus on the recruitment of physician- scientists, the reorganization of the clinical services, and the education and training of hematology- Edward Chu, MD Chief oncology fellows and Internal Medicine housestaff. We are pleased to highlight the following faculty recogni- The Division continues to concentrate on the recruitment of phy- tions and awards in FY 2019-2020: sician-scientists and research sci- • Michael Boyiadzis, MD, was promoted to entists to meet strategic needs in Professor of Medicine. He chairs the Society for several key areas. Despite challeng- lmmunotherapy of Cancer (SICT) Committee es with COVID-19, the Division has that is focused on the development of national been able to recruit two new faculty guidelines for the use of immunotherapies in members: acute leukemias. • Yvonne Chao, MD, PhD, will join the faculty as Assistant Professor of • Adam M. Brufsky, MD, PhD, is the PI of the NCI- Medicine specializing in lung cancer, funded UG1 grant that supports the conduct of cancer signaling and invasion and phase 3 clinical trials that are developed by the metastasis. She will be joining the NCI cooperative groups. Lung Cancer Disease Team and be a member of the HCC Cancer Biology • Timothy Burns, MD, PhD, was awarded an NCI Program. R01 grant that is investigating the HGF-MET- • Riyue (Sunny) Bao, PhD, joined the TWIST1 pathway and its role in the development faculty as Research Associate Profes- sor of Medicine. She is a bioinformat- of resistance to EGFR TKI therapies. He was also ics investigator with a strong focus awarded the 2019 HemOnc Today NExtGen on cancer immunotherapy, and she Innovators Award to highlight his stature in is a member of the HCC Cancer Im- munology and Immunotherapy Pro- the field of lung cancer as both a clinician and gram. She also serves an important clinical investigator. role in the HCC as Co-Director of the • Edward Chu, MD, is the PI of the NCI-funded HCC Cancer Bioinformatics Services Shared Resource. UM1 grant that supports the conduct of phase 1 and phase 2 clinical trials that are developed and coordinated by NCI-CTEP. • Diwakar Davar, MD, was awarded a grant from the Melanoma Research Foundation that is focused on developing neoadjuvant immunotherapy in patients with stage III melanoma and predictive biomarkers and an NCI R01 grant that is developing new immunotherapy combination regimens in melanoma. • Laura M. DeCastro, MD, MHSc, is serving a 4-year term as a member of the American Society of Hematology (ASH) Committee on Practice and is also a member of the ASH Committee on Training and Practice. • Robert Ferguson, PhD, was awarded an NCI R01 grant that is focused on developing a mobile device and cognitive behavioral therapy for chemotherapy-related cognitive

Division of Hematology/Oncology FACULTY

Edward Chu, MD Timothy F. Burns, MD, PhD Jonathan E. Harms, PhD Chief, Division of Hematology- Assistant Professor of Medicine Research Instructor of Medicine Oncology Professor of Medicine and Pharmacology & Chemical Biology Lan G. Coffman, MD, PhD Rimi Hazra, PhD Associate Director, UPMC Hillman Assistant Professor of Medicine Research Assistant Professor of Cancer Center Medicine Associate Director, Drug Discovery Diwakar Davar, MD Institute Assistant Professor of Medicine James G. Herman, MD Professor of Medicine Leonard J. Appleman, MD, PhD Laura M. De Castro, MD, MHSc UPMC Endowed Chair for Lung Cancer Associate Professor of Medicine Associate Professor of Medicine Research Clinical Chief, Benign Hematology Co-Director, Lung Cancer Program Nathan Bahary, MD, PhD Director of Benign Hematology, Associate Professor of Medicine and Vitalant and Hillman Cancer Center Charles C. Horn, PhD Molecular Genetics & Biochemistry Director of Clinical Translational Associate Professor of Medicine Medical Director, Pancreatic Cancer Research, Sickle Cell Center of Program Excellence Annie P. Im, MD Co-Director, UPMC Pancreatic Cancer Assistant Professor of Medicine Center of Excellence Albert D. Donnenberg, PhD Director, Hematology/Oncology Professor of Medicine and Infectious Fellowship Program Riyue Bao, PhD Disease & Microbiology Research Associate Professor of Director, UPMC Hematopoietic Stem Sawa Ito, MD, PhD Medicine Cell Laboratories Assistant Professor of Medicine Co-Director of Bioinformatics, UPMC Director, HCC Flow Cytometry Facility Hillman Cancer Center Maria Kapetanaki, PhD Kathleen A. Dorritie, MD Research Assistant Professor of Chitralekha Bhattacharya, PhD Assistant Professor of Medicine Medicine Research Instructor of Medicine Jan Drappatz, MD Gregory J. Kato, MD Franklin A. Bontempo, MD Associate Professor of Neurology and Professor of Medicine Associate Professor of Medicine Medicine Director, Adult Sickle Cell Center of Medical Director, Coagulation Associate Director, Adult Neuro- Excellence Laboratory Oncology Program Principal Investigator, Vascular Medicine Institute Michael Boyiadzis, MD, MHSc Leisha A. Emens, MD Associate Professor of Medicine Professor of Medicine John M. Kirkwood, MD Director, Clinical and Translational Usher Professor of Medicine, Research Program Robert J. Ferguson, PhD Dermatology & Translational Science Assistant Professor of Medicine Co-Leader, Melanoma and Skin Adam M. Brufsky, MD, PhD Cancer Program Professor of Medicine Lanie K. Francis, MD Associate Chief, Division of Research Instructor of Medicine Joseph E. Kiss, MD Hematology/Oncology Professor of Medicine Co-Director, Comprehensive Breast Deborah L. Galson, PhD Medical Director, Hemapheresis and Cancer Center Associate Professor of Medicine and Blood Services, CBB/Vitalant Associate Director, Clinical Microbiology & Molecular Genetics Investigation Director, Pittsburgh Center for Bone & Anuradha Krishnamurthy, MD Mineral Research Assistant Professor of Medicine Ronald J. Buckanovich, MD, PhD Professor of Medicine Samit Ghosh, PhD Daniel Lee, MD, PhD Co-Director, Women’s Cancer Research Assistant Professor of Assistant Professor of Medicine Research Center, Magee-Womens Medicine Research Institute Frank S. Lieberman, MD Vikram C. Gorantla, MD Professor of Neurology and Medicine Melissa A. Burgess, MD Clinical Assistant Professor of Chief, Adult Neuro-Oncology Service Assistant Professor of Medicine Medicine

Department of Medicine 2020 Annual Report Anna E. Lokshin, PhD Donna M. Posluszny, PhD Roy E. Smith, MD Professor of Medicine, Pathology, Assistant Professor of Medicine Professor of Medicine and Obstetrics, Gynecology & Associate Director of Training, Reproductive Sciences Biobehavioral Medicine in Oncology Ashwin Somasundaram, MD Director, Luminex Core Facility Program Assistant Professor of Medicine

Carissa A. Low, PhD Tirthadipa Pradhan-Sundd, PhD Richard A. Steinman, MD, PhD Assistant Professor of Medicine and Research Assistant Professor of Associate Professor of Medicine and Psychology Medicine Pharmacology Core Faculty, Center for Behavioral Associate Dean and Director, Medical Health and Smart Technology Margaret V. Ragni, MD, MPH Scientist Training Program Adjunct Faculty, Human Computer Professor of Medicine and Clinical Interaction Institute, Carnegie Mellon Translational Science Quanhong Sun, PhD University Director, Hemophilia Center of Research Instructor in Medicine Western PA Jason J. Luke, MD Darcy L. Thull, MS Associate Professor of Medicine Priya Rastogi, MD Instructor in Medicine Director, Cancer Immunotherapeutics Associate Professor of Medicine Genetic Counselor, UPMC Cancer Center Genetics Program Robert L. Redner, MD Yana G. Najjar, MD Professor of Medicine Gijsberta J. van Londen, MD, MS Assistant Professor of Medicine Associate Professor of Medicine Linda B. Robertson, DPH, MSN Enrico M. Novelli, MD, MS Assistant Professor of Medicine and Liza C. Villaruz, MD Associate Professor of Medicine Nursing Associate Professor of Medicine Director, Benign Hematology Section Associate Director, Health Equity and Director, UPMC Adult Sickle Cell Community Outreach & Engagement Donald V. Woytowitz, MD Disease Program Clinical Assistant Professor of Principal Investigator, Vascular John C. Schmitz, PhD Medicine Medicine Institute Research Associate Professor of Medicine Antoinette Wozniak, MD Solomon F. Ofori-Acquah, PhD Co-Director, Cancer Pharmacokinetics Visiting Professor of Medicine Associate Professor of Medicine and and Pharmacodynamics Facility Associate Director, Clinical Research, Human Genetics UPMC Hillman Cancer Center Director, Center for Translational and Craig D. Seaman, MD, MS Director, Lung Cancer Disease Unit International Hematology Assistant Professor of Medicine Co-Director, UPMC Lung Cancer Principal Investigator, Vascular Associate Director, Hemophilia Center Center of Excellence Medicine Institute of Western Pennsylvania Dan P. Zandberg, MD Ellen M. Ormond, PhD Alison R. Sehgal, MD Associate Professor of Medicine Assistant Professor of Medicine Research Instructor of Medicine Director, Head and Neck and Thyroid Cancer Disease Sections Amma T. Owusu-Ansah, MD Malabika Sen, PhD Co-Director, UPMC Hillman Cancer Assistant Professor of Medicine Research Assistant Professor of Center Head and Neck Cancer Clinical Director, Center for Medicine Research Program Translational and International Hematology Warren D. Shlomchik, MD Hassane M. Zarour, MD Professor of Medicine and Professor of Medicine, Immunology, Vida Cecilia A. Passero, MD, Immunology and Dermatology MBA Director, Hematopoietic Stem Cell James W. and Frances G. McGlothlin Clinical Assistant Professor of Transplant and Cell Therapy Chair in Melanoma Immunotherapy Medicine Vice-Chief of Hematologic Research Associate Director, Hematology/ Malignancies, Hematopoietic Stem Co-Leader, Melanoma Program Oncology Fellowship Program Cell Transplantation and T cell Division Chief, Hematology/Oncology, Immunotherapy VA Pittsburgh Healthcare System

Division of Hematology/Oncology CHIEF'S MESSAGE

dysfunction and to conduct a multi-center randomized controlled clinical trial. • John Kirkwood, MD, was appointed Distinguished Professor by the University of Pittsburgh. • Anna Lokshin, PhD, was awarded two new NCI R01 grants, with one grant focused on the development of novel ovarian cancer biomarkers for early detection and the other one focused on development of novel biomarkers for detection of pancreatic cancer. • Carissa Low, PhD, was awarded an NCI R37 grant that focuses on developing a mobile sensing system to monitor symptoms during systemic chemotherapy. • Megan Mantica, MD, was awarded a NeuroNEXT Clinical Research Award. • Four Division faculty members were awarded the 2019 HemOnc Today NExtGen Innovators Award to highlight their stature in their respective disease areas, and they include Yana Najjar, MD (melanoma); Diwakar Davar, MD (melanoma); Jason Luke, MD (melanoma); and Dan Zandberg, MD (head and neck cancer). • Yana Najjar, MD, is the PI of a grant recently awarded from the Melanoma Research Alliance to investigate the evolution of metabolic and immune dysfunction in in-transit melanoma. • Margaret V. Ragni, MD, MPH, is a member of the FDA Blood Products Advisory Committee, and serves on several other committees for the Hemostasis & Thrombosis Research Society of North America, International Society of Hemostasis and Thrombosis, and National Hemophilia Foundation. • Richard Steinman, MD, PhD, continues to play an important role in the education and training mission of the University of Pittsburgh School of Medicine as he continues to serve as Director of the MSTP Program, Director of the PSTP Program, and Director of the Physician-Scientist Incubator. • Antoinette Wozniak, MD, was appointed Editor-in-Chief of the journal Clinical Lung Cancer. • Hassane Zarour, MD, is the corresponding PI of a recently awarded, multi-PI NCI R01 grant that is developing new neoadjuvant immunotherapy combination regimens in melanoma.

Department of Medicine 2020 Annual Report CLINICAL ACTIVITIES

he Division of Hematology-Oncology is composed of 39 clinical faculty and 14 research Tfaculty who are dedicated to excellence in patient care, teaching the next generation of physician-scientists, and conducting innovative cancer-focused basic, clinical, translational, and population research. In addition, there are 77 members of the voluntary faculty, the majority of whom are employed by UPMC Hillman Cancer Center and practice in a UPMC Hillman Cancer Center site in western Penn- sylvania and/or eastern Ohio.

Inpatient Service In FY2018-2019, Division faculty continued to focus on clinical care, which includes the inpatient service and the outpatient clinic at the Hillman Cancer Center. The Division realized an 7% increase in inpatient WRVUs and a stable outpatient WRVU total when compared with FY2017-2018. Total WRVUs billed for FY2018-2019 were 89,571 (excluding psycho-oncology faculty and staff). In 2019, the Division saw an overall 2% increase in total WRVUs. There are three inpatient oncology/solid tumor attending services at UPMC Shadyside, and these services are coordinated with our clinical colleagues from the UPMC Hillman Cancer Center. Two of these inpatient services are staffed by Advanced Practice Providers and Hospitalist Nocturnists, while the third service is the housestaff teaching service supported by Fellows, Internal Medicine Interns and Residents, and Hospitalist Nocturnists. A total of 4,716 patient admissions were seen by these three inpatient services. The overall number of admissions represents a 7% increase from FY2017-2018. This number does not include inpatient oncology admissions to Magee-Womens Hos- pital, where patients with breast cancer are admitted to a dedicated inpatient hospitalist service. These patients are seen by the inpatient oncology consult service, which is staffed by Division faculty members. In addition to the inpatient attending services, there are 10 solid-tumor oncology and hematology consult services: • Bone Marrow and Stem Cell transplant at UPMC Shadyside • Hematologic Malignancy consults at UPMC Shadyside • Hematologic Malignancy consults at UPMC Presbyterian and Magee-Womens Hospital • Benign Hematology consults at UPMC Presbyterian and Magee-Womens Hospital • Benign Hematology consults at UPMC Shadyside • Solid Tumor Oncology consults at UPMC Shadyside • Solid Tumor Oncology consults at UPMC Presbyterian and Magee-Womens Hospital • Neuro-Oncology consults at UPMC Shadyside, UPMC Presbyterian, and Magee-Womens Hospital • Hematology/Oncology consults at the Pittsburgh VA Medical Center

Division of Hematology/Oncology CLINICAL

Until July 2020, there was also an inpatient consult service—initially established in FY15—to care specifically for patients with sickle cell disease (SCD). This service provided comprehensive inpatient care at UPMC Presbyterian and Magee-Womens Hospital of UPMC. Drs. Enrico Novelli, Laura De Castro, and Gregory Kato were the three faculty members who staffed this service, which was also supported by advance practice providers. In addition, Hematology/Oncology fellows provided weekend coverage for this SCD service. After the departure of Dr. Kato earlier this year, the shortfall in attending coverage along with the need to further increase residents and fellows’ training in SCD, prompted the benign hematology faculty to incorporate the SCD consult service within the Benign Hematology inpatient consult service.

Outpatient Service Division faculty continue to have robust outpatient clinical practices at the Hillman Cancer Center and Magee-Womens Hospital. Both are hospital-based clinics and since June 1, 2013, both outpatient services fall under the umbrella of Magee-Womens Hospital as a hospital-based practice. Since October 2013, faculty based at the Hillman Cancer Center have used Aria, an electronic medical record (EMR). This system was designed specifically for use by medical oncologists and allows for the ordering and dispensing of chemotherapeutic agents. At Magee-Womens Hospital, our breast cancer medical oncologists use Epic, which is the EMR used by the rest of the UPMC clinical programs.

Benign Hematology The Division has a Benign Hematology Section with more than 10 physician-scientists and research investigators, and this group is now considered to be one of the largest benign hematology programs in the U.S. As a result of recent growth, grant funding and participation in clinical trials have increased, continued positive upward trajectory over the next few years is expected. Hemophilia is one of the real strengths of our benign hematology program. The leader of the hemophilia program is Dr. Margaret Ragni, one of the world’s pre-eminent leaders and whose clinical and research activities are housed in the state-of-the-art Hemophilia Center of Western Pennsyl- vania (HCWP). The Benign Hematology Section continues to enjoy an extremely close collaboration with Vitalant, Inc (previously, the Institute for Transfusion Medicine) and together they continue their efforts to focus on project planning and program building of the Benign Hematology Center of Excellence, funded by a federal government HRSA grant. This Center provides needed comprehensive outpatient clinical services for the spectrum of thrombosis and hemostasis disorders. It also conducts state-of-the-art clinical and translational research in this population with an emphasis on hemophilia. In parallel with the Center’s planning and development phases, patient-specific treatment plans, protocols, and guidelines of care have been established, updated, individualized and delivered to patients within an outpatient Day Hospital care model, currently housed in the UPMC Hillman Can- cer Center. These clinical improvement and quality assurance interventions have been paired with efforts at increasing patient’s uptake of disease-modifying treatments, particularly in SCD, where three newly approved FDA disease-specific therapies—crizanlizumab, L-glutamine, and voxelotor— have joined hydroxyurea and chronic blood transfusion. As a major focus of the benign hematology clinical program, individualized pain management protocols have been developed and personnel have been hired to longitudinally support these efforts. The UPMC Adult Sickle Cell Program is currently staffed by two dedicated faculty members (Drs. De Castro and Novelli), three APPs, and other health care professional, and is one of the largest in the country. The program recently opened a new ambulatory intensive management (AIM) clinic, a monthly clinic aimed at providing comprehensive, holistic care to those patients with SCD with the highest health care utilization. The AIM clinic is staffed by MDs, APPs, 1 social worker, nurses, 1 8

Department of Medicine 2020 Annual Report psychologist, 1 psychiatrist, and representatives of the Children’s Sickle Cell Foundation, a community-based organization. As of 2020, the longstanding efforts to identify a new location for the Benign Hematology clinics have resulted in three major developments. First, major progress has been made towards relocating the Benign Hematology outpatient clinics and infusion center from the Shadyside campus to Presbyteri- an Hospital and the Oakland area, where dedicated space is being identified. This move, if successful, will expand the capacity of the infusion center and reposition the fulcrum of the outpatient Benign Hematology activities into the Oakland campus, where closer collaboration with other Internal Med- icine Divisions will be spurred. Second, a parallel effort is being conducted to secure the financial stability of the Section by exploring the feasibility of a 340B program for Benign Hematology. Third, the clinical research team supporting the Benign Hematology research studies has relocated to the Kaufmann building and administratively away from the Hillman Clinical Research Services team and under the umbrella of the Department of Medicine. The clinical research team, named ARCH, includes 6 clinical research staff members and oversees >20 clinical studies, primarily in SCD, but with a growing num- Benign Hematology Telemedicine ber of protocols in other areas of benign hematology such The Benign Hematology Section as acquired platelet disorders and autoimmune hemolytic has been at the forefront of val- anemias. ARCH members, in collaboration with other staff ue-based quality of care and health members from the Department of Medicine, are actively care economics-based initiatives developing a hematology database, titled Orchestra, that for many years. In response to the will greatly aid research activities and will harness the in- coronavirus pandemic, the Benign formation contained in various electronic medical records. Hematology Section has successfully adopted telemedicine-based pa- The physical and administrative move of the ARCH team tient management. The faculty has to Oakland has resulted in a stronger and more cohesive rapidly transitioned 25%-30% of the team that is able to manage all aspect of clinical research, outpatient encounters to telemedi- e.g., protocol and infrastructure development, regulatory cine, and the goal over the next year and budgetary management, study coordination, patient is to increase the proportion of en- engagement and data safety review. counters that are managed by telemedicine to 40%-50%, particularly A major priority of the Benign Hematology Section is to ac- focusing on continuation of care tively recruit junior and mid-career academic-oriented he- and longitudinal follow up. In-per- matologists to increase the research and clinical expertise son management will be reserved portfolio of the Section. In particular, efforts have been ori- for new consults, thus increasing ented towards hiring experts in the science of hemostasis capacity in this area, and for those and thrombosis and in the area of rare hematological dis- interventions that require a treat- orders. A national search is being conducted via multiple ment in clinic (e.g., transfusions and strategies. infusions of biologicals and chemo- therapeutics). In addition, the Section has opened Psycho-Oncology Program a weekly rapid access clinic (RAC) di- The Section of Psycho-Oncology brings together both be- rected to decrease the wait time for havioral health for oncology patients, with faculty who span new patient referrals and consults. both clinical and research activities. Under the title “The The RAC clinic is primarily manned Center for Counseling and Cancer Support (CCCS),” clini- by Dr. Roy Smith, one of the Sec- tion’s senior faculty members, who cians added important medical leadership as Robin Valpey, has pioneered eConsults and tele- MD, assumed the role of medical director, working closely medicine, and is now actively spear- with Jack Cahalane, PhD, who serves as Program Director. heading other value-based interven- The clinical staff at CCCS includes 3 psychiatrists and 5 clin- tions, including the development of ical psychologists, as well as one full-time nurse with ex- a Section-wide hematology eConsult pertise in oncology. Patients are seen across various sites, service and the organization of di- including our main site in the Shadyside Medical Building, rect oral anticoagulant therapy and as well as Magee-Womens Hospital and UPMC Passavant thrombophilia testing at UPMC.

Division of Hematology/Oncology CLINICAL

hospital. The group continues to provide a wide range of clinical services to cancer patients and their families, including management of mood disorders, anxiety, sleep and appetite disturbances, substance use disorders, cognitive impairments, and other neuropsychiatric manifestations of cancer and its treatment. In addition to individualized care, we are expanding services to include group-based interventions, with a 4-session Memory and Attention Adaptation Training class for treatment of cancer-related cognitive impairment and a monthly Caregiver Group. Increasing emphasis has been placed on providing telemedicine services, in hopes of reaching even more of our underserved population in the Western Pennsylvania region and beyond. The Center is also expanding collaboration with other services both inside and out of UPMC to provide optimal care. In addition to ongoing direct clinical care of shared patients, we have continued collaborating with Palliative Care outpatient providers through a monthly inter-disciplinary team meeting, and with hematologists caring for the sickle cell population in biweekly case collaboration meetings. We also frequently collaborate with our colleagues seeing inpatient consultations through Consult-Liaison Psychiatry services and hope to continue to expand our role for hospi- talized cancer patients going forward. We have also had increasing collaboration with community partners that provide support for our cancer patients, both in providing educational lectures and mutual outreach. Educational opportunities have continued to expand both for medical and psychology trainees. The formal residency elective in psycho-oncology through the Department of Psychiatry has been revamped for the upcoming academic year, and Consult-Liaison Psychiatry fellows continue their 6-month rotation at our main site in Shadyside, with development of more formalized curriculum and structure training in Memory and Attention Adaptation Training. Graduate psychology trainees are also participating at various clinical sites (both inpatient and outpatient) with our psychologists, and clinical experiences are offered for fellows in palliative care, breast oncology surgery and other oncology programs, with frequent shadowing of most clinicians in our group. The Center for Counseling and Cancer Support continues its close partnership with the research arm, the HCC Biobehavioral Oncology Research Program, under the direction of Dana Bovbjerg, PhD. Together, they are working to identify opportunities for clinical and translational research and to develop innovative care approaches. Providers remain active in the local, national, and international communities through research collaborations, speaking invitations, and participation in sym- posiums, panel discussions, and poster presentations at local and national conferences. The following are this year’s updates on the work of our esteemed colleagues (in alphabetical order): Dr. Angela Dean, Clinical Assistant Professor in the Department of Psychiatry, serves patients in three locations (UPMC Magee Women’s Hospital, UPMC Shadyside, and UPMC Passavant). She su- pervises graduate psychology students in provision of health care services at UPMC Passavant, with a focus on developing integrated care within the cancer center and provision of care to both patients and family members affected by cancer. As such, she began a monthly educational series for caregivers at UPMC Passavant Hospital, which has been well received by the community and Cancer Center colleagues. In March, she partnered with Dr. Ferguson in presenting research on cognitive dysfunction at the national meeting of Society of Behavioral Medicine. She is also an active member of the caregiving and health care disparities special interest groups for the American Psychosocial Oncology Society. Because of her commitment to providing interdisciplinary care, Dr. Dean will be teaching students in the Medical Interviewing course through the School of Medicine in the Fall of 2019, and she has been invited to present at the 6th Annual Wound Care Conference hosted by UPMC Wound Healing Services. Dr. Rob Ferguson, Assistant Professor of Medicine, has continued to work in cognitive-behavioral treatment for cancer-related cognitive impairment, and he has had numerous grant-funded research projects sponsored by NCI, NIH Office of Research on Women’s Health, and the Beckwith

Department of Medicine 2020 Annual Report Foundation. In the latest academic year, he has submitted an R01 proposal for a multisite clinical trial of cognitive-behavioral management of cancer-related cognitive dysfunction for breast cancer survivors with colleagues at Indiana University, Simon Cancer Center, with fMRI brain imaging to evaluate post-treatment cortical activation changes. A new grant from the Shadyside Hospital Foun- dation was received this year in collaboration with Dr. Annette Duensing of the HCC Cancer Thera- peutics Program to track neurocognitive function of patients with gastrointestinal stromal tumors. Dr. Ferguson has also received a grant from MiroHealth, a technology company developing an iP- ad-artificial intelligence based neurocognitive assessment tool for evaluation among breast cancer survivors. In the coming months, he will be working with Oxford University Press on publishing the book titled, “Memory and Attention Adaptation Training: A Cognitive-Behavioral Treatment Program for Cancer Survivors.” Dr. Shelly Kucherer, Assistant Professor of Psychiatry, is joining the Center for Counseling and Can- cer Support in August 2019 after completing a fellowship in consultation-liaison psychiatry at UPMC. During her residency and fellowship, one of her clinical interests focused on psycho-oncology, and she had several projects related to this interest during her training. In collaboration with Dr. Rob- ert Ferguson, she developed a group program for cancer-related cognitive dysfunction, which is currently being offered as a free service to patients and their caregivers. Another research interest is focused on sexual dysfunction in cancer survivors, and she recently published a manuscript in General Hospital Psychiatry with Dr. Valpey. Dr. Carissa Low, Assistant Professor of Medicine, has continued to grow the Mobile Sensing + Health Institute with support from the UPMC Hillman Cancer Center and Carnegie Mellon Uni- versity. Over the past one year, she has hired technical and data science staff and launched a new internship with the University of Pittsburgh School of Computing and Information to provide biobehavioral oncology research training opportunities to computer and data science students. In recognition of her novel research in this field, she was recently awarded a 5-year $2 million R37 MERIT award from the National Cancer Institute to fund a project that will combine smartphone and wearable sensor data with machine learning to remotely monitor symptoms during chemotherapy and to develop and test within the Gastrointestinal Oncology clinics a system that automatically triggers patient-provider contact when severe symptoms are detected. She also initiated a NCI-funded randomized controlled trial investigating the effects of a perioperative sedentary behavior intervention on postoperative outcomes in surgical oncology patients. Dr. Low was invited to present her research at the International Congress of Behavioral Medicine in Santiago, Chile, as well as at the Association for Psychological Science Convention in Washington, DC, and she serves as an Associate Editor for the International Journal of Behavioral Medicine. Dr. Ellen Ormond, Assistant Professor of Medicine, continues to focus on QI initiatives for the Di- vision. Current projects include: (1) Collaboration with Division medical oncologists and Palliative Care to add an Advanced Care Planning template to ARIA and to improve ACP conversation at UPMC Hillman Cancer Center; (2) Evaluating the use of the RAI (Risk Assessment Index) and PROs at Magee hospital as predictors of frailty; (3) A survey of Advance Care Planning documents in the inpatient oncology EMR at Shadyside Hospital. An abstract on this project has been accepted for ASCO’s Qual- ity Symposium for September 2019; and (4) Collaboration with Hematology and Palliative Care at the Hillman Cancer Center to initiate palliative care for all geriatric AML and MDS patients, and all high-risk allogeneic stem cell transplant patients. Dr. Ormond serves on the Shadyside Quality and Safety Committee, and planning committees for the Shadyside Oncology Emergency Department and UPMC’s Safenet project. Over the past year, she has worked with the Oncology-Hematology Fellowship Program on ASCO’s Resilience Skills Training for first-year oncology fellows, and has lec- tured on burnout and stress management for HCC physicians and medical teams. Dr. Donna Posluszny, Assistant Professor of Medicine, continues to play an important role in the Division’s education and training mission as the Associate Director of Training, Biobehavioral Medi- cine in Oncology Program. On the research front, she is piloting a behavioral intervention to help al-

Division of Hematology/Oncology CLINICAL

logeneic hematopoietic cell transplantation (HCT) patients and their family caregivers manage each component of the post-HCT regimen together, thus improving psychological and health outcomes, in preparation for a NIH grant submission. She was recently awarded pilot funds from the newly formed University of Pittsburgh Center for Caregiver Research, Education, and Training to conduct a study investigating the family caregiver’s role at the hospital, when the patient is admitted for a long period of time (e.g., one month), and the impact on patient and caregiver psychological and health outcomes. Dr. Robin Valpey, Assistant Professor of Psychiatry, has continued to follow her passion of providing optimal psychiatric care for medically complex patients, particularly those with co-occurring disorders. Given her additional expertise in both eating disorders and addiction, she has utilized these skills in direct management of patients and in dissemination to colleagues through local grand rounds presentations, national poster and oral presentations (Academy of Consult-Liaison Psychia- try 2018, American Psychosocial Oncology Society 2019), and publications (sexual health in female cancer survivors). Since the departure of the former Medical Director in December 2018, she has expanded her leadership role to facilitate optimum patient care, with development of monthly physician meetings and increased collaboration/integration with both clinical providers and research colleagues in various service lines throughout UPMC. She is excited for her new role as Medical Di- rector, with specific vision of expanding both inpatient and outpatient services in innovative ways in order to address the needs of cancer patients, particularly those most underserved.

Department of Medicine 2020 Annual Report QUALITY IMPROVEMENT INITIATIVES

Over the past year, significant efforts have been placed on quality improvement activities relating to patient care. The admission process for cancer patients from the ED, clinic, home, etc., was dramatically revamped due to curriculum changes in the fellowship program that caused increased time to admission and frustration. Education of various hospital staff, and primarily the ED, was implemented, including a 3-pager system. These efforts resulted in a significant improvement in the flow of- pa tient admissions from the ED as well as a significantly decreased time to admission for our patients. Another area for improvement related to the effective transfer of cancer patients from the ICU to the regular nursing floor. A new paging process was instituted that added "warning" pages to the admitting teams—and direct phone calls were used between the ICU and oncology teams. These two initiatives have resulted in a marked improvement in the number of "missed" patients.

Standardization of Inpatient CPR Status Discussions and Documentation within the Division of Hematology-Oncology and UPMC Shadyside. Medical professionals are trained to provide life-sustaining and cardiac resuscitation measures for admitted hospital patients. However, not all patients desire such aggressive measures. The lack of discussion and/or documentation about resuscitation preferences has led to care incongruous with patient’s wishes (as previously documented or reported to providers or family members). In 2016, an average of 45% of patients admitted to the inpatient hematology and oncology services at UPMC Shadyside had a code status discussion documented prior to discharge. The aim of this quality improvement project was to improve the quality and rates of CPR status conversations with our cancer patients admitted to the inpatient service. A working group was formed in January 2017, and it comprised key stakeholders representing oncology physicians and fellows, palliative care faculty, oncology nursing, advance practice providers (APPs), and internal medicine house staff. A quality improvement (QI) proposal was developed and approved by the UPMC Quality Improvement Committee in February 2017. All oncology faculty, fellows, housestaff, and advance practice providers were reminded weekly to complete CPR status conversations and documentation. APPs were formally trained by palliative care specialists to discuss and document CPR/code status with all admitted patients. Hospital leadership received a monthly update of CPR status documentation rates. Since implementation of this project in 2017, there has been a significant improvement in the CPR status orders, which rose to >80%. In July 2017, 82% of our patients at UPMC Shadyside had a documented CPR status assessment at discharge, and this high level of >80% has continued over the past year. Formal system-wide expectations are being developed by the CPR assessment workgroup that all admitted patients should have CPR/Code status discussion and documentation upon admission. Overall, the Division has found that standardization of CPR status assessment with formal training of clinicians and APPs has resulted in a significant increase in the number of CPR status assessments on the inpatient setting, which has been sustained >80%. This practice has been so successful that a manuscript the reports on the important QI project has recently been accepted to the Journal of Oncology Practice, which is a highly respected peer-reviewed journal sponsored by the American Society of Clinical Oncology. 13

Division of Hematology/Oncology CLINICAL

CLINICAL LOCATIONS

Hematology/Oncology at UPMC Hillman Cancer Center 5115 Centre Avenue Pittsburgh (Shadyside), PA, 15232

Includes Center for Counseling and Cancer Support 5110 Centre Avenue, Suite A-140 Pittsburgh (Shadyside), PA 15232

Women’s Cancer Center—Magee-Womens Hospital of UPMC 300 Halket Street, Suite 4628 Pittsburgh (Oakland), PA 15213

Includes Center for Counseling and Cancer Support 300 Halket Street, Suite 0704 (Ground Floor) Pittsburgh (Oakland), PA 15213

Center for Counseling and Cancer Support—UPMC Passavant 9100 Babcock Boulevard, Ground Floor Pittsburgh, PA 15237

Center for Counseling and Cancer Support—UPMC McKeesport Mansfield Building, D Level 1500 Fifth Avenue McKeesport, PA 15132

Department of Medicine 2020 Annual Report 15

Division of Hematology/Oncology RESEARCH

RESEARCH ACTIVITIES

he Division continues to place a high priority on clinical and translational research. Clin- Tical faculty devote considerable time and effort to developing clinical trials that investigate novel agents and/or combination regimens.

The Division faculty continue to play important roles in the Phase I, Phase II, and Phase III clinical drug development programs. These are supported by the NCI with Dr. Chu serving as the PI of the NCI UM1 grant that funds Phase 1 and Phase 2 clinical trials, and Dr. Brufsky serves as the PI of the NCI UG1 grant that supports the Phase 3 clinical program. In FY2019-2020, Division faculty enrolled over 1,200 patients on therapeutic and non-therapeutic clinical trials.

Research Grants Among the several key faculty members with noteworthy peer-reviewed grants are: • Edward Chu, MD, is PI of the NCI T32 training grant focused on cancer therapeutics. • Edward Chu, MD, is PI of the NCI UM1 grant focused on the development and conduct of Phase 1 and Phase 2 clinical trials. This grant represents a collaborative effort between HCC and the Albert Einstein Cancer Center as its second consortium partner. • Adam Brufsky, MD, PhD, is PI of the NCI UG1 grant titled "NCTN Network Lead Academic Site." • Tim Burns, MD, PhD, is PI of newly funded NCI R01 grant titled ”Targeting the HGF-TWIST1 Pathway to Overcome EGFR TKI Resis- tance in NSCLC.” • Diwakar Davar, MD, is PI of a grant GRANTS & CONTRACTS AWARDED from the Melanoma Research Foun- FY20 dation that is focused on developing RESEARCH neoadjuvant immunotherapy in pa- BY THE NUMBERS tients with stage III melanoma and predictive biomarkers and a newly In FY20, the Division of awarded multi-PI NCI R01 grant that Hematology/Oncology is developing new neoadjuvant im- received over $31m in munotherapy combination regimens research funding from in locally advanced melanoma. the Public Health Service and other government • Robert Ferguson, PhD, is PI of a new- agencies, industry, and ly funded NCI R01 grant titled “Devel- various societies and oping a Mobile Device and Cognitive foundations. Research Behavioral Therapy for Chemothera- expenditures exceeded py-Related Cognitive Dysfunction”. $19.5m. • Jim Herman, MD, is PI of the NCI-sup- 16

Department of Medicine 2020 Annual Report GRANTS & CONTRACTS AWARDED RESEARCH EXPENDITURES FY20 FY16-FY20

Division of Hematology/Oncology RESEARCH

ported U01 grant titled “Ultrasensitive Detection of Tumor Specific DNA Methylation Changes for the Early Detection of Lung Cancer”. • Charles Horn, PhD, is PI of an NIDDK grant titled “Therapeutic Potential of Vagal Neurostimulation to Reduce Food Intake”. • Greg Kato, MD, was awarded the first benign hematology T32 training grant at UPMC to train the next generation of physician scientists with a focus in benign hematology. This grant leverages the expertise of both the clinical and basic science faculty at the Vascular Medicine Institute and in the Section. With his departure, Drs. Novelli and Ragni have assumed the roles as Co-PIs of this training grant. • Carissa Low, PhD, is PI of a new NCI grant titled “A Mobile Sensing System to Monitor Symptoms During Chemotherapy”. • Yana Najjar, MD, is PI of the U.S. Department of Defense grant "Metabolic Remodeling of the Tumor Microenvironment to Improve the Efficacy of Immunotherapy” and is the PI of a grant recently awarded from the Melanoma Research Alliance to investigate the evolution of metabolic and immune dysfunction in in-transit melanoma. • Hassane Zarour, MD, is PI of 2 NCI R01 grants “Targeting TIGIT and PD-1 in Melanoma“ and "Fecal Microbiota Transplant and PD-1 Blockade in Melanoma”. He is the corresponding PI of a recently awarded multi-PI NCI R01 grant that is developing new neoadjuvant immunotherapy combination regimens in melanoma.

Research Service Division of Hematology-Oncology faculty members are deeply committed to advancing this nation’s research agenda, and they play important roles on various committees of the National Cancer In- stitute, the National Institutes of Health, and other federal agencies, as well as major professional cancer-focused organizations. This list highlights some of these noteworthy committees: • Len Appleman, MD, PhD, is a member of the Eastern Cooperative Group Genitourinary Core Committee and a member of the NCI Renal Cancer Task Force. • Nathan Bahary, MD, PhD, is a member of the NCI Pancreatic Task Force of the GI Cancer Steering Committee. • Edward Chu, MD, serves as a member of the following committees: the NCI Investigational Drug Steering Committee, the NCI Experimental Therapeutics Committee, the American Association of Cancer Research Scientific Program Committee, and the NCI Subcommittee F Study Section on Training. • Laura DeCastro, MD, MHSc, is a member of the American Society of Hematology Committee on Practice and a member of the Food and Drug Administration Orphan Products Development Committee. • Jan Drappatz, MD, is a member of the Alliance Cooperative Group Neuro-oncology Committee. • Leisha Emens, MD, PhD, is a member of the Board of Directors of the Society for Immunotherapy of Cancer. She is also a member of the Oncology Drugs Advisory Committee (ODAC) for the US food and Drug Administration. • Deborah Galson, PhD, is a member of the Scientific Program Committee for the American Society for Bone and Mineral Research and the ASBMR Finance Committee. • John Kirkwood, MD, is a member of the ECOG-ACRIN Scientific Planning Committee and the ECOG-ACRIN Principal Investigator Committee. He just stepped down as chair of the ECOG-ACRIN Melanoma Committee and continues to serve as a member of that committee. Among his other memberships are the Society for Immunotherapy of Cancer

Department of Medicine 2020 Annual Report Fellowship Review Task Force and the American Society of Clinical Oncology Research Policy Immunotherapy Working Group. • Frank Lieberman, MD, is a member of three ECOG-ACRIN panels: the Biomarkers Committee, the Experimental Imaging Committee, and the CNS Tumor Committee. He also serves on the NCI Adult Brain Tumor Consortium. • Anna Lokshin, PhD, is a member of the NCI Cancer Prevention Research Small Grant Program Committee and a member of the NIH SBIR/STTR Cancer Diagnostic and Treatment Committee. • Enrico Novelli, MD, MS, is a member of the American Heart Association Study Section and a member of the NIH SBIR/STTR Study Section. • Solomon Ofori-Acquah, PhD, is a member of the NIH Respiratory Integrative Biology and Translational Science Study Section. He also serves on the ASH Minority Medical Student Award Committee, and he chairs the ASH Minority Graduate Student Abstract Achievement Award Committee. • Priya Rastogi, MD, is a member of the NCI Breast Cancer Steering Committee. • Margaret Ragni, MD, MPH, is a member of the FDA Blood Products Advisory Committee, the American Society of Hematology (ASH) Scientific Committee on Hemostasis, and the National Health Foundation Medical and Scientific Advisory Committee. • Warren Shlomchik, MD, is a member of the NCI Cancer Immunology and Immunopathology Study Section. • Josie van Londen, MD, is a member of the ASCO Cancer Survivorship Committee, the ASCO Geriatric Oncology Special Interest Group Committee, and the ASCO Survivorship Guideline Advisory Committee. • Antoinette Wozniak, MD, is a member of the Southwest Oncology Group (SWOG) Lung Committee and a member of the Scientific Committee of the International Association for the Study of Lung Cancer (IASCLC). • Hassane Zarour, MD, is a member of the NCI Experimental Therapeutics SBIR Study Section and has served as a reviewer for the NCI SPORE Program.

Division of Hematology/Oncology RESEARCH

Faculty Research Interests and Activities

Edward Chu, MD Division Chief Dr. Chu conducts basic, clinical, and translational cancer research. His basic research interests have focused on characterizing the molecular mechanisms underlying the development of cellular drug resistance, especially as it relates to the fluoropyrimidine class of anticancer agents. His research group was the first to identify translational autoregulation as a novel regulatory mechanism in eu- karyotes for controlling the expression of the folate-dependent enzymes, thymidylate synthase, and dihydrofolate reductase. His clinical translational research efforts have focused on identifying novel drugs and treatment strategies for colorectal cancer and other GI cancers and in developing early-phase I/II clinical trials. Dr. Chu has a strong interest in integrating Chinese herbal medicine with standard cancer chemotherapy with the goal of enhancing clinical activity and reducing the toxicity associated with chemotherapy. The Chu lab has been investigating the potential role of antisense and siRNAs as novel therapeutic molecules for the treatment of colorectal cancer. The goal of these studies is to identify novel molecules to prevent and/or overcome the development of cellular drug resistance to inhibitor compounds that target thymidylate synthase, a well-established target for cancer chemotherapy. The Chu lab observed that siRNAs were significantly more potent and specific in their ability to repress TS mRNA translation, resulting in potent inhibition of TS synthesis. Moreover, they were able to completely restore chemosensitivity to anticancer agents that target TS, including the fluoropyrimidines and TS antifolate inhibitors. Study Sections • Member/Reviewer, International Grant Review Committee, National Health Research Council of Italy, 2005-present • Member/Reviewer, University Grants Committee, University of Hong Kong, 2005-present • Member/Reviewer, Grants Committee, Singapore National Medical Research Council, 2008-present Advisory Committee Memberships and Leadership Positions • Taiwan Cooperative Oncology Group, National Health Research Institutes of Taiwan, Taiwan, 1998-present • Scientific Advisory Board, Division of Clinical Research, National Health Research Institutes of Taiwan, Taiwan, 1999-present • Chair, Clinical Research Committee, Consortium for Globalization of Chinese Herbal Medicine, 2003-present • Scientific Advisory Board, Celator, Vancouver, BC, 2005-present • Scientific Advisory Board, Albert Einstein Cancer Center, Bronx, NY, 2006-present • Scientific Advisory Board, Dartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon, NH, 2007-present • Co-Leader, Cancer Therapeutics Program, UPMC Hillman Cancer Center, 2010-present • Member, Biomarkers Steering Committee, UPMC Hillman Cancer Center, 2010-present • Member, Clinical Executive Committee, UPMC Hillman Cancer Center, 2010-present • Member, Clinical Research Oversight Committee, UPMC Hillman Cancer Center, 2010-present • Member, Senior Leadership Committee, UPMC Hillman Cancer Center, 2010-present • Scientific Advisory Board, Saladex, Bethlehem, PA, 2010-present • Investigational Drug Steering Committee, National Cancer Institute, 2010-present • Member, Hematology/Oncology Fellowship Curriculum Committee, UPMC Hillman Cancer Center, 2011-present • Member, Material Transfer Agreement Exception Committee, University of Pittsburgh, 2011-present • Member, Oncology EMR Governance Committee, UPMC Hillman Cancer Center,

Department of Medicine 2020 Annual Report 2011-present • Scientific Advisory Board, Salzburg Therapeutics, Winston-Salem, NC, 2011-present • Chair, Scientific Advisory Board, University of Vermont Cancer Center, Burlington, VT, 2012-present • Experimental Therapeutics Committee (NeXT), National Cancer Institute, 2012-present • Scientific Advisory Board, Herbert Irving Columbia Cancer Center, New York, NY, 2012-present • Scientific Advisory Board, USC Norris Cancer Center, Los Angeles, CA, 2012-present • Member, Chemical Biology Facility Committee, UPMC Hillman Cancer Center, 2013-present • Scientific Advisory Board, Case Western Seidman Cancer Center, Cleveland, OH, 2013-present • Scientific Advisory Board, Medical University of South Carolina Hollings Cancer Center, NCI Cancer Centers, Charleston, SC, 2013-present • Member, Oncology Executive Management Committee, UPMC Hillman Cancer Center, 2014-present • Scientific Advisory Board, Indiana University Simon Cancer Center, Indianapolis, IN, 2014-present • Executive Council, Global Consortium for Chinese Herbal Medicine, 2015-present • Oncology Scientific Committee, International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), 2015-present • Full Member, Subcommittee F, National Cancer Institute, 2016-2020 • Chair, Scientific Advisory Board, University of Arizona Cancer Center, Tucson, AZ, 2016-present • Member, Shared Resources Oversight Committee, UPMC Hillman Cancer Center, 2016-present • Member, Colon Cancer Alliance, Washington DC, 2016-present • Educational Committee, American Association for Cancer Research, 2017-2020 • Scientific Program Committee, American Association for Cancer Research, 2017-2020 • External Advisory Board, P50 GI SPORE, Vanderbilt-Ingram Cancer Center, Nashville, TN, 2017-present • Scientific Advisory Board, University of Michigan Cancer Center, NCI Cancer Centers, Ann Arbor, MI, 2017-present • Scientific Advisory Board, Hope Biosciences, Irvine, CA, 2017-present • Scientific Advisory Board, Karmanos Cancer Institute, NCI Cancer Centers, Detroit, MI, 2017-present • Scientific Advisory Board, Duke Cancer Institute, Durham, NC, 2017-present • External Advisory Board, T32 Training Program, Northwestern University, Evanston, IL, 2018-present • Scientific Advisory Board, University of Kentucky Markey Cancer Center, NCI Cancer Centers, Lexington, KY, 2018-present • Member, Pharmacy and Therapeutics Committee, UPMC Hillman Cancer Center, 2019-present • Scientific Advisory Board, St. Jude’s Cancer Center, NCI Cancer Centers, Memphis, TN, 2019-present • Chair, Exhibits Committee, American Association for Cancer Research, 2019-present Professional Affiliations and Society Memberships • Fellow, American College of Physicians, 1985-present • Member, American Federation for Medical Research, 1985-present • Member, American Association for Cancer Research, 1985-present • Member, International Colorectal Cancer Club, 1995-present • Member, American Society of Clinical Oncology, 1990-present 21

Division of Hematology/Oncology RESEARCH

• Member, European Society for Medical Oncology, 2000-present • Fellow, American Association for the Advancement of Science, 2005-present Editorships • Reviewer, Multiple journals, 1987-present • Editorial Board, International Journal of Oncology, 1997-present • Founding Editor-in-Chief, Clinical Colorectal Cancer, 2000-present • Editorial Board, Oncology Special Edition, 2003-present • Editorial Board, Current Reviews in Hematology and Oncology, 2004-present • Editorial Board, Journal of Chemotherapy, 2004-present • Editorial Board, Oncology, 2006-present • Scientific Advisory Board, Principles and Practice of Oncology: The Cancer Journal, 2006-present • Editorial Board, Oncology News International, 2006-present • Co-Editor-in-Chief, Oncology Research, 2008-present • Editorial Board, Clinical Oncology News, 2008-present • Editorial Board, Journal of Clinical Oncology, 2008-present • Editorial Board, Journal of Experimental and Clinical Medicine, 2009-present Major Lectureships and Seminars • Program Chair and Lecturer, UPCI ASCO Review, Pittsburgh, PA, 2017-2019 • Lecturer, George Washington University, Medical Oncology Board Review Course, Alexandria, VA, August 2019 • Lecturer, Stanford Cancer Institute, TOPS Annual Symposium, Palo Alto, CA, October 2019 • Lecturer, Xiangya Cancer Center, 2019 Xiangya Medicine Forum: Symposium on Cancer Genoics and Immunology, Changsha, Hunan, China, October 2019 Honors and Awards • Recipient, Castle Connolly America’s Top Doctor for Cancer Award, 2005-present • Named, Top Doctor, U.S. News and World Report, 2011-present • Distinguished Professor, Xiangya Hospital, Central South University, Changsha, China, 2019-present

Leonard J. Appleman, MD, PhD Dr. Appleman’s current research efforts in the field of tumor immunology include collaborating with Dr. Pawel Kalinski on conducting clinical trial of an autologous dendritic cell vaccine in patients with biochemical recurrence of prostate cancer (UPCI 06-070). Dr. Appleman is also working with Dr. Michael Lotze on another investigator-initiated phase I study of high dose interleukin-2 plus hydroxychloroquine (UPCI 11-080), and he has co-authored a review on inhibiting autophagy in renal cell carcinoma with his collaborators (Lotze, Maranchie, and Appleman 2013, Cancer J.). He is site Principal Investigator for the NCI-funded Cancer Immunotherapy Trials Network (CITN) study of interleukin-7 and sipuleucel-T for men with castration-refractory prostate cancer and was the site P.I. for the Cytokine Working Group IL-2 Select study (McDermott et al. 2014, Clin. Cancer Res.). Dr. Appleman also serves as site PI for several industry-sponsored studies that are investigating cancer immunotherapy. One of these studies was presented at ASCO in 2014 (Choueiri et al.). Advisory Committee Memberships and Leadership Positions • Co-Leader, Bladder Cancer Pathway, Via Oncology, 2012-present • Chair, Protocol Review Board, Committee B, UPMC Hillman Cancer Center, 2013-present • Member, Testicular Cancer Pathway, Via Oncology, 2013-present • Co-Leader, GU Disease Team, Pennsylvania Cancer Consortium, 2015-present • Member, Renal Cancer Task Force, National Cancer Institute, 2016-present Professional Affiliations and Society Memberships

Department of Medicine 2020 Annual Report • Member, American Society of Clinical Oncology, 2007-present • Member, Society for the Immunotherapy of Cancer, 2016-present Editorships • Reviewer, Multiple journals, 2004-present • Associate Editor, Clinical Genitourinary Oncology, 2016-present Major Lectureships and Seminars • Invited Speaker, University of Pennsylvania, Kidney Cancer Symposium, October 2019

Nathan Bahary, MD, PhD Dr. Bahary’s principal research interest is to combine the power and insight of vertebrate development to elucidate basic molecular processes and the treatment of cancer. One of the methods used to characterize the discrete steps involved in normal vertebrate development and initiation and progression of tumors is the generation of mutants and alteration of specific gene expression. In this regard, the zebrafish Danio( rerio) is an especially robust vertebrate system for isolating and defining the novel factors affecting these processes. The developing embryos are transparent, facilitating visualization, and have functioning organ systems by 24 hours post-fertilization. Transgenic zebrafish, made by fusing the promoter elements of genes with a fluorescent marker (GFP), are being used to help elucidate the key steps in cancer development. This work will help provide the basis for designing rational, molecularly based disease directed therapies. Study Sections • Standing Member, Special Emphasis Review Panel, Postdoctoral Fellowship applications for Digestive Diseases and Nutrition, NIDDK, 2011-present Advisory Committee Memberships/Leadership Position • Faculty Interviewer, BMG Graduate School, University of Pittsburgh School of Medicine, 2003-present • Faculty Interviewer, Medical Residency Program, University of Pittsburgh School of Medicine, 2003-present • Faculty Interviewer, Medical School Admissions Committee, University of Pittsburgh School of Medicine, 2003-present • Member, GI Steering Committee, Eastern Cooperative Oncology Group, 2004-present • Director, GI Tumor Board, UPMC Hillman Cancer Center, 2007-present • Member, BMG Student Review Committee, University of Pittsburgh School of Medicine, 2007-present • Member, Fellowship Curriculum Committee, UPMC Hillman Cancer Center, 2011-present • Rotation Site Director, Complex General Surgical Oncology Fellowship, UPMC Hillman Cancer Center, 2013-present • Member, Pancreatic Task Force, National Cancer Institute, 2017-present • Course Director, 2019 PancreasFest, 7/1/2019 Professional Affiliations and Society Memberships • Member, American Society of Clinical Oncology, 2015-present • Member, Society for Clinical and Translational Science, 2015-present • Member, American Association for Cancer Research, 2015-present • Member, North American Neuroendocrine Tumor Society, 2015-present • Member, National Surgical Adjuvant Breast and Bowel Project, 2015-present • Member, Pancreatic Cancer Research Team, 2015-present • Member, Eastern Cooperative Oncology group (ECOG), 2015-present • Member, Liver Center-Interest Group: Liver Tumorigenesis, University of Pittsburgh, 2019-present Editorships • Editorial Advisory Board, Oncology Research, 2015-present 23

Division of Hematology/Oncology RESEARCH

• Editorial Advisory Board, Clinical Colorectal Cancer, 2015-present • Reviewer, Multiple journals, 2015-present Major Lectureships and Seminars • Lecturer, Medicine Grand Rounds, UPMC Shadyside, Pittsburgh, PA, April 2020

Riyue Bao, PhD Dr. Bao develops machine learning frameworks integrating multi-dimensional genomics, proteom- ics, metabolomics, and microbiome data for the discovery of novel drug targets, in combination with mining biological patterns from large databases to provide guidance on the drug discovery process, through investigating front line patients’ clinical response and their genomics/metabolism/microbe signatures with a strong focus on immunotherapy. Study Sections • Reviewer, Pilot Grant Study Section, UPMC Hillman Cancer Center, June 2020 Professional Affiliations and Society Memberships • Member, Society for Immunotherapy of Cancer, 2016-present • Member, International Society for Computational Biology, 2020-present • Member, The American Association of Immunologists, 2020-present Editorships • Reviewer, The American Medical Informatics Association, 2016-present • Reviewer, Multiple journals (Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, Oncology Research), 2019-present Honors and Awards • Recipient, Hillman Senior Faculty Fellow for Innovative Cancer Research, UPMC Hillman Cancer Center, 2020

Franklin A. Bontempo, MD Dr. Bontempo is a hematologist and attending physician at several UPMC facilities, providing on-call services for hospital consultations and also seeing patients at the Hillman Cancer Center. Addition- ally, he serves as the Medical Director of the coagulation laboratory at The Institute For Transfusion Medicine, the Associate Director of the Hemophilia Center of Western Pennsylvania, and on the advisory board of the Hemostasis and Vascular Biology Institute. In these roles, he sees patients for consultation of coagulation issues at the outpatient clinic of The Institute for Transfusion Medicine, provides coagulation interpretations of blood samples that are processed through the coagulation laboratory from across the tri-state region in assisting other physicians with test result interpretations, diagnoses, and treatment plans. He specializes in the treatment of myeloproliferative disease, a bone marrow disorder that can evolve into leukemia. A prominent speaker in local, regional, and national forums, Dr. Bontempo is an educator and mentor to the many medical students, residents, and fellows that participate in the Coagulation Rotation which has become a standard course offer- ing of the School of Medicine at the University of Pittsburgh. Advisory Committee Memberships and Leadership Positions • Director, Coagulation Rotation, University of Pittsburgh School of Medicine, 1985-present • Director, Cascade Pittsburgh Coagulation Seminar, 2009-present Professional Affiliations and Society Memberships • Member, American Society of Hematology, 1990-present • Member, International Liver Transplant Society, 2014-present • Faculty Member, Alpha Omega Alpha Honor Medical Society, 2014-present Editorships • Reviewer, Multiple journals, 2018-present

Department of Medicine 2020 Annual Report Major Lectureships and Seminars • Presenter, Grand Rounds, UPMC Mercy, Pittsburgh, PA, 2019 • Presenter, Grand Rounds, UPMC Shadyside, Pittsburgh, PA, 2019 • Presenter, UPMC Passavant Conference, Pittsburgh, PA, 2019

Michael Boyiadzis, MD, MHSc Dr. Boyiadzis’s research focuses on natural killer-cell biology, immunotherapy, and hematopoeitc stem cell transplantation. Study Sections • Scientific Reviewer, Experimental Transplantation - GVHD and GVL, American Society of Hematology, 48th Annual Meeting, Orlando, FL, December 2019 • Study Co-Chair, Chronic Graft-Versus-Host Disease Relapse and Risk Factor Analyses, Center for International Blood and Marrow Transplant Research (CIBMTR), 2006-present • Chair, Immunotherapy Guidelines for Acute Leukemia, Society for Immunotherapy of Cancer, 2014-present Professional Affiliations and Society Memberships • Member, American Society of Clinical Oncology, 2001-present • Member, American Society of Hematology, 2002-present • Member, American College of Physicians, 2003-present • Member, Society for Immunotherapy of Cancer (SITC), 2018-present • Editorships • Ad hoc reviewer, Multiple journals, 2006-present • Editorial Board, Oncology Research, 2015-present

Adam M. Brufsky, MD, PhD Dr. Brufsky’s research interests include novel clinical therapeutics for breast cancer, bone-breast cancer interactions and therapeutics, molecular biology of metastatic breast cancer, and novel management strategies for metastatic breast cancer. Study Sections • Leader, Experimental Therapeutics 2 Study Section, Department of Defense Congressionally Mandated Breast Cancer Research Program, 2009-present • Leader, Postdoctoral Fellowship Study Section, Susan G. Komen, 2010-present Advisory Committee Memberships and Leadership Positions • Member, Breast Committee, National Surgical Adjuvant Breast and Bowel Project, 2006-present • Co-Chair and Moderator, Chemotherapy Foundation, 37th Annual Chemotherapy Foundation Symposium, New York, NY, 2019 • Moderator, Physicians’ Education Resources (PER), 37th Annual Miami Breast Cancer Conference, Miami, FL, 2020 Editorships • Reviewer, Multiple journals, 1998-present • Editorial Board, Journal of Clinical Oncology, 2010-present • Editorial Board, World Journal of Orthopaedics, 2010-present • Editorial Board, Journal of Bone Oncology, 2012-present Major Lectureships and Seminars • Invited Lecturer, Trinity Medical Center, Trinity Medical Center Tumor Board, Trinity, FL, August 2019 • Invited Lecturer, Mayo Clinic Jacksonville, Mayo Clinic Oncology Rounds, Jacksonville, FL, August 2019

Division of Hematology/Oncology RESEARCH

• Invited Lecturer, NYU Winthrop Medical Center, 4th Annual Breast Health Symposium, Garden City, NY, September 2019 • Invited Lecturer, European Society for Clinical Oncology (ESCO), ESCO Annual Meeting, Barcelona, Spain, September 2019 • Invited Lecturer, Malaysian Oncology Society, Penang, Malaysia, October 2019 • Invited Lecturer, Chemotherapy Foundation, 37th Annual Chemotherapy Foundation Symposium, New York, NY, November 2019 • Invited Lecturer, Northwell Hospital, Lake Success, NY, February 2020 • Invited Lecturer, John Theurer Cancer Center, 2019 SABCS Review, Hackensack, NJ, February 2020 • Invited Lecturer, Physicians’ Education Resources (PER), 37th Annual Miami Breast Cancer Conference, Miami, FL, March 2020

Ronald J. Buckanovich, MD, PhD Dr. Buckanovich’s research interests are ovarian cancer stem cells, mesenchymal stem cells, tumor vascular niche, ovarian cancer therapeutics, and ovarian cancer clinical trials. Study Sections • Standing member, NIH/NCI Tumor microenvironment study section, 2019-2025 Advisory Committee Memberships and Leadership Positions • Member, Scientific Advisory Committee, Ovarian Cancer Research Fund, 2013-present • Member, Research Executive Advisory Committee, UPMC Hillman Cancer Center, 2017-present • Member, Scientific Advisory Committee, Immune Transplant and Therapy Center (ITTC), UPMC, 2017-present

• Chair, Education Funds Committee, Womens Cancer Photo Research Center, 2018-present Dr. Buckanovich was named a HIllman • Chair, Womens Cancer Research and Education Funds Fellow for Innovative Developmental Committee, Magee-Womens Research Institute (MWRI), Cancer Research in 2019. 2018-present • Co-Director, Cancer Biology Program, Magee-Womens Research Institute (MWRI), 2018-present • Member, Education Committee, UPMC Hillman Cancer Center, 2018-present • Member, Translational and Clinical Research Subcommittee, UPMC Hillman Cancer Center, 2018-present • Member, Internal Advisory Committee, Basic and Translational Reproductive Health Training Program, Magee-Womens Research Institute (MWRI), 2019-present • Member, GETV Core Review Committee, Magee-Womens Research Institute (MWRI), 2020-present • Member, Internal Advisory Board, UPMC Hillman Cancer Center SPORE Head and Neck, 2020-present Professional Affiliations and Society Memberships • Member, American Society of Clinical Investigation, 2012-present • Member, Department of Defense Ovarian Cancer Academy, 2013-present Editorships • Reviewer, Multiple journals (Cancer Biology and Therapy, Cancer Research, Clinical Cancer Research, Gynecologic Oncology, Journal of Clinical Oncology, Journal of Laboratory Investigation, Cancer Epidemiology and Biomarkers, Translational Research Medicine, Cell Cycle, Journal of Clinical Investigation, Journal of Experimental Medicine, JAMA-Onc),

Department of Medicine 2020 Annual Report 2006-present • Editorial Board, The Journal of Translational Research, 2009-present • Editorial Board, Gynecologic Oncology, 2017-present • Editorial Board, Cancers, 2019-present Major Lectureships and Seminars • Lecturer, American Society of Clinical Oncology (ASCO), ASCO Annual Meeting, Chicago, IL, 2019 • Lecturer, Webinar, SHARE Cancer Support, SHARE Webinar, Pittsburgh, PA, December 2019 Honors and Awards • Hillman Fellow for Innovative Developmental Cancer Research, UPMC Hillman Cancer Center, 2019

Melissa A. Burgess, MD Dr. Burgess is a clinical and translational investigator in sarcoma with active involvement in current clinical trials. Her research efforts include a collaboration with Dr. Lisa Butterfield, former director of the Immune Monitoring and Cellular Products Laboratory (IMCPL) at the University of Pittsburgh Cancer Institute (UPCI), and a focus on analyzing peripheral blood samples from SARC 028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas. Planned analyses include the assessment of T-cell populations and other immune markers in the circulation with correlation to tumor response to pembrolizumab. Results will be combined with the other correlative studies from SARC 028, including correlation of response with PD-L1 status and immune monitoring within the tumor. These transitional studies should offer unique insights into the biology of PD-1 blockade in sarcoma. Dr. Burgess serves as local Principal Investigator for SARC 028, a clinical trial through Sarcoma Alliance for Research through Collaboration (SARC), of which the University of Pittsburgh is a participating institution. Results of soluble checkpoints and cytokines and other serum inflammatory markers were presented as a poster at ASCO-SITC in Feb- ruary 2017. Updated efficacy results and tumor PD-L1 analyses were presented at the ASCO Annual Meeting in June 2017 by Dr. Burgess during the Sarcoma Oral Abstract Session. Efficacy results and biomarker analyses were submitted for publication to Lancet Oncology in May 2017 with Dr. Burgess as the second author. Advisory Committee Memberships and Leadership Positions • Member, Protocol Review Committee B, UPMC Hillman Cancer Center, 2014-present • Member, Fellowship Clinical Competency and Program Evaluation Committees, University of Pittsburgh Hematology-Oncology Fellowship, 2015-present • Member, Fundraising Committee, Pittsburgh Cure Sarcoma, 2015-present • Member and Co-Founder, Pittsburgh Sarcoma Alliance for Research through Collaboration, 2017-present • Member, Quality and Safety Committee, UPMC, 2018-present • Member, Hospital Readmissions Committee, UPMC, 2019-present Professional Affiliations and Society Memberships • Member, Sarcoma Alliance for Research through Collaboration, 2015-present • Member, Connective Tissue Oncology Society, 2015-present • Member, American Society of Clinical Oncology, 2015-present • Member, American Association for Cancer Research (AACR), 2017-present • Member, National LeioMyoSarcoma Foundation, 2017-present • Member, Epithelioid Hemangioendothelioma Foundation, 2017-present • Member, Pittsburgh Cure Sarcoma, 2019-present Editorships • Reviewer, Multiple journals, 2016-present

Division of Hematology/Oncology RESEARCH

Major Lectureships and Seminars • Invited Lecturer, Pittsburgh Sarcoma Alliance for Research through Collaboration (PSaRC) Symposium, Pittsburgh, PA, September 2019

Timothy F. Burns, MD, PhD Dr. Burns’s research interests include the development of targeted therapies for KRAS-mutant NS- CLC as well as novel strategies to overcome resistance to targeted therapies for EGFR-mutant and MET-altered NSCLC. The first line of research in his laboratory is the role of the epithelial-mesenchymal transition transcription factor TWIST1 in oncogene-driven NSCLC. They have demonstrated that TWIST1 is essential for lung tumorigenesis for KRAS- mutant, EGFR-mutant and MET-mutant, and that amplified NSCLC and TWIST1 overexpression leads to resistance to EGFR- and MET- targeted therapies. They are examining the mechanism(s) through which this occurs and developing therapeutic combinations to overcome this resistance. Dr. Burns’s lab is also exploring whether targeting the HGF-MET-TWIST1 pathway can be an effective strategy for preventing or treating lung brain metastases. Importantly, researchers have developed a novel TWIST1 inhibitor that serves as a tool compound for their therapeutic studies and serves as the basis for the current drug screening efforts in order to develop a clinical TWIST1 inhibitor. His lab’s second line of research is the study of mechanisms of resistance to the Hsp90 inhibitor, ganetespib, in KRAS-mutant NSCLC and to use this data to develop a rationally designed Hsp90 inhibitor combination for the clinic that can prevent or overcome resistance. They have recently demonstrated that the ERK-p90RSK-CDC25C pathway plays a key role in resistance to Hsp90 inhibitors through bypass of a G2/M checkpoint. They have found several Hsp90 inhibitor drug combinations that may be effective in KRAS-mutant NSCLC, and that they hope to test in early phase trials soon. Finally, they are actively engaged in exploring the role of ERK inhibitor combinations in targeting KRAS- and EGFR-mutant NSCLCs both in the de novo and acquired-resistance setting. Study Sections • Reviewer and Study Section Member, CMRF, 2014-present • Reviewer and Study Section Member, American Lung Association, 2015-present • Reviewer, British Lung Foundation, 2016-present • Reviewer and Study Section Member, LUNGevity Foundation, 2016-present • Reviewer and Study Section Member, Genomic Applications Partnership Program, GenomeCanada, 2016-present • Ad hoc Reviewer, MRC New Investigator Research Grant, 2017-present • Reviewer and Study Section Member, Tumor Progression and Metastasis Section, National Cancer Institute, 2018-present • Reviewer and Study Section Member, Clinical and Translational R21 and OMNIBUS R03, National Cancer Institute, 2020-present • Reviewer and Study Section Member, Physician Scientist Fellowship Competition, Doris Duke Charitable Foundation, 2020-present • Reviewer, Wellcome Trust, DBT India Alliance, 2020 Advisory Committee Memberships/Leadership Position • Advisory Board Member, Blueprint Medicines, November 2019 • Member, Hematology/Oncology Fellowship Curriculum Committee, UPMC Hillman Cancer Center, 2012-present • Member, Protocol Review Committee, UPMC, 2016-present • Associate Program Director for Research, Hematology/Oncology Fellowship Program, UPMC Hillman Cancer Center, 2019-present Professional Affiliations and Society Memberships • Member, American Medical Association, 1998-present • Member, American Association for Cancer Research, 1998-present • Member, American Association of Clinical Oncology, 2008-present 28

Department of Medicine 2020 Annual Report • Member, International Association for the Study of Lung Cancer, 2010-present • Member, Eastern Cooperative Oncology Group, 2012-present • Member, Alliance for Clinical Trials in Oncology, 2013-present Editorships • Reviewer, Multiple journals, 2013-present • Associate Editor, Cancer Biology & Therapy, 2015-present • Breaking Insights Editor, Cancer Research, 2017-present • Associate Editor, Cancer Molecular Targets and Therapeutics Section, Frontiers in Oncology, 2019-present • Editorial Board, Clinical Lung Cancer, 2020-present Major Lectureships and Seminars • Speaker, OncLive, State of the Science Summit, Pittsburgh, PA, September 2019 • Discussant, ASCO Clinical Science Symposium, ASCO Annual Meeting, Virtual, May 2020 Honors and Awards • Recipient, Next Gen Innovators, HemOnc Today, 2019

Lan G. Coffman, MD, PhD Dr. Coffman’s research focuses on understanding and targeting the cancer supporting stromal tissues that are critical to the survival, growth, and spread of ovarian cancer. Specifically, Dr. Coffman’s lab studies a critical non-malignant component of the ovarian cancer microenvironment, the carcinoma-associated mesenchymal stem cell (CA-MSC). CA-MSCs are stromal progenitor cells, which significantly increase cancer growth, enrich the cancer stem cell pool and increase chemotherapy resistance. The lab studies how CA-MSCs are formed and develop tumor supporting properties. The lab also focuses on identifying important tumor cell:CA-MSC interactions which mediate CA-MSC’s pro-tumorigenic functions and have potential for translation into new therapeutic targets. Additionally, the lab studies how CA-MSCs impact the development of ovarian cancer metastasis and the metastatic microenvironment. The ultimate goal of this research is to translate novel laboratory findings into powerful therapeutic approaches for the prevention and treatment of ovarian cancer. Study Sections • Ad hoc reviewer, Ovarian Cancer Research Program, DOD CDMRP Peer Review Committee, September 2019 • Member, YIA, American Society of Clinical Oncology, February 2020 • Ad hoc reviewer, SBIR-STTR, National Institutes of Health, March 2020 • Ad hoc reviewer, NCI-J, National Institutes of Health, June 2020 Honors and Awards • Recipient, Allen Humphrey Excellence in Mentoring Award, UPMC Hillman Cancer Center, 2019-2020 • Recipient, Hillman Fellow for Innovative Developmental Cancer Research, UPMC Hillman Cancer Center, 2019-2020 • Recipient, Junior Scholar Award in Basic Cancer Research, UPMC Hillman Cancer Center, 2019-2020

Diwakar Davar, MD Dr. Davar’s initial work evaluated survival among patients with stage IV melanoma in various coun- tries. It was noted that despite similar access to treatment, overall survival in stage IV patients differed by country. These results, presented at Perspectives in Melanoma XV, provided the first hint that melanoma biology differed by geography. Other authors have since demonstrated that this is secondary to geographic variations in molecular epidemiology (BRAF, NRAS, CKIT mutational inci- 29

Division of Hematology/Oncology RESEARCH

dence). A retrospective single-institution analysis of melanoma patients treated with HD IL-2 was subsequently performed. This experience was initially presented at ASCO 2013 and suggested that administration of HD IL-2 in a non-ICU setting without pressor and/or ventilator support to max- imize dose intensity did not compromise outcomes. Updated analyses with 1-/2-/3- year survival data and mutational information have been published. Another area of research has been in translational cancer immunotherapy and early-phase clinical trials. He is working with Drs. Zarour and Kirkwood to coordinate the clinical care and translational research of a novel trial combining PD-1 inhibitor Pembrolizumab with immunomodulatory PEG-IFN. Preliminary results were presented at ASCO 2015. Final results have been collated along with correlative analyses and are pending publication. More recently, in collaboration with Bristol-Myers Squibb and based on published findings by Dr. Zarour’s laboratory, Dr. Davar contributed to the development and implementation of a first-in-human study of TIGIT mAb (BMS-986207) singly and in combination with Nivolumab that is presently in active accrual and for which he is the institutional Principle Investigator. He is also the institutional Principle Investigator for first-in-human studies of GITR mAb (TRX-518), pegylated arginase (AEB1102), and IDO inhibitor (BMS-986205). Based on emerging data implicating intestinal dysbiosis in mediating non-response to PD-1 blockade, Dr. Davar developed, collaboratively with Dr. Zarour, a protocol evaluating fecal microbiota transplant in combination with PD-1 blockade to treat PD-1 non-responders. This first-in-human study was selected for funding by Merck to support the clinical costs and is IRB approved. In the context of this trial, Dr. Davar is working in close collaboration with Dr. Zarour and co-investigators Drs. Methé and Benos, for the performance of the correlative studies in the context of the new clinical trial with fecal transplant microbiota and pembrolizumab in PD-1 refractory melanoma patients. Study Sections • Abstract Reviewer, Society for Immunotherapy of Cancer, 2019 • Member, Study Section, UPMC, Department of Medicine Research Day, Pittsburgh, PA, 2019 Advisory Committee Memberships and Leadership Positions • Member, Protocol Review Committee B, UPMC Hillman Cancer Center, 2014-present • Member, Scientific Advisory Board, Vedanta Biosciences, 2019-2020 • Member, Scientific Advisory Board, Checkmate Pharmaceuticals, 2019-2020 • Member, Scientific Advisory Board, Shionogi, 2019-2020 Professional Affiliations and Society Memberships • Member, Pennsylvania Medical Society, 2009-present • Member, American Society of Clinical Oncology, 2011-present • Member, Allegheny County Medical Society, 2011-present • Member, American Association for Cancer Research, 2014-present Editorships • Editorial Board, Clinical GU Oncology, 2014-present • Editorial Board, Cancer Medicine, 2015-present • Editorial Board, Case Reports in Internal Medicine, 2015-present • Editorial Board, Journal for ImmunoTherapy of Cancer, 2016-present • Editorial Board, Cancer, 2018-present • Editorial Board, Journal of Clinical Oncology, 2018-present Major Lectureships and Seminars • Invited Speaker, Microbiome Movement Oncology Response Summit, July 2019 • Invited Speaker, Best of ASCO Review, UPMC Hillman Cancer Center, September 2019 • Invited Speaker, UPMC Symposium on Cancer Genomics and Immunology, UPMC Hillman Cancer Center, October 2019 • Invited Speaker, Mini-Symposium on Precision Oncology, UPMC Hillman Cancer Center, October 2019

Department of Medicine 2020 Annual Report • Invited Speaker, Microbiome Connect, Skin and Human Virtual Conference, June 2020 Honors and Awards • Recipient, 2020 Top Physicians Under 40 Award, Pennsylvania Medical Society, April 2020

Laura M. De Castro, MD, MHSc Dr. De Castro’s research interests include sickle cell-related psychosocial issues, pulmonary hypertension, drug development, and pregnancy and obstetric outcomes. She has developed research hypotheses, designed studies, and applied for extramural support as well as managed data collec- tion and research-related clinical trials. Dr. De Castro has also implemented the planning and development of phase II and III and translational research clinical trials. Study Sections • Ad hoc grant reviewer, American Society of Hematology, 2012-present • Ad hoc grant reviewer, National Heart, Lung, and Blood Institute (NHLBI), 2012-present • Ad hoc grant reviewer, Agency for Healthcare Research and Quality (AHRQ), 2012-present • Ad hoc grant reviewer, FDA Office of Orphan Products Development, 2012-present Advisory Committee Memberships and Leadership Positions • Career Mentor, American Society of Hematology Minority Medical Student Award Program, 2008-present • Member, Advocacy Leadership Program, American Society of Hematology, 2010-present • Member, Executive Committee, Study to Compare bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease, 2012-present • Clinical Chief, Benign Hematology Program, University of Pittsburgh Medical Center, 2014-present • Co-Director, Sickle Cell Disease Module, University of Pittsburgh, 2014-present • Member, Clinical Competency Evaluation and Selection Committee, UPMC Hematology/ Oncology Fellowship Program, 2014-present • Member, Diversity and Inclusion Committee, Department of Medicine, University of Pittsburgh, 2015-present • Member, Committee on Practice, ASH, 2016-present • ASH Liaison/Representative, Society of Hospital Medicine Society, 2017-present • Member, Committee for Excellence in Cancer Education and Training, UPMC Hillman Cancer Center, 2017-present • Member, Recruitment and Retention Subcommittee, ASH, 2017-present • Member, SCD Health Care Professional Education and Training (HPET) workgroup, ASH, 2017-present • Member, Sickle Cell Disease Executive and Incubator Committees, Vascular Medicine Institute, 2017-present • Member, Sickle Cell Guidelines Development Committee, ASH, 2017-present • Votin Member, Data and Safety Monitor Board, The Sickle Cell Trevor Thompson Transition Project, 2018-present • Consultant, Pfizer, 2019-2020 • Consultant, Novartis, 2019-2020 • Consultant, Global Blood Therapeutics, 2019-2020 Professional Affiliations and Society Memberships • Member, American Society of Hematology, 1996-present • Founding Member, Sickle Cell Adult Provider Network (SCAPN), 2004-present • Inaugural Member, ASH Ambassador Program, 2017-present • Member, European Hematology Association, 2017-present

Division of Hematology/Oncology RESEARCH

• Member, American Heart Association, 2017-present • Member, Society of Hospital Medicine, 2017-present Editorships • Editor, Multiple journals, 1996-present Major Lectureships and Seminars • Lecturer, X Congreso International de Hematologia, Dominican Republic, July 2019 • Presenter, Mayo Clinic, 29th Annual Mayo Clinic Hematology and Oncology Review, Amelia Island, FL, August 2019

Albert D. Donnenberg, PhD Dr. Donnenberg’s research interests focus on cancer stem cells and their role in tumorigenesis, invasion, and metastasis. He views stemness in epithelial cancers as a state rather than the property of a unique cell type, with individual tumor cells transiting in and out of the cancer stem cell state. According to this interpretation, the more aggressive the tumor, the more cells exist in the stem-like state at any given time. In xenograft models, tumorigenicity is dependent on this state, which can be recognized by the expression of a number of markers that are associated with normal mesenchymal stem cells. In epithelial cancers, mesenchymal markers are associated with invasion, immune suppression and drug resistance. Taken together, the cancer stem cell paradigm has converged with the bidirectional epithelial to mesenchymal/mesenchymal to epithelial transitions (EMT/MET). The Donnenbergs’s working hypothesis is that neoplastic transformation and conferral of invasiveness are often independent processes, the later on wound-healing signals present in the tumor microenvironment. Thus, a carcinoma in situ and an invasive carcinoma may share a common mutational profile but exist in very different microenvironments. Since the environment is controlled to a large part by tissue macrophages and stromal cells, which interact at close distances with tumor cells, their research efforts are currently aimed at understanding how polarization toward wound healing influences tumor cell behavior, and how tumor cells influence polarization. Advisory Committee Memberships and Leadership Positions • Director, UPMC Hillman Cancer Center Flow Cytometry Facility, 1998-present • Director, Hematopoietic Stem Cell Laboratory, UPMC Hillman Cancer Center, 1998-present • Laboratory Director, Hematopoietic Stem Cell Laboratory, Children’s Hospital of Pittsburgh, 2002-present • Scientific Advisory Board, Beckman Coulter, 2008-present • Director of Cellular Therapy, UPMC Aesthetic Plastic Surgery Center, 2010-present • Member, Joint Task Force on Stem Call/Fat Grafting, ASAPS/ASPS, 2010-present • Operating Committee, Michigan/Pittsburgh/Wyss Regenerative Medicine Consortium, 2016-present • International Representatives Board, Eurasian Hematology Society, 2017-present • Consultant, Point of Care Cell Processing Service Line, UPMC Salvator Mundi International Hospital, Rome, Italy, 2018-present • Vice Chair, Board of Trustees, Contemporary Craft, Pittsburgh, PA, 2019-present Professional Affiliations and Society Memberships • Member, International Society for Experimental Hematology, 1984-present • Member, American Association of Immunologists, 1985-present • Member, American Society of Hematology, 1989-present • Member, The Clinical Immunology Society, 1991-present • Member, Association of Medical Laboratory Immunologists, 1992-present • Member, International Society for Hematotherapy and Graft Engineering, 1992-present • Member, American Society for Blood and Marrow Transplantation, 1993-present • Member, International Society for Analytical Cytology, 1999-present

Department of Medicine 2020 Annual Report • Member, The Transplantation Society, 2005-present • Member, International Society for Stem Cell Research, 2005-present • Ambassador, Eurasian Hematology Oncology Congress, 2018-present Editorships • Ad hoc reviewer, Multiple journals, 1989-present • Editorial Board, Clinical and Applied Immunology Reviewer (CAIR), 2000-present Major Lectureships and Seminars • Invited Speaker, Session Chair, Eurasian Society of Hematology and Oncology, Istanbul Turkey, October 2019

Kathleen Dorritie, MD Dr. Dorritie’s research centers on the development of early phase clinical trials in hematologic malignancies, in particular lymphoid malignancies. Previously, she had conducted laboratory research focused on the development of novel therapeutic agents for acute myeloid leukemia. A member of the HCC Cancer Therapeutics Team, she has played a key role in the development of the chimeric antigen receptor (CAR) T-cell program and serves as lead or co-investigator on several clinical studies of CAR T-cell therapy at UPMC. Dr. Dorritie has also been playing a key role in the development of a stem cell transplant program for patients with hemoglobinopathies, including sickle cell disease. Dr. Dorritie teaches a number of didactic lectures for both medical students and fellows and serves as a block director for the MS2 Hematology course. And, she teaches clinically on the leukemia, stem cell transplant, and malignant hematology services. Professional Affiliations and Society Memberships • Member, American Society of Hematology, 2011-present • Member, American Society of Clinical Oncology, 2011-present • Member, American Association for Cancer Research, 2011-present • Member, American Society for Blood and Marrow Transplantation, 2012-present Editorships • Reviewer, Multiple journals, 2015-present Major Lectureships and Seminars • Lecturer, UPMC Shadyside, Medicine Grand Rounds, October 2019 • Lecturer, Leukemia & Lymphoma Society, Pennsylvania Blood Cancer Conference, November 2019 • Lecturer, Arnold Palmer Cancer Center, Journal Club, December 2019

Jan Drappatz, MD Dr. Drappatz’s primary areas of research involve the development of novel agents for the treatment of glioblastoma, central nervous system lymphoma, and other primary and metastatic brain tumors. He has served as the principal investigator of numerous clinical trials to identify effective therapies for patients with brain tumors and other neurological ailments associated with cancer. He is currently leading several clinical trials involving immune therapy and new targeted therapies as well as treatments targeting tumor vasculature. His work has been presented nationally and inter- nationally and has resulted in well over 150 manuscripts, book chapters, and abstracts. He serves as a peer reviewer for multiple journals. Study Section • Abstract Reviewer, Organizing Committee, Society of Neuro-Oncology Meeting, New Orleans, LA, 2017-present • Co-Chair, Neuro-Oncology Section, American Neurological Association, 2019 ANA Annual Meeting, St. Louis, MO, 2019 Advisory Committee Memberships and Leadership Positions

Division of Hematology/Oncology RESEARCH

• Neuro-Oncology Committee, Alliance for Clinical Trials in Oncology, 2012-present • Director, Neuro-Oncology Fellowship Program, UPMC, 2017-present • Director, Neuro-Oncology, Via Oncology / Elsevier Pathways, 2019-present • Advisory Board, Agios, 2020-present Professional Affiliations and Society Memberships • Member, Society for Neuro-Oncology, 2005-present Editorships • Reviewer, Multiple journals (Journal of Neuro-Oncology, Neuro-Oncology, Expert Review of Anti-Cancer Therapy, Frontiers Oncology, Cancer Chemotherapy and Pharmacology, Frontiers Neurology), 2007-present Honors and Awards • Honoree, Best Doctors, Pittsburgh Magazine, 2009-present • Recipient, Top Doctors, Castle Connolly, 2012-present

Leisha A. Emens, MD Dr. Emens was recruited to the UPMC Hillman Cancer Center as Director of Translational Immuno- therapy for the Women’s Cancer Research Center at Magee Women’s Hospital, and as Co-Leader of the Cancer Immunology and Immunotherapy Research Program. In these leadership roles, she will promote interdisciplinary translational and clinical cancer immunotherapy research and oversee the strategic expansion, integration, and operations of early phase immunotherapy trials at HCC and Magee Women’s Hospital. Dr. Emens will work with investigators in the HCC research programs, including Cancer Therapeutics, Cancer Immunology and Immunotherapy, Cancer Biology, Genome Instability, and Cancer Epidemiology and Prevention to develop novel clinical and translational immune-based investigations for the detection, screening, prevention, and treatment of breast and gynecologic cancers. She will work closely with members of the Breast Disease Team to develop strong multi- and inter-disciplinary treatment approaches to breast cancer care. She will be co-PI of the UPMC Hillman Cancer Center Breast SPORE, planned for submission in the next 12 months. She will also participate in other team science grants in the Women’s Cancer Research Center and the Cancer Immunology and Immunotherapy Program. She will actively participate as a member of the NSABP Foundation, and will serve as UPMC Hillman PI for the Translational Breast Cancer Research Consortium (TBCRC), both of which are clinical translational research groups that test innovative, scientifically-driven therapeutic strategies with deeply rooted biomarker studies through cross-institutional collaborations. She will also work with the Breast and Gynecologic Disease Teams to develop investigator-initiated trials that collaboratively evaluate novel therapies that target common elements of disease biology in women’s cancers. Study Sections • Judge, President’s Award, Society for Immunotherapy of Cancer, 2018-present • Member, Young Investigator’s Award Review Committee, Society for Immunotherapy of Cancer, 2018-present • Review Committee, Basic Cancer Research Grants, American Association for Cancer Research, 2018-present • Selection Committee, Outstanding Investigator Award for Breast Cancer Research, American Association for Cancer Research, 2018-present • Selection Committee, Outstanding Investigator Award for Breast Cancer Research, American Association for Cancer Research, 2018-present • Co-Chair, Organizing Committee, Society for Immunotherapy of Cancer Winter School for Cancer Immunotherapy, 2018-present • Co-Chair, Publications Committee, Society for Immunotherapy of Cancer, 2018-present • Education and Training Committee, Society for Immunotherapy of Cancer, 2018-present • Abstract Review Committee, Society for Immunotherapy of Cancer (SITC), 2019-present

Department of Medicine 2020 Annual Report • Exceptional Project Grant Review Committee, Breast Cancer Alliance, 2019-present • Reviewer, Pilot Grants, UPMC Hillman Cancer Center, 2019-present Advisory Committee Memberships and Leadership Positions • Organizing Committee, Translational Research Cancer Centers Consortium (TRCCC), March 2020 • Scientific Advisory Board, Molecuvax, 2016-present • TiMIOS Scientific Advisory Board, Society for Immunotherapy of Cancer, 2017-2019 • Selection Committee, Presidential YIA Award, Presidential Session, Society for Immunotherapy of Cancer (SITC), National Harbor, MD, 2017-2019 • External Advisory Board, Vanderbilt-Ingram Cancer Center Breast SPORE, 2017-present • Margetuxmab Advisory Council, Macrogenics, 2017-present • Scientific Advisory Board, eTHeRNA, 2017-present • Scientific Advisory Board, Bayer Pharmaceuticals, 2017-present • Scientific Advisory Board, Replimune, 2017-present • Co-Chair, Strategic Vision Committee in Cancer Immunotherapy, UPMC Hillman Cancer Center, 2018-present • Co-Leader, Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, 2018-present • External Advisory Board, Fred Hutchinson Cancer Research Center Andy Hill Cancer Research, 2018-present • External Advisory Board, Baylor College of Medicine Breast SPORE, 2018-present • Member, Academic Incentive Plan Committee, UPMC Hillman Cancer Center, 2018-present • Member, Executive Committee, Cancer Immunology Training Program, University of Pittsburgh, 2018-present • Member, Research Executive Advisory Committee, UPMC Hillman Cancer Center, 2018-present • Scientific Advisory Board, Roche, 2018-present • Stakeholder’s Council, Society for Immunotherapy of Cancer, 2018-present • Advisory Board, Silverback, 2019-present • Advisory Board, Chugai, 2019-present • Breast Cancer Working Group Committee, NRG Oncology, 2019-present • External Advisory Board, Breast SPORE, MD Anderson Cancer Center, Houston, TX, 2019-present • External Advisory Board, SPORE in Radiation and Immunotherapy, Weill Cornell Medical College, New York, NY, 2019-present • Immunotherapy and Immune Modulation Committee, NRG Oncology, 2019-present • Member, Facilities and Shared Equipment Committee, UPMC Hillman Cancer Center, 2019-present • Nominating Committee, Translational Research Cancer Centers Consortium (TRCCC), 2019-present • Board of Directors Vice President/President-Elect, Society for Immunotherapy of Cancer, 2020-present • Executive Council, Society for Immunotherapy of Cancer, 2020 • Nominating Committee, Society for Immunotherapy of Cancer, 2020 • Co-Chair, Breast Cancer Immunotherapy Guidelines Committee, Society for Immunotherapy of Cancer (SITC), 2020 Professional Affiliations and Society Memberships • Member, American College of Physicians (ACP), 1995-present • Member, American Society for Clinical Oncology (ASCO), 1998-present • Member, American Association for Cancer Research (AACR), 1999-present

Division of Hematology/Oncology RESEARCH

• Member, Society for the Immunotherapy of Cancer (SITC), 2001-present • Member, Eastern Cooperative Oncology Group (ECOG), 2003-present • Member, Federation of Clinical Immunology Societies (FOCIS), 2017-present • Member, European Society for Medical Oncology (ESMO), 2018-present • Member, National Adjuvant Breast and Bowel Project (NSABP), 2018-present • Member, NRG Oncology Cooperative Group, 2019-present Editorships • Reviewer, Multiple journals, 2002-present • Editorial Board, Annals of Translational Medicine, 2012-present • Editorial Board, Journal for the Immunotherapy of Cancer, 2013-present • Editorial Board, Cancer Research, 2013-present • Editorial Board, Breast Journal, 2015-present • Section Editor, Clinical Trials Monitor, Journal for Immunotherapy of Cancer, 2015-present Major Lectureships and Seminars • Invited Speaker, Gordon Research, Conference on Hormone-Dependent Cancers, Sunday River, ME, August 2019 • Invited Speaker, Alfred Benzon Foundation, Benzon Symposium: Targeting Breast and Ovarian Cancers, Copenhagen, Denmark, September 2019 • Invited Speaker, European Society for Medical Oncology, Metastatic Breast Cancer Session, Barcelona, Spain, September 2019 • Invited Speaker, European Society for Medical Oncology, Industry Satellite Symposium, Barcelona, Spain, September 2019 • Lecturer, Minisymposium on Precision Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, October 2019 • Invited Speaker, 21st Century C.A.R.E., 31st Annual Fall Foliage Cancer Conference, Asheville, NC, October 2019 • Invited Speaker, Society for Immunotherapy of Cancer, Annual SITC Primer on Immunotherapy, Washington, DC, November 2019 • Invited Speaker, Physician’s Education Resource, 4th Annual International Congress on Immunotherapies in Cancer, New York, NY, December 2019 • Invited Speaker, Bridge 2019, Immunotherapy Bridge Conference, Naples, Italy, December 2019 • Invited Speaker, Japanese Physician Forum, San Antonio, TX, December 2019 • Invited Speaker, MEDSCAPE, MEDSCAPE Education Spotlight, December 2019 • Invited Speaker, PeerView Institute for Education, San Antonio, TX, December 2019 • Invited Speaker, NRG Oncology, NRG Fall Meeting Workshop, Houston, TX, January 2020 • Lecturer, San Antonio Breast Cancer Symposium Update, Pittsburgh, PA, UPMC Hillman Cancer Center, February 2020 • Session Organizer, Cancer Immunotherapy Intersections, UPMC Hillman Cancer Center, 31st Annual Scientific Retreat, 2019-present Honors and Awards • Hillman Scholar for Innovative Cancer Research, Hillman Cancer Center, 2019 • Hillman Scholar for Team Science, Hillman Cancer Center, 2019 • Laura Ziskin Prize in Translational Research, Stand Up to Cancer, 2020

Robert J. Ferguson, PhD Dr. Ferguson’s research interests include the cognitive-behavioral treatment of late cognitive effects of cancer, cancer survivorship, and palliative care. He focuses on the development of cognitive-behavioral therapies for cancer-related cognitive impairment (CRCI) and designing and carrying out randomized clinical trials to evaluate treatments. Funding for this work includes grants from the National Cancer Institute, NIH Office of Research on Women’s Health, and the Lance Armstrong 36

Department of Medicine 2020 Annual Report Foundation. Advisory Committee Memberships and Leadership Positions • Member, Rehab Steering Committee, UPMC Hillman Cancer Center, 2017-present • External Advisor, K-Award for Medical Oncologists, University of Rochester, Wilmot Cancer Institute, 2018-present • Member, International Cognition and Cancer Task Force, 2019-present • Member, Behavioral Health Smart Technologies, University of Pittsburgh, 2019-present Professional Affiliations and Society Memberships • Member, American Psychological Association, 1994-present • Member, Task Force Co-Leader, Society of Behavioral Medicine, 1994-present • Member, American Psychosocial Oncology Society, 2016-present • Member, Pennsylvania Psychological Association, 2016-present Editorships • Reviewer, Multiple journals (Psycho-Oncology, Journal of Clinical Oncology, Journal of Cancer Survivorship), 2006-present • Book Proposal Reviewer, Oxford University Press, 2019-present

Deborah L. Galson, PhD Dr. Galson investigates signal transduction pathways and gene regulation in osteoclasts (OCL) and osteoblasts (OB,) both during normal differentiation and in pathological states. The goal is to better understand pathological changes in the bone microenvironment, particularly OCL and OB, in Paget’s disease of bone and Multiple Myeloma (MM) bone disease. Her current studies focus on four main areas: (1) Determine the mechanism by which Measles virus nucleocapsid protein (MVNP) alters expression of cellular genes and increases osteoclast differentiation in Paget’s disease of bone. Dr. Galson has shown that MVNP signals through interaction with the IKK family members TBK1 and optineurin to generate pagetic OCL. Additional studies aim to determine the mechanism of cooper- ation between MVNP and p62 (SQSTM1) with pagetic mutations (eg. p62P392L) to generate Paget’s lesions. (2) Determine the mechanism by which MM cells suppress the differentiation capacity of osteoblast progenitor cells, which persists even after removal of the MM cells. These MM-altered bone marrow stromal cells also enhance osteoclastogenesis and microenvironmental support of myeloma growth. The focus is on understanding signaling mechanisms and the epigenetic changes induced in BMSC by MM cells. (3) Determine the roles of Gfi1 and EZH2 in osteoclasts. These studies derive from finding a key role for these proteins in MM-induced epigenetic changes in BMSC. (4) De- termine if inhibition of TBK1/IKKe signaling is a useful therapeutic strategy to inhibit MM bone disease. Inhibition of TBK1/IKKe signaling blocks OCL formation and slows MM growth in vitro. These studies are being extended to in vivo MM models. Dr. Galson is also involved in additional studies involving other cancers that invade the bone, such as breast cancer. Study Sections • Permanent Member, CMRF, University of Pittsburgh, 2004-present • Member/Abstract Reviewer, ASBMR Scientific Program Committee, 2016-present • Ad hoc Reviewer, Blood Cancer UK, 2019 • Reviewer, SBDD, National Institutes of Health, 2020 • Reviewer, ZRG1 MOS-R(02), Conflict Special Emphasis Panel, National Institutes of Health, 2020 Advisory Committee Memberships and Leadership Positions • Vice Chair, Subcommittee of Research Safety/Biosafety, VAPHS, 2005-present • Member, Luminex Core Advisory Committee, UPMC Hillman Cancer Center, 2015-present • Member, Finance Committee, ASBMR, 2016-2019 • Member, In Vivo Imaging Facility Advisory Committee, UPMC Hillman Cancer Center,

Division of Hematology/Oncology RESEARCH

2018-present • Member, PhD Faculty Task Force, University of Pittsburgh Department of Medicine, 2018-present • Member, Women’s Task Force, UPMC Hillman Cancer Center, 2018-present • Session Moderator, American Society for Bone and Mineral Research, 2019 • Member, Senior Faculty Event Planning Committee, Women in the Department of Medicine, 2019-2020 Professional Affiliations and Society Memberships • Fellow, American Society for Bone and Mineral Research, 1996-present • Member, American Society for Biochemistry and Molecular Biology, 1996-present • Member, Federation of American Societies for Experimental Biology, 1996-present • Member, American Society of Hematology, 2014-present • Member, American Association for Cancer Research, 2015-present • Member, Cancer and Bone Society, 2016-present Editorships • Reviewer, Multiple journals, 1995-present Honors and Awards • Recipient, Best of AACR Journals Award for most-cited research articles published in 2017, March 2019

Samit Ghosh, PhD Dr. Ghosh’s research goal is to delineate a translational pathway and to design platforms to expe- dite repair and regenerative therapeutics for the treatment of pulmonary complications of sickle cell disease (SCD). He investigates the underlying mechanisms that lead to acute or chronic pulmonary complications of SCD. His research involves two major components of SCD. One is to determine the role of TLR4 signaling and vascular adhesion machinery in the development of Acute Chest Syndrome in SCD. The other component is to define Nrf2 regulated redox mechanisms that can be targeted therapeutically to prevent chronic disease progression leading to end organ damage in SCD. His research could provide a solid foundation identifying precision drugs for protection and/ or attenuation of acute and chronic lung complications in SCD. In addition, his studies offer the potential of identifying the sub-group of SCD patients at higher risk of end-organ damage, who will be more suitable for high-risk experimental therapy.

James G. Herman, MD A member of The Cancer Genome Atlas, Dr. Herman has characterized genome-wide epigenetic changes in cancer in multiple forms of cancer. Dr. Herman’s research explores changes in DNA methylation in cancer, and his lab is the first to demonstrate that tumor suppressor genes are si- lenced by promoter region methylation. They have characterized changes in methylation associated with the development and progression of cancer, including the demonstration of changes in DNA methylation in premalignant lesions. Current research is aimed at utilizing these findings to improve the management of patients through the development of prognostic, predictive, and early detection epigenetic biomarkers, and in studies of epigenetic therapy. They have developed new methods for study of DNA methylation (methylation specific PCR, in Situ MSP, ERMA, and, more recently, nan- otechnology-based detection methods, included MS-QFRET and MOB, DREAMing). These sensitive methods have been used for the early detection of cancer and for developing predictive biomarkers. Advisory Committee Memberships and Leadership Positions • Co-Leader, Cancer Epidemiology & Prevention Program, University of Pittsburgh, 2018-present • Co-Chair, Executive Committee Member, Lung Cancer Group, National Cancer Institute, Early Detection Research Network, 2019-present

Department of Medicine 2020 Annual Report Professional Affiliations and Society Memberships • Member, American Association for Cancer Research, 1997-present Editorships • Editor, Clinical Cancer Research, 2003-present • Ad hoc reviewer, Multiple journals, 2003-present • Senior Editor, Epigenomics, 2009-present • Editorial Board, Cancer Prevention Research, 2010-present • Editor, Cancer Research, 2016-present Major Lectureships and Seminars • Presenter, Clinical Application of Circulating Biomarkers, 6th Annual Clinical Application of Circulating Biomarkers Conference, Washington, DC, August 2019 • Lecturer, EDRN, 11th EDRN Scientific Workshop, Bethesda, MD, September 2019 • Lecturer, OncLive, OncLive State of the Science Summit Lung Cancer, September 2019 • Lecturer, University of Hangzhou, Symposium in Molecular Pathology and Cancer Diagnosis, China, October 2019 • Lecturer, Hope College, Thompson Lecture in Translational Research, Holland, MI, November 2019

Charles C. Horn, PhD Dr. Horn’s primary research is the neurobiology of vagus nerve signaling. This research uses neuromodulation devices to control nerve-organ communication for the treatment of cancer, inflammation, gastrointestinal motility, and side effects of cancer therapies. Study Sections • Reviewer, National Institutes of Health, July 2020 Advisory Committee Memberships and Leadership Positions • Chair, NIH SPARC Cross-Team Communication Committee, 2017-present • Chair, Data Portal Committee, NIH SPARC Blue Team, 2019-present • SPARC Database Portal Change Control Board, National Institutes of Health, 2019-2020 Professional Affiliations and Society Memberships • Member, Society for Neuroscience, 1992-present • Member, American Physiological Society, 2007-present Honors and Awards • Recipient, First Prize, NIH SPARC Hackathon, Bethesda, MD, December 2018

Annie P. Im, MD Dr. Im’s research involves clinical trials in elderly AML and in GVHD, as well as late complications after stem cell transplant. She also conducts educational research on interactive learning in oncology fellowships. Study Sections • Abstract Reviewer, American Society of Hematology, 2019 ASH Annual Meeting, 2019 Advisory Committee Memberships and Leadership Positions • Fundraising Member, Team in Training, Leukemia & Lymphoma Society of the Western Pennsylvania and West Virginia Chapter, 2011-present Photo • Member, Protocol Review Board, UPMC Hillman Cancer Center, As Director of the Fellowship Program, Dr. Im has been working 2011-present with fellows and faculty to adjust • Member, Molecular Target Drug Discovery Translational Science the curriculum to optimize the Group, UPMC Hillman Cancer Center, 2012-present fellows' experience and wellness. 39

Division of Hematology/Oncology RESEARCH

• Leukemia/BMT Core Committee, ECOG-ACRIN, 2012-present • Program Evaluation Committee and Core Competency Committee, Hematology/ Oncology Fellowship Program, UPMC Hillman Cancer Center, 2013-present • Associate Clinical Investigator, National Cancer Institute, 2014-present • Medical Review Team, National Bone Marrow Transplant Link, 2014-present • Advisory Board, PA/WV Chapter of the Leukemia & Lymphoma Society, 2015-present • GVHD Committee, Center for International Blood and Marrow Transplant Research, 2015-present • GVHD Symposium Planning Committee, Meredith Cowden Foundation, 2015-present • Director, Hematology/Oncology Fellowship Program, University of Pittsburgh, 2017-present • Later Effects Working Committee, Center for International Blood and Marrow Transplant Research, 2018-present • Chair, Faculty Development Task Force, American Society of Clinical Oncology, 2019 • Co-Chair, Protocol Steering Committee, Gravitas 309, Incyte, 2019-present • Chair, Faculty Development Task Force, American Society of Clinical Oncology, 2019-present • Committee on Education, American Society of Transplantation and Cellular Therapy, 2020-present • Chair-Elect, Oncology Training Programs Committee, American Society of Clinical Oncology, 2020 • Scientific Program Committee, American Society of Clinical Oncology, ASCO Annual Meeting, 2020 Professional Affiliations and Society Memberships • Member, American Society of Clinical Oncology, 2011-present • Member, American Society of Hematology, 2012-present • Member, American Society of Blood and Marrow Transplantation, 2012-present • Member, American Association for Cancer Research, 2013-present Editorships • Reviewer, Multiple Journals, 2016-present Major Lectureships and Seminars • Lecturer, Training Program Director’s Workshop, American Society of Hematology, ASH Annual Meeting, 2019 • Lecturer, Program Director’s Section, American Society of Clinical Oncology, ASCO Annual Meeting, 2020

Sawa Ito, MD, PhD For many, bone marrow stem cell transplantation is the only curative treatment for leukemia and lymphoma-blood cancers. This technique has shown that immune cells of the donor which are trans- ferred in the transplant can eradicate blood cancer, a process known as the graft-versus-leukemia (GVL) effect. Dr. Ito’s research work is directed at finding ways to harness this GVL immune effect to cure leukemia and lymphoma. She is particularly interested in preventing and treating post-transplant relapse, which remains the major cause of transplant failure. This involves two approaches: The first is to improve the results of transplants for people with leukemia by increasing the GVL effect and decreasing the hazards of the transplant through biomarker-directed personalized medicine and adoptive cellular immunotherapy. The second is to find ways to create a GVL effect to boost the patient’s own immune system and thus avoid the complication of transplantation altogether. Study Sections • Reviewer, ASH Scholar Awards, American Society of Hematology, 2019-present • Reviewer, Hematology Opportunities for the Next Generation of Research Scientists

Department of Medicine 2020 Annual Report (HONORS) Award, American Society of Hematology, 2019-present • Reviewer/Interviewer, Research Training Award for Fellows (RTAF), American Society of Hematology, 2019-present • Reviewer, CRYOSTEM Projects, CRYOSTEM, 2020 Professional Affiliations and Society Memberships • Member, American Society of Hematology, 2009-present • Member, American Society for Blood and Marrow Transplantation, 2011-present • Member, American Society of Clinical Oncology, 2011-present • Member, International Society for Cellular Therapy, 2012-present Editorships • Review and Editor, Frontiers in Hematology and Oncology, 2014-present • Reviewer, Multiple journals (Bone Marrow Transplantation, Blood Advances, British Journal of Haematology), 2013-present

Maria Kapetanaki, PhD Dr. Kapetanaki is a molecular biologist with a long-standing interest in the regulation of gene expression in human diseases affecting normal lung function. Her research focuses on identifying the molecular pathways underlying pulmonary hypertension, which is a common complication in the sickle cell patient population. Her current projects include the study of the regulatory mechanism of heme-induced Placenta Growth Factor (PlGF) and the role of heme-induced genes in hematopoietic cells. More specifically, she investigates the role of oxidant response pathways, especially the Nrf-2 transcription factor and its upstream regulators. She employs cell culture and murine models where she applies techniques, such as gene silencing, gene editing and drug treatment to describe the steps of heme activation.

Gregory J. Kato, MD Dr. Kato’s research specialties comprise blood flow physiology studies, clinical trials, and proteomic analysis of plasma to unravel new mechanisms contributing to pulmonary hypertension and other complications of sickle cell disease. He has formulated a model to suggest that pulmonary hypertension, stroke, leg ulcers and priapism share features of vasculopathy and more severe hemolytic anemia, and that pain crisis, acute chest syndrome, and avascular necrosis share evidence of poor blood circulation due to viscosity. These two groups overlap and are not completely distinct. Advisory Committee Memberships and Leadership Positions • Member, Steering Committee, Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC), 2014-present • Medical Director, Children’s Sickle Cell Foundation, Pittsburgh, PA, 2014-present • Consultant, CSL Behring, King of Prussia, PA, 2015-present • Chair, Africa Clinical Trials Data and Safety Monitoring Board, National Heart, Blood and Lung Institute: Sickle Cell, 2017-2021 Professional Affiliations and Society Memberships • Member, American Society of Hematology, 1993-present • Member, American Society of Pediatric Hematology-Oncology, 2001-present • Member, Society for Free Radical Biology and Medicine, 2006-present Editorships • Reviewer, Acta Haematologica, 1991-present • Reviewer, Sickle Cell Trait Literature, Social and Behavioral Research Branch, National Human Genome Research Institute, 2011-present • Editorial Board, Heliyon, 2015-present Honors and Awards • Recipient, American Society for Hematology Research Training Award for Fellows Study 41

Division of Hematology/Oncology RESEARCH

Section, 2018

John M. Kirkwood, MD Dr. Kirkwood’s research focuses on melanoma immunobiology, therapy, and prevention. His translational laboratory studies have shown the immunological basis of IFN adjuvant benefits in the first neoadjuvant immunotherapy trial for melanoma. His research is now expanding these studies at Hillman and through ECOG-ACRIN, probing the role of molecularly targeted agents (BRAF, MEK, and PI3Kδ/γ inhibitors) that may improve upon the efficacy of anti-PD1 immunotherapy for adjuvant therapy of operable high-risk melanoma and treatment of advanced melanoma. His studies of monoclonal antibodies to the gangliosides of melanoma—and peptide differentiation antigens of melanoma alone and in combination with cytokine and growth factor immunomodulators—paved the way for the recent progress with immunotherapies in multiple other cancers. He has advanced the multimodal therapy of melanoma with surgery, stereotactic radiotherapy, and molecular antitumor agents. He is now pioneering novel clinical trials to assess the multiple potential combinations of recently-approved molecular and immunological therapies that are the focus of translational clinical research trials in melanoma for the forseeable future. Dr. Kirkwood’s laboratory is also engaged in the molecular and immunohistological analysis of melanoma and its non-obligate risk marker and potential precursor known as the dysplastic/atypical nevus. His studies of tissues obtained from institutional, regional, national, and international trials of therapy are resources for investigators working upon melanoma in the NCTN, and the international melanoma research community. Tumor tissues from patients participating in new combination therapies, neoadjuvant trials, and prevention interventions probed using current immunopatho- logical and molecular approaches seek biomarkers that will more accuarately predict response and toxicity of these interventions. Study Sections • Member, Scientific Advisory Committee and Grants Study Section, National Cancer Center, New York, NY, 1984-present • Member, Scientific Advisory Committee and Grants Review Member, Cancer Research Institute, 1988-present • Permanent Member, Research Proposal Review Section, The Harry J. Lloyd Charitable Trust, 2003-present • Member, Melanoma Advisory Board and Study Section, The Harry J. Lloyd Charitable Trust, 2008-present • Permanent Member, Peer Reviewed Cancer Research Program, Congressionally Directed Medical Research Programs (CDMRP), 2009-present • Member, Scientific Grant Review Committee, Ocular Melanoma Foundation Fellowship, American Association for Cancer Research, 2014-present • Permanent Member, Grant Review Study Section, Cancer Research Institute Clinic and Laboratory Integration Program (CLIP), 2014-present • Member, Sentinel Node Biopsy in Melanoma Guideline Expert Panel, ASCO/SSO, 2016-present • Permanent Member, The Italian Association of Medical Oncology (AIOM), 2016-present • Member, Expert Panel, systemic Therapy for Melanoma Guidelines, ASCO, 2018-present • Programmatic Panel Chair, Melanoma Research Program, Congressionally Directed Medical Research Programs (CDMRP), 2019-present Advisory Committee Memberships and Leadership Positions • Member, Principal Investigator Committee, ECOG-ACRIN, 1982-present • Chair, Melanoma Committee, ECOG-ACRIN, 1989-present • Member, Cancer and Tumor Registry Committee, University of Pittsburgh Medical Center, 1992-present • Member, Combined Allied Health Professionals Review Subcommittee, University of

Department of Medicine 2020 Annual Report Pittsburgh, 1993-present • Chair, Medical Advisory Board, Our Clubhouse, 2004-present • Member, Board of Directors, Medical Advisory Board, AIM at Melanoma, 2004-present • Co-Chair, International Melanoma Working Group, 2005-present • Member, TAFC Faculty Oversight Committee, University of Pittsburgh, 2005-present • Member, Committee on Tenure, Appointments, and Promotions, University of Pittsburgh Department of Medicine, 2007-present • Member, Ad Hoc Appeals Committee, University of Pittsburgh School of Medicine, 2009-present • Co-Chair, Melanoma Medical Oncology Committee, Via Pathways, 2010-present • Member, Research and Education Foundation, ECOG-ACRIN, 2011-present • Member, Scientific Planning Committee, ECOG-ACRIN, 2012-present • Member, Interdisciplinary Biomedical Graduate Program, Cellular and Molecular Pathology, University of Pittsburgh, 2013-present • Honorary Chair, 321Ride, The Woiner Foundation, 2013-present • Honorary Chair, Steps Against Melanoma, AIM for Melanoma, 2016-present • Member, Melanoma World Society, 2016-present • Member, European Academy for Tumor Immunology (EATI), 2016-present • Member, External Steering Committee, Melanoma Value Stream, Oregon Health & Science University, 2016-present • Member, Research Methodologies in Immunotherapy Development Working Group, American Society of Clinical Oncology (ASCO), 2016-present • Member, Scientific Advisory Board, Istari Oncology, 2018-2022 • Member, Academic Incentive Committee, University of Pittsburgh, 2018-present • Member, Scholarly Research Project Program, University of Pittsburgh, 2018-present • Member, Translational Cancer Immunotherapy Committee, University of Pittsburgh, 2018-present • Consultant, I-O Unbranded Content Update, Bristol-Myers Squibb (BMS), 2019-2020 • Member, NKTR-214 AACR Scientific Advisory Council, Bristol-Meyers Squibb (BMS), 2019- 2021 • Member, Tafinlar-Mekinist + Spartalizumab Advisory Board, Novartis, 2019-2021 • Chair, Prevention Subcommittee, ECOG-ACRIN, 2019-present • Member, Cancer Prevention Steering Committee, National Cancer Institute, 2019-present • Member, Clinical Advisory Board, Harbour BioMed, 2020-2021 • Member, Metastatic Melanoma Advisory Board, Iovance Biotherapeutics, 2020-2021 • Sparta-DT Advisory Board, Novartis, 2020-2022 • Member, Moon Shots Scientific Advisory Board, MD Anderson Cancer Center, 2020-2025 Professional Affiliations and Society Memberships • Member, American Federation for Medical Research, 1973-present • Member, New York Academy of Sciences, 1974-present • Member, American Society for Clinical Oncology, 1975-present • Member, American Association for Cancer Research, 1975-present • Member, ECOG-ACRIN, 1978-present • Member, National Cancer Foundation, 1981-present • Member, International Society for Interferon and Cytokine Research, 1986-present • Member, Society for Immunotherapy of Cancer, 1986-present • Member, International Society for Interferon and Cytokine Research, 1986-present • Member, Clinical Immunology Society, 1990-present • Member, Society for Investigative Dermatology, 1991-present • Member, Society of Melanoma Research, 2007-present • Member, American Medical Association, 2014-present • Elected Member, Association of American Physicians, 2015-present 43

Division of Hematology/Oncology RESEARCH

• Member, European Academy for Tumor Immunology (EATI), 2016-present Editorships • Associate Editor, Clinical Cancer Research, 1995-present • Editorial Board, Melanoma Research, 1998-present • Editorial Board, Hem-Onc Today, 1998-present • Member, American Journal of Clinical Oncology, 1998-present • Editorial Board, Clinical Advances in Hematology & Oncology, 2002-present • Editorial Board Member, Compendium Editorial Board Subcommittee, Guidelines for Melanoma Committee, ASCO Cancer Education Committee, 2005-present • Reviewer, Multiple Journals, 2010-present • Editorial Board Member, Journal of Translational Medicine, Combinational Strategies Section, 2010-present • Editorial Board, OncoImmunology, 2012-present • Editorial Board, Melanoma Management, 2013-present Major Lectureships and Seminars • Presenter, Cambridge Healthtech Institute, Immunomodulatory Therapeutic Antibodies for Cancer, Boston, MA, August 2019 • Abstract Presenter, Society for Immunotherapy of Cancer (SITC), National Harbor, MD, November 2019 • Presenter, The Cutaneous Malignancies Forum, Skin Disease Education Foundation, 20th Annual Las Vegas Dermatology Seminar, Las Vegas, NV, November 2019 • Presenter, IO Unbranded Expert Program Activity, BMS, Altoona, PA, January 2020 Honors and Awards • Recipient, Best Doctors in America, 1996-present • Recipient, Castle Connolly America’s Top Doctors, 2001-present • Recipient, Castle Connolly America’s Top Doctors for Cancer, 2005-present • Honoree, Best Doctors, Pittsburgh Magazine, 2005-present • Honoree, G. David Roodman, MD, Excellence in Mentoring, University of Pittsburgh, October 2019 • Distinguished Service Professor of Medicine, University of Pittsburgh, October 2019

Joseph E. Kiss, MD As a clinical investigator, Dr. Kiss has received federal funding for 13 years while part of several NHLBI-sponsored research programs, including the Transfusion Medicine Hemostasis/Thrombosis Clinical Trials Network (TMH-CTN), REDS-II and III programs [the Retrovirus(REDS-II) or Recipient (REDS-III) Epidemiology in Donors Study], and through the R01 award mechanism (STRIDE-Strate- gies to Reduce Iron Deficiency). His research interests include studies in thrombotic microangiop- athies, particularly thrombotic thrombocytopenic purpura (TTP). He served as protocol lead/PI on the multicenter Study of TTP and Rituximab (STAR) trial in 2009. Although the trial was closed early, the study was innovative in its design to utilize immunotherapy (rituximab) up front in a randomized controlled trial in acquired (autoimmune) TTP that has served as a template for other non-randomized studies performed successfully in Europe. He continues his research work in TTP as a site PI for caplacizumab, a novel heavy chain monoclonal antibody that blocks VonWillebrand A1domain-platelet receptor Ib binding. He is also pursuing therapies for other thrombotic micro- angiopathies, such as Thrombocytopenia-associated Multiorgan Failure (TAMOF), and has plans for designing a randomized pilot trial utilizing plasma exchange. Advisory Committee Memberships and Leadership Positions • Invited Member, Joint Commission eCQM Blood Management Technical Advisory Panel, 2014-present • Member, TTP Advisory Board, Sanofi-Genzyme, 2015-present

Department of Medicine 2020 Annual Report • Co-Chair, TTP/TMA Subcommittee, American Society for Apheresis, 2016-present • Member, Heparin-induced Thrombocytopenia (HIT) subcommittee, American Society for Apheresis, 2016-present • Member, Research Committee, American Society for Apheresis, 2016-present • Member, Plasma Advisory Council, Haemonetics Corp., Braintree, MA, 2019-present Professional Affiliations and Society Memberships • Member, AABB, 2019-2020 • Member, American Society for Apheresis (ASFA), 2019-2020 • Member, American Society for Hematology (ASH), 2019-2020 Editorships • Reviewer, Multiple journals, 2008-present Major Lectureships and Seminars • Lecturer, Medicine Grand Rounds, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, November 2019 • Lecturer, Emerging Research in Convalescent Plasma Haemonetics, Webinar, May 2020

Anuradha Krishnamurthy, MBBS Dr. Krishnamurthy strongly believes that drug development and translational research should be an integral part of cancer care. To that end, during a two-year drug development fellowship at the University of Colorado, she participated in writing early phase clinical trial protocols, reviewing industry written protocols, attending safety meetings and enrolling patients on clinical trials. She also attended the ASCO/AACR Methods in Clinical Cancer Research Workshop in 2017. While at Colorado, Dr. Krishnamurthy was involved in a phase I clinical trial that combined selume- tinib, a MEK inhibitor with Cyclosporin A, a Wnt inhibitor. Wnt pathway dysregulation is commonly seen in colorectal cancer, and this study looked at the toxicities and potential anti-tumor effects of the combination of Wnt and MEK inhibition. Results of this study have been promising. She has also been involved in the development of an early phase clinical trial combining a PD-1 inhibitor (Pem- brolizumab) with a MEK inhibitor (Binimetinib) and a VEGF inhibitor (Bevacizumab) which examines the effectiveness of combining an immune checkpoint inhibitor with the immune modulatory effects of MEK AND VEGF inhibition. Advisory Committee Memberships and Leadership Positions • Member, Protocol Review Committee, UPMC Hillman Cancer Center, 2019-present Professional Affiliations and Society Memberships • Member, American Association for Cancer Research, 2018-present • Member, American Society of Clinical Oncology, 2018-present Major Lectureships and Seminars • Invited Speaker, Updates in Gastrointestinal Cancer, Arnold Palmer Cancer Center, 2018- 2019

Daniel Lee, MD, PhD Dr. Lee’s research focuses on a mechanistic understanding of conditions and the development of novel therapies. Professional Affiliations and Society Memberships • Member, American Society of Clinical Oncology, 2014-present

Frank S. Lieberman, MD Dr. Lieberman is director of the adult neuro-oncology program in the UPMC Hillman Cancer Center, and he oversees the design and conduct of clinical trials for patients with primary and metastatic brain tumors. He has more than 30 years of experience in the design and conduct of translation-

Division of Hematology/Oncology RESEARCH

al therapeutic trials for brain tumor patients and currently serves as HCC’s Principal Investigator for participation in the Adult Brain Tumor Consortium, NRG Consortium, and ECOG-ACRIN and the Brain Tumor Treatment Consortium, having previously served as our institutional Principal Inves- tigator for participation in the Collaborative Ependymoma Research Network. Dr. Lieberman also serves on the CNS Tumor Committee, Experimental Imaging, and Biomarker Committees for ECOG- ACRIN. He has a developed expertise and interest in immunotherapeutic and molecularly targeted approaches to high and low grade gliomas and is currently serving as principal investigator and co-investigator in glioma vaccine trials as well immune checkpoint inhibitor trials and in trials evaluating molecularly targeted therapeutic drugs. Additionally, Dr. Lieberman is a co-investigator on institutional imaging projects assessing novel PET tracers, high field strength MRI spectroscopy, and dynamic contrast imaging as early biomarkers of response in immunotherapeutic and molecularly targeted clinical trials for newly diagnosed and recurrent anaplastic glioblastomas. Dr. Lieberman has chaired the working group for Clinical Trials Design and Development for the NCI Quantitative Imaging Network. In collaboration with Marina Nikaforovna and Ronald Hamilton in the Department of Pathology, he has also participated in the development of one of the nation’s largest clinically annotated molecular genomic databases for high- and low-grade gliomas. Advisory Committee Memberships and Leadership Positions • Member, Experimental Imaging Committee, ECOG, 2015-present Professional Affiliations and Society Memberships • Member, Neurooncology Section, American Academy of Neurology, 1990-present • Member, Society for Neurooncology, 1996-present • Member, American Society of Clinical Oncology, 1996-present • Fellow, American Neurological Association, 2018-2020 Major Lectureships and Seminars • Lecturer, Neurology Grand Rounds, University of Pittsburgh School of Medicine, 2019 Honors and Awards • Honoree, Best Doctors, Pittsburgh Magazine, 2016-2020

Anna E. Lokshin, PhD Dr. Lokshin’s research centers on the discovery and characterization of biomarkers for screening, diagnosis, and prognosis of cancer, particularly ovarian and pancreatic cancers. Her group has identified biomarker combinations that recognize ovarian cancer 1-4 years earlier than current methods (CA125 and transvaginal ultrasound) and pancreatic cancer 2-6 years earlier. Her lab is currently working on discovering biomarkers in several bodily fluids, including serum/plasma and urine and in exosomes obtained from these fluids. In additional, they are investigating the role of glycolysis and coagulation pathways in the early preneoplastic events of high-grade serous ovarian carcinoma and the role of exosomes in these events. Study Sections • Ad Hoc Reviewer, Cancer Drug Development & Therapeutics Oncology 2, U01 review PAR-18-91, National Institutes of Health, 2017-present Professional Affiliations and Society Memberships • Member, American Association for Cancer Research, 1989-present • Member, Early Detection Research Network, 2003-present • Member, American Society of Clinical Oncology, 2009-present Editorships • Associate Editor, Cancer Biomarkers Journal, 2004-present • Reviewer, Multiple journals, 2006-present

Carissa A. Low, PhD

Department of Medicine 2020 Annual Report Dr. Low’s research focuses on interactions between behavior, biology, and patient-centered outcomes in the context of cancer. She is particularly interested in the use of mobile and online technology to monitor and change health behaviors, psychological stress, and symptoms during cancer treatment. Current projects include a randomized controlled trial testing a smartphone- and smart- watch-delivered sedentary behavior intervention before and after cancer surgery and a project that combines smartphone and wearable sensor data with machine learning to remotely monitor symptoms during chemotherapy. Study Sections • Reviewer, Special Emphasis Panel, National Cancer Institute, March 2020 Professional Affiliations and Society Memberships • Member, American Psychosomatic Society, 2006-present • Member, Society of Behavioral Medicine, 2014-present Editorships • Associate Editor, International Journal of Behavioral Medicine, 2018-present Major Lectureships and Seminars • Speaker, Health Services Research Seminar, October 2019 • Speaker, Society for Personality and Social Psychology, Preconference, New Orleans, LA, February 2020

Jason J. Luke, MD Dr. Luke focuses on translational therapeutic advances for malignant melanoma and early phase drug development for advanced cancers with particular expertise in the immunotherapy of cancer, having been a lead investigator for immunotherapies such as anti-PD1/L1, CTLA4, LAG3, TIM3, GITR, OX40, CD137, CD40, inhibitors of indolamine-dioxygenase, adenosine A2a receptor & arginase as well as agonists of STING & oncolytic virus. Dr. Luke maintains an ongoing interest in the molecular biology of cancer and particularly in the intersection between oncogene targeted small molecules and immunotherapy. Advisory Committee Memberships and Leadership Positions • Member, Protocol Review Committee A, UPMC Hillman Cancer Center, 2019-present • Co-Chair, SITC Policy Committee, SITC, 2019-2020 • Member, Organizing Committee, Society for Melanoma Research, 2020 Professional Affiliations and Society Memberships • Member, American College of Physicians (ACP, 2006-present • Member, American Association for Cancer Research, 2012-present • Fellow, American Society for Clinical Oncology (ASCO), 2013-present • Member, Society for Immunotherapy of Cancer (SITC), 2014-present Editorships • Member, Editorial Board, Oncology & Biotech News, 2013-present • Member, Editorial Board, Oncology Live, 2013-present • Associate Editor, Clinical Cancer Research, 2019-present • Social Media Editor, Journal of Immunotherapy of Cancer, 2019-present Major Lectureships and Seminars • Presenter, European Society of Medical Oncology (ESMO), 2019 ESMO Annual Meeting, Barcelona, Spain, September 2019 • Presenter, Clinica Universidad de Navarra, Facts and Hopes in Cancer Immunotherapy, Madrid, Spain, September 2019 • Presenter, SITC, SITC 2019 Annual Meeting, Washington, DC, November 2019 • Presenter, Melanoma Bridge 2019, Naples, Italy, December 2019 • Presenter, Cancer Cross Links, Oslo University Hospital, Oslo, Norway, January 2020 47

Division of Hematology/Oncology RESEARCH

• Presenter, Physician Education Resource, LLC, 16th Annual International Symposium on Melanoma and Other Cutaneous Malignancies, February 2020

Yana G. Najjar, MD Dr. Najjar seeks to advance the treatment of melanoma by complementing clinical care with the principles of translational science. Specifically, her research focuses on immunotherapy in advanced melanoma and its impact on the tumor microenvironment and the peripheral immune system. Dr. Najjar’s goal is to develop rational combinations of immunotherapy, targeted therapy, and other agents that may potentially remodel the tumor microenvironment in order to render it less hostile to the host immune system. Current, ongoing projects include the impact of metabolism on immunotherapy in patients with advanced melanoma; uveal melanoma; targeted therapy plus immunotherapy in the first and second line setting; and neoadjuvant treatment approaches in melanoma. Study Sections • Member, Study Section, Department of Defense, January 2020 Advisory Committee Memberships and Leadership Positions • Director, UPMC Hillman Cancer seminar series, 2018-present • Member, Hillman Cancer Center Women’s Task Force, 2018-present • Member, Immunological Monitoring and Cellular Products Laboratory Advisory Board, 2018-present • Member, Melanoma Steering Committee, ECOG, 2018-present • Chair, Cancer Immune Responsiveness Task Force, SITC, July 2019 • Co-Chair, SITC Workshop, Society for Immunotherapy of Cancer, Houston, TX, July 2019 • Organizer, Cancer Immunotherapy Workshop Clinical Trails, SITC, 2020 Professional Affiliations and Society Memberships • Associate Member, American Association for Cancer Research, 2010-present • Member, American Society of Clinical Oncology, 2012-present • Member, Society for Immunotherapy of Cancer, 2014-present • Member, Society for Melanoma Research, 2017-present • Member, Melanoma Core Committee, ECOG, 2018-present Editorships • Reviewer, Multiple journals, 2018-2019 Major Lectureships and Seminars • Presenter, Regional Melanoma Translational Research Consortium, 2017-present • Speaker, EDRN, 2019-2020 • Lecturer, SITC Women in Cancer Immunotherapy, WIN Leadership Institute, Seattle, WA, July 2019 • Speaker, ASCO Presentation-Melanoma, September 2019 • Speaker, TTT Retreat, October 2019 • Mentor, Leadership and Discovery Program (LEAD), December 2019 • Speaker, Immunotherapy Bridge Conference, Italy, December 2019 • Speaker, University of Pittsburgh Department of Biomedical Informatics, February 2020 • Speaker, TRCCC and RMTRC Meetings, March 2020 • Speaker, IC-ONC, 2020 Honors and Awards • Scholar Award in Clinical Research, UPMC Hillman Cancer Center, July 2019

Enrico M. Novelli, MD, MS The Novelli Lab focuses on elucidating the fundamental mechanisms underlying vascular dysfunction in sickle cell disease (SCD). Dr. Novelli’s initial research sought to clarify the mechanisms underlying pulmonary hypertension in sickle cell disease. Most recently, his research has focused on the 48

Department of Medicine 2020 Annual Report risk factors and mechanisms of cognitive impairment in sickle cell disease. Dr. Novelli is conducting an R01-funded longitudinal study of cognitive impairment and its neuroradiological correlates in adult patients with SCD. The study’s goal is to explore small vessel disease biomarkers by MRI and how they predict the trajectory of cognitive impairment. A parallel study in sickle mice is also being conducted in Dr. Novelli’s lab to explore the mechanistic pathways that lead to cognitive impairments in patients with SCD. Study Sections • Member, AHA Study Section, 2013-present • Member, SBIR/STTR Study Section, NIH, 2015-present Advisory Committee Memberships and Leadership Positions • Director, Benign Hematology Conference, University of Pittsburgh, 2013-present • Member, Scientific Committee on Thrombosis and Vascular Biology, American Society of Hematology, 2016-2020 Photo • Member,) Committee on Addressing Sickle Cell Disease, The Chief of the Benign Hematology National Academies of Science, Engineering, and Medicine, Section, Dr. Novelli directs the Department's new T32 focused on 2019-present benign hematology. Professional Affiliations and Society Memberships • Member, American Society of Tropical Medicine and Hygiene, 2008-present • Member, American Society of Hematology, 2005-present • Member, European Hematology Association, 2017-present • Member, American Heart Association, 2017-present Editorships • Reviewer, Multiple journals, 2011-present • Editorial Advisory Board, American Journal of Hematology, 2015-present • Peer Reviewer, UpToDate, 2016-present

Solomon F. Ofori-Acquah, PhD Dr. Ofori-Acquah has a research interest in molecular hematology, endothelial barrier function, sickle cell disease (SCD), and global health. His basic science research is on the mechanisms of neutralizing erythroid danger associated molecular pattern (eDAMP) molecules. This work encom- passes studies of developmental, genetic, and epigenetic regulation of hemopexin and heme oxy- genase-1—the key neutralizing molecules of extracellular heme the prototypical eDAMP. His basic research is translated to understanding the role and mechanism of extracellular heme in the patho- biology of vascular complications in SCD. A major translational focus is acute chest syndrome, the leading cause of premature death in SCD. The Ofori-Acquah lab developed the first mouse model of acute chest syndrome. This preclinical model is currently being used to find targeted therapies for this syndrome. His global health research centers on a longitudinal observational study of a large newborn cohort in Ghana to define markers of end-organ damage in SCD. Additional global health work focused also on SCD is performed under the auspices of the H3Africa consortium with a multi-disciplinary team of collaborators in Cameroon, Tanzania, and South Africa. Dr. Ofori-Acquah directs a research education NIH-funded R25 program aimed at catalyzing the training of gradu- ates, postdocs, and junior faculty in blood science research. He is Visiting Professor and Director of a Human Genetics graduate course in a Wellcome Trust-funded DELTAS (Developing Excellence in Leadership, Training and Science) program at the University of Ghana in collaboration with the Pitt Graduate School of Public Health. Study Sections • Member, Respiratory Integrative Biology and Translational (RIBT) Science Study Section, NIH, 2013-2019 • Member, Ad Hoc Grant Review Committee, Minority Medical Student Award, American

Division of Hematology/Oncology RESEARCH

Society of Hematology, 2010-present Advisory Committee Memberships and Leadership Positions • Member, Medical Advisory Board, Parent’s Guide to Cord Blood Foundation, 2009-present • Member, Medical Research Advisory Committee, Sickle Cell Disease Association of America, 2009-present • Member, Executive Planning Committee, Sickle Cell National Annual Symposium, 2009-present • Consultant, Newborn Screening Quality Assurance Program, Centers for Disease Control and Prevention, 2010-present • Chair, Minority Graduate Student Abstract Achievement Award Committee, American Society of Hematology, 2011-present Professional Affiliations and Society Memberships • Member, American Thoracic Society, 2004-present • Member, American Association for Cancer Research, 2005-present • Member, American Society of Hematology, 2004-present • Member, Ghana Biomedical Convention, 2008-present

Ellen M. Ormond, PhD Dr. Ormond’s research is focused on quality improvement initiatives in advance care planning, assessment of frailty, patient-reported outcomes, and end of life care. Advisory Committee Memberships and Leadership Positions • Member, Ethics Committee, UPMC Presbyterian/Shadyside, 2014-present • Member, Allied Health Committee, UPMC Presbyterian/Shadyside, 2015-present • Member, Clinical Leadership Council, University of Pittsburgh Department of Medicine, 2016-present • Member, UPMC Safenet Initiative, 2017-present • Member, Oncology ED Steering Committee, UPMC Hillman Cancer Center, 2017-present • Member, Patient Education Governance Committee, UPMC, 2018-present • Member, Quality and Safety Committee, UPMC Shadyside Hospital, 2018-present Professional Affiliations and Society Memberships • Member, American Society of Clinical Oncology, 2017-present

Amma T. Owusu-Ansah, MD Dr. Owusu-Ansah’s primary research interest is in translating novel or repurposed therapeutics into clinical settings to prevent or halt the progression of complications of sickle cell disease. Her other interests are in global health and implementation research, specifically identifying strategies to improve access to state-of-the-art medical care for individuals with benign hematologic disorders in different demographic regions of the world. Professional Affiliations and Society Memberships • Member, Global Sickle Cell Disease Network, 2010-present • Member, American Society of Hematology, 2011-present • Member, American Society of Pediatric Hematology and Oncology, 2011-present

Vida Cecilia A. Passero, MD, MBA Dr. Passero’s research interests include the development of collaborative, innovative cancer care models using telemedicine.

Donna M. Posluszny, PhD Dr. Posluszny has conducted psychosocial and behavioral research in a variety of cancer popula- 50

Department of Medicine 2020 Annual Report tions, including breast, gynecologic, head and neck, and hematological malignancies. She recently completed an NIH-funded prospective, longitudinal study examining adherence to the medical regimen for hematological cancer patients who are post allogeneic hematopoietic cell transplantation (HCT) and their family caregivers. To enhance outcomes and minimize risks associated with HCT, patients and their caregivers must work together as a team to carefully adhere to the multi-component post-HCT medical regimen, consisting of multiple daily medications, frequent clinic visits, strict catheter care, health monitoring, and dietary and lifestyle restrictions. Dr. Posluszny is currently examining psychosocial and behavioral strategies to help HCT patients and family caregivers manage each component of the post-HCT regimen together, and thus improving psychological and health outcomes. She is also interested in family caregiver well-being, health, burden, and impact on patient outcomes. Advisory Committee Memberships and Leadership Positions • President, Board of Directors, nbmtLINK, 2019-present Professional Affiliations and Society Memberships • Member, American Psychological Association, 1994-present • Member, Division of Clinical Psychology, APA, 2002-present • Member, Psychologists in Academic Health Centers, APA, 2003-present • Member, Pennsylvania Psychological Association, 2003-present • Member, Division of Health Psychology, 2008-present • Member, Society of Behavioral Medicine, 2009-present • Member, American Society of Clinical Oncology, 2014-present • Member, American Psycho-social Oncology Society, 2015-present Editorships • Ad hoc reviewer, Multiple journals, 2014-present Major Lectureships and Seminars • Invited Speaker on behalf of the Leukemia and Lymphoma Society, Oncology Nursing Society, Greater Pittsburgh Chapter, October 2019

Tirthadipa Pradhan-Sundd, PhD Liver fibrosis, inflammation and loss of blood biliary barrier are the hallmark of chronic liver injury. Several experimental models have been used to mimic the end-stage pathophysiology of chronic liver injury. However, the underlying differences in the molecular mechanism driving liver injury in different models remains largely unknown due to our inability to visualize the progression of liver injury in vivo in mice. Dr. Pradhan-Sundd has introduced quantitative Liver Intravital Microscopy (qLIM) that enables real-time assessment of bile transport and blood-bile barrier (BBlB) integrity in the intact liver of live mice (Pradhan-Sundd et al., Hepatology, 2017, Gastroenterology, 2018). Using qLIM, she seeks to understand the mechanisms of chronic live injury initiation, progression, and recovery processes in experimental and disease models. Another of Dr. Pradhan-Sundd’s longstanding interests is to understand the molecular mechanism of Sickle cell hepatic crisis. Sickle cell disease (SCD) is an autosomal recessive genetic disorder that affects ~100,000 Americans and millions of people worldwide. Sickle cell anemia can affect any part of the body and one of the main organs to be affected is the hepatobiliary system. Using qLIM in a transgenic, humanized mouse model of SCD that exclusively expresses sickle human hemoglobin, she has identified sinusoidal ischemia, impairment of canalicular bile secretion, and intrahepatic accumulation of bile acids in SCD mice. Understanding the molecular events that initiate and promulgate SCD induced hepatobiliary injury has great potential to prevent hepatic insult and progressive liver damage in SCD.

Margaret V. Ragni, MD, MPH Dr. Ragni has actively initiated and participated in clinical translational research in congenital hemostasis and thrombosis disorders. She has served as chair of clinical trials, prospective epidemiolog-

Division of Hematology/Oncology RESEARCH

ic, observational, case-control studies, cost-effectiveness analyses, and investigator-initiated new drug trials in hemophilia and VWD. Dr. Ragni’s research studies were among the first multi-center NIH-funded investigator-initiated studies in hemophilia malignancy (NCI), hemophilia inhibitor formation (NHLBI), hemophilia HIV/HCV infection (NHLBI), hemophilia AIDS therapy (NIAID), and hemophilia adult prophylaxis (NHLBI). She co-chaired the State of the Science NHLBI Working Group to Prevent and Eradicate Inhibitor in hemophilia; and co-chaired the State of the NHLBI Science SOS Hemophilia & VWD Subcommittee to design future trials, with one U01 NHLBI trial in VWD, one X01 NHLBI grant to design rare trials, a T35 Training Grant, and two past U34NHLBI trials and one past R34 NHLBI trial in hemophilia and VWD. She has collaborated on multi-center organ transplant HIV trials (NIAID), hemophilia gene therapy trials (NHLBI), VWD genotype-phenotype studies (NHLBI), novel therapeutics (siRNA-AT3 and extended half-life protein trials (VIIa, VIII, IX) for hemophilia, and rhIL-11 and recombinant VWF for VWD. Dr. Ragni is planning to serve as PI of a UG3UH3 multicenter clinical trialto prevent and eradicate inhibitors, and as Co-Director of a T32 Clinical Translational Hematology Grant. Study Sections • Member, Research Award Review Committee, Foundation Women Girls Bleed Disorders (FWGBD), 2015-present • Annual Grant Reviewer, Foundation Women Girls Blood Disorders (FWGBD), 2019-present • Member, The Beutler Prize Selection Committee, American Society of Hematology, Women in Hematology, 2019 • P3HVB Grant Reviewer, Vascular Medicine Institute, 2019 • Ad Hoc Reviewer, Grant K99 ZHL1 CSR-Q, National Institutes of Health (NHLBI), 2020 Advisory Committee Memberships and Leadership Positions • Board Member, Hemostasis & Thrombosis Research Society, 1990-present • Member, Medical and Scientific Advisory Committee, National Hemophilia Foundation, 1991-present • Member, Advisory Board, Foundation for Women & Girls with Blood Disorders, 2011-present • Ad Hoc Consultant, Food and Drug Administration (FDA), 2015-2019 • Member, Fitusiran Alnylam Advisory Board, Sanofi, 2016-present • Chair, Inhibitor Treatment Guidelines Working Group, World Federation Hemophilia (WFH), 2016-present • Member, Hemophilia Treatment Guidelines Working Group, World Federation of Hemophilia, 2016-present • Member, rVWF Advisory Board, Shire/Takeda, 2017-present • Member, ASH-A-Palooza Committee, American Society of Hematology, 2018-2019 • Member, Women in Hematology Committee, American Society of Hematology, 2018- 2019 • Elected Member, HTRS/NASTH Board of Directors, Hemostasis & Thrombosis Research Society (HTRS), 2018-2020 • Co-Chair, Research Colloquium, Hemostasis Thrombosis Research Society (HTRS), 2019-present • Member, Advisory Board, Spark/Roche, 2019-present • Member, BIV001 Advisory Board, Bioverativ/Sanofi, 2019-present • Member, BMN Gene Therapy Advisory Board, Biomarin, 2019-present • Chair and Author, ATHN 11 Protocol, American Hemostasis Thrombosis Network (ATHN), 2019 • Member, ATHN 2 Protocol Steering Committee, American Hemostasis Thrombosis Network (ATHN), 2019 • Member, ATHN 5/6 Protocols Steering Committee, American Hemostasis Thrombosis

Department of Medicine 2020 Annual Report Network (ATHN), 2019 • Member, Mock FDA Blood Products Advisory Meeting, Sutimlimab, Sanofi, 2020 Professional Affiliations and Society Memberships • Member, American Society of Hematology, 1983-present • Member, World Federation of Hemophilia, 1984-present • Member, National Hemophilia Foundation, 1987-present • Member, National Heart Lung Blood Institute, 2002-present • Member, International Society of Hemostasis and Thrombosis, 2007-present Editorships • Editorial Board, Hemophilia, 2000-present • Associate Editor and Member, Editorial Board, Blood Advances, 2016-present • Reviewer, Multiple journals (Academic Medicine, Annals Internal Medicine, Blood, Expert Review Hematology, Haemophilia, Haematologica, JAMA, J Thrombosis Haemostasis, New England Journal of Medicine), 2019-present Major Lectureships and Seminars • Invited Speaker, National Hemophilia Foundation, Annual Meeting, October 2019 • Invited Speaker, Education Program, American Society of Hematology (ASH), ASH Annual Meeting, Orlando, FL, December 2019 • Invited Speaker, Centers for Disease Control (CDC), Inhibitor Prevention Seminar, 2020 • Ariel Distenfeld Memorial Lecturer, New York University, 2020 • Invited Speaker, National Institutes of Health (NHLBI), Inhibitor Prevention and Eradication Protocol Seminar, April 2020 • Invited Speaker, World Federation of Hemophilia (WFH), Annual Meeting, June 2020 Honors and Awards • Honoree, Best Doctors in America, Pittsburgh Magazine, 2016-present

Priya Rastogi, MD Dr. Rastogi is involved with the development and implementation of Phase II and Phase III clinical trials, and she serves as the protocol officer for Phase II and Phase III adjuvant and neoadjuvant breast cancer clinical trials. Her research has been published in several medical journals, including Journal of Clinical Oncology, Clinical Breast Cancer, New England Journal of Medicine, Oncology, Oncology Nurse Forum, Onkologie, Menopause, and Breast Cancer Research Treatment. Advisory Committee Memberships and Leadership Positions • Member, Working Group, NSABP Breast Committee, 2005-present • Vice Chair, Medical Affairs, NSABP, 2006-present • Member, Steering Committee, CALOR, 2012-present • Member, Operations Committee, Kathrine Trial, 2012-present • Member, Breast, Working Group, and Publications Committees, NRG Oncology, 2013-present • Member, Steering and Executive Committees, Olympia Trial, 2013-present • Member, Steering Committee, NCI MBC Endpoints Working Group, 2016-present • Co-Chair, New Investigator Committee, NRG Oncology, 2020-present Professional Affiliations and Society Memberships • Member, American Society of Clinical Oncology, 2002-present • Member, American Association for Cancer Research, 2003-present • Medical Director, NSABP Foundation, 2011-present Major Lectureships and Seminars • Presenter, NRG Oncology, Semi-Annual NRG Oncology Meetings, Philadephia, PA and Houston, TX, 2019-2020

Division of Hematology/Oncology RESEARCH

• Presenter, UPMC Hillman Cancer Center, San Antonio Breast Cancer Symposium, Pittsburgh, PA, February 2020

Robert L. Redner, MD A member of the Cancer Therapeutics Program of the University of Pittsburgh Cancer Institute, Dr. Redner researches the molecular biology of leukemic transformation and myeloid differentiation. A major focus of his laboratory has been the mechanism underlying differentiation arrest in myeloid leukemia, investigating acute promyelocytic leukemia (APL) as a model system. His group first cloned the NPM-RAR translocation that characterizes the t(5;17) variant of APL, and his lab has had an active program studying the mechanism by which NPM-RAR generates the leukemic phenotype. Study Sections • Judge, Poster Session, UPMC Hillman Cancer Center, Annual Scientific Retreat, Pittsburgh, PA, 2019 • Member, TMDC Committee, American Society of Hematology, 2010-present Advisory Committee Memberships and Leadership Positions • Director, Clinical Oncology and Hematology Grand Rounds, UPMC Hillman Cancer Center, 2006-present • Co-Chair, MDS Pathway, VIA Oncology, 2010-present Professional Affiliations and Society Memberships • Member, American Society of Hematology, 1995-present Editorships • Editorial Board, Clinical Medicine: Blood Disorders, 2008-present • Editorial Board, Leukemia and Lymphoma, 2009-present • Reviewer, Multiple journals, 2018-present

Linda B. Robertson, DPH, MSN Dr. Robertson has multiple research interests, including decision-making, particularly as it relates to cancer prevention and early detection, including preventative vaccines. She continues to explore the growing problem of HPV infection in our community. In particular, she is interested in the assessment of individuals of lower SES and their knowledge of HPV infection, specifically methods of transmission, the potential for illness/disease, and prevention of HPV through behavior and vaccination. In addition, Dr. Robertson studies issues related to health equity and cancer care as the site PI for the RCT for “Accountability for Cancer Care through Undoing Racism and Equity (ACCURE).” Finally, Dr. Robertson, working with a multidisciplinary team, recently completed a pilot study using a mixed qualitative and geostatistical approach to characterize psychosocial stressors—and their spatial relationships with air pollution—across the city of Pittsburgh and to explore possible relationships with other exposures and cancer incidence. Advisory Committee Memberships and Leadership Positions • Board Chair, PA Immunization Coalition, 2015-present • Co-Chair, Colorectal Cancer Committee, PA Department of Health, 2017-present • Member, Executive Committee, PA Department of Health Cancer Coalition, 2019-present Professional Affiliations and Society Memberships • Member, American Public Health Association, 2015-present Editorships • Reviewer, Multiple journals (International Journal of Prevention Practice and Research, Journal of Qualitative Research, 2009-present Major Lectureships and Seminars • Lecturer, American Society for Radiation Oncology, Annual Meeting, Chicago, IL, September 2019 54

Department of Medicine 2020 Annual Report Honors and Awards • Pennsylvania Breast Cancer Partner Recognition Award, Adagio Health, PA Commission for Women, 2019

John C. Schmitz, PhD As Co-Director of the Cancer Pharmacokinetics and Pharmacodynamics Facility, Dr. Schmitz provides integrated pharmacodynamic (PD) services in support of translational and clinical HCC research programs. This includes (a) facilitating patient sample acquisition, processing, and storage; (b) analysis of serum-based biomarkers; (c) implementing existing NCI/CTEP PD assays; and (d) developing assays for measurement of novel PD endpoints. Our PD lab has developed and validated a quantitative multiplexed immunoblot assay for detection of phosphorylation of ATM in patients treated with DNA-damaging radiotherapy and chemotherapy. Dr. Schmitz’s basic research focuses on development of novel chemotherapeutic targets and agents for the treatment of human colorectal cancer (CRC). Other research interests include identification and validation of traditional Chinese herbal medicines and/or natural compounds with anticancer activity by themselves and in combination with current therapies. Dr. Schmitz’s lab has identified a 5-herb formulation that can enhance the cytotoxicity of 5-fluorouracil in animal models through inhibition of the RB/E2F1/TS pathway. Lab researchers are investigating the role of each herb in this interaction. His lab has also demonstrated that the quassinoid bruceantinol has potent antiproliferative activity against colorectal cancer cells and tumors. The lab revealed that the mechanism of action of bruceantinol was through inhibition of the STAT3 signaling pathway resulting in cancer cell growth inhibition. Advisory Committee Memberships and Leadership Positions • Member, UPMC HCC Protocol Review Committee, 2015-present Professional Affiliations and Society Memberships • Member, AACR, 1991-present Editorships • Editorial Board, Oncology Research, 2015-present • Reviewer, Multiple Journals, 2016-present • Editorial Board, Cancer Chemotherapy and Pharmacology, 2019-present Major Lectureships and Seminars • Keynote Speaker, Chinese Pharmacological Society, 12th Academic Conference on Traditional Chinese Medicine and Natural Medicine Pharmacology, Tianjin, China, October 2019 • Invited Lecturer, Shanghai University of Traditional Chinese Medicine, Shanghai, China, October 2019 • Invited Lecturer, Southern Medical University, Guangzhou, China, October 2019

Craig D. Seaman, MD, MS Dr. Seaman’s primary research focus is the role of aging and aging-related conditions in hereditary bleeding disorders, specifically von Willebrand disease and hemophilia. His current research interests include the role of cardiovascular disease and related disorders in von Willebrand disease and hemophilia; the effects of aging on von Willebrand factor levels and bleeding phenotype in von Will- ebrand disease; and the use of alternative descriptors of body weight for clotting factor concentrate dosing in overweight and obese patients with hemophilia. Advisory Committee Memberships and Leadership Positions • Member, Advisory Board, Bayer Pharmaceutics Company, 2017-present • Member, Advisory Board, Genentech, 2018-present • Member, Advisory Board, Spark Therapeutics, 2018-present • Member, Presentation and Publication Committee, Community Counts: CDC Public Health Surveillance Project for Bleeding Disorders, 2018-present 55

Division of Hematology/Oncology RESEARCH

• Member, Advisory Board, Takeda Pharmaceutical Company, 2019-present • Member, Special K Committee, Hematology T32 Training Grant, 2019-present • Member, Mid-Atlantic Region III Executive Committee, Federally Funded Hemophilia Treatment Centers, 2020-present Professional Affiliations and Society Memberships • Member, American Society of Hematology, 2011-present • Member, Hemostasis and Thrombosis Research Society, 2013-present • Member, International Society on Thrombosis and Hemostasis, 2015-present Editorships • Reviewer, Multiple journals (Journal of Thrombosis and Hemostasis, Clinical and Applied Hemostasis/Thrombosis), 2017-present Major Lectureships and Seminars • Presenter, Benign Hematology Year in Review, University of Pittsburgh Department of Medicine, Grand Rounds, February 2020

Malabika Sen, PhD Dr. Sen’s research focusses on understanding and characterizing epigenetic changes in lung tumor and the tumor microenvironment and development of therapeutic strategies based upon epigenetic alterations. In addition, her work includes studying the alterations in DNA methylation for use as predictive biomarkers for early detection of lung cancer. Her research seeks to elucidate epigenetic alterations contributing to increased oncogenic signaling and investigate mechanisms including the role of the tumor microenvironment in a series of preclinical models and use therapeutic strategies to predict sensitivity in NSCLC. Study Sections • External Reviewer, Cancer Research Training Travel Awards for LMIC Investigators, CRDF Global, on behalf of the National Cancer Institute, 2019 Editorships • Editorial Board Member, Journal of Cancer Diagnosis, 2016-present • Reviewer, Multiple journals (Molecular Carcinogenesis, Scientific Reports, Cancer), 2019-present

Warren D. Shlomchik, MD Dr. Shlomchik’s research program is dedicated to understanding the complex immunology of allogeneic hematopoietic stem cell transplantation. At the bench, Dr. Shlomchik’s research has primarily taken genetic approaches with mouse models to test fundamental hypotheses regarding alloSCT immunology, in particular mechanisms of graft-vs-host disease (GVHD), graft-vs-leukemia (GVL) and GVL-resistance. A goal of these studies is to make discoveries that can be translated in the clinic. One such discovery resulted in co-developing a reagent to deplete naïve T cells (TN) from stem cell products, thereby allowing the transfer of only memory phenotype T cells. The results of the first- in-human trial of this approach in patients with acute leukemia suggest that the depletion of naïve T cells results in a remarkably low rate of chronic GVHD without an increase in relapse or infections. This approach is now being examined in a 4-arm clinical trial that includes high or lower intensity conditioning and grafts that are from HLA-matched related HLA-matched unrelated donors. Recently, Dr. Shlomchik published his research that for effective GVL, myeloblastic leukemias must be stimulated by IFN- whereas chronic phase CML does not require any IFN stimulation as demonstrated by GVL sensitivity of chronic phase CML genetically lacking the IFN-R and IFNAR1 or lacking STAT1 and STAT2 (JCI, 2017). He is now trying to understand how IFN- sensitizes myeloblasts and is in the planning stages of a clinical trial of IFN- therapy in collaboration with the Royal Brisbane Hospital. Dr. Shlomchik has also established a system wherein GVHD-inducing T cells can be clonally tracked, and using this system he has strong preliminary data that GVHD is locally maintained in 56

Department of Medicine 2020 Annual Report tissues, rather than alloreactive T cells in different tissues and secondary lymphoid tissues being in equilibrium. Additionally, Dr. Shlmochik has been using a tractable GVL system to understand GVL failure, determining that GVL-inducing T cells fail due to the progressive loss of antigen stimulation and due to T cell exhaustion. Antigen presentation can be augmented by an agonist antibody to CD40 whereas exhaustion can also be diminished by anti-CD40 and even more so by PD-1 blockade. He has found no evidence for selection of GVL-resistant leukemias, though this can happen clinically. Lastly, current research has also suggested that use of minor H antigen (miHA)-specific memory T cells can dramatically improve allogeneic bone marrow engraftment without GVHD and that this is also augmented by anti-CD40. Future work will test this approach in autoimmunity models and to create tolerance to solid organ transplants. Study Sections • Ad hoc Reviewer, P01, NIH, 2019-2020 • Ad hoc Reviewer, special emphasis panel, NIH, 2019-2020 Advisory Committee Memberships and Leadership Positions • Director, Hematopoietic Stem Cell Transplant, Cell Therapy, and Hematologic Malignancy Program, UPMC/University of Pittsburgh, 2015-present • Member, Advisory Board, Immune Transplant Therapy Center, 2016-present • Member, Advisory Committee, Cancer Center IMCPL, 2016-present • Director, Clinical Research Search Committee, University of Pittsburgh, 2017-present • Member, Starzl Executive Committee, 2018-present • Member, Advisory Committee, Discovery Acceleration and Support Hub (DASH), 2018-present • Member, Organizing Committee, 4th International Workshop on Clinical Tolerance, 2018-present • Member, Scientific Advisory Committee, Washington University SPORE in Leukemia, 2019-2020 • Member, T32 Advisory Committee, University of North Carolina, 2019-2020 • Member, Scientific Organizing Committee, American Society for Transplantation and Cellular Therapy/Center International Blood and Marrow Transplant Research, 2019- 2021 • Head, Scientific Advisory Board, Bluesphere Bio, 2019-present • Member, Scientific Organizing Committee, Transplant and Cellular Therapy Meeting, 2020 Professional Affiliations and Society Memberships • Member, American Society for Clinical Investigation, 2017-present • Member, American Society for Hematology, 2017-present • Member, American Society for Transplantation and Cellular Therapy, 2017-present • Member, American Association of Immunology, 2017-present • Member, Association of American Physicians, 2019-present Editorships • Reviewer, Multiple journals, 1999-present • Consulting Editor, JCI Insight, 2019-present Major Lectureships and Seminars • Invited Plenary Speaker, Institute of Xuzhou Medical University, 11th Annual Meeting of the Chinese Society of Bone Marrow Transplantation in Hefei, Jiangsu Province, China, September 2019 • Invited Speaker, Chinese Society for Blood and Marrow Transplant, 11th Annual Meeting, Hefei, China, September 2019 • Invited Speaker, Fondazione Ri.Med, 13th Ri MED Scientific Symposium, Palermo, Italy, October 2019

Division of Hematology/Oncology RESEARCH

• Invited Speaker, University of Michigan, Hematopoiesis and Immunology (CHI) Program Lecture Series, Ann Arbor, MI, 2020

Roy E. Smith, MD Dr. Smith served as the Director of Medical Affairs for the NABP. He has had an interest in breast and colorectal clinical trials for many years. Dr. Smith is a former chairman of the Central Investi- gational Review Board for Cancer Therapy Evaluation Program of the National Cancer Institute and has played a key role in revising its role in the conduct of Cooperative Group Program trials. He is interested in immune thrombocytopenic purpura and porphyria. Advisory Committee Memberships and Leadership Positions • Member, Coagulation Committee, The American Society for Pheresis, 2014-present • Inaugural Director, ASH Medical Educators Institute, 2014-present • Member, Governance Committee, National Pulmonary Embolus Response Team Consortium, 2014-present • Member, Advisory Board, Cold Aggultinin Disease, June 2020 Professional Affiliations and Society Memberships • Member, American Medical Association, 1978-present • Member, American Society of Clinical Oncology, 1979-present • Member, American Society of Hematology, 1980-present • Fellow, American College of Physicians, 1980-present • Member, American Society for Apheresis, 1996-present • Member, Internal Society of Thrombosis and Haemostasis, 2014-present • Member, North American Society of Thrombosis and Hemostasis, 2014-present Editorships • Editorial Board, Journal of Hematology & Thrombosis, 2014-present • Editorial Board, Journal of Blood Disorders and Medicine, 2015-present • Editorial Board, General Medicine Journal of OMICS Publishing Group, 2016-present Major Lectureships and Seminars • Co-Moderator, Case Presenter, PERT Consortium Meeting, 2019-2020 • Presenter, Shadyside Grand Rounds, UPMC Shadyside, 2019-2020 • Presenter, UPMC, Internal Medicine Residency Noon Conference, 2019-2020

Richard A. Steinman, MD, PhD Dr. Steinman’s laboratory studies the cancer microenvironment with a focus on the molecular and functional interactions between cancer cells, fibroblasts, and platelets in work supported over the past year by a Pennsylvania CURE grant. Platelets have been shown to support the growth and spread of cancer cells in multiple pre-clinical models. Dr. Steinman’s laboratory has identified an unex- pected pathway that appears to be necessary for platelets to aggregate in response to agonists, to secrete pro-tumorigenic molecules, and to interact with cancer cells. This pathway is a target of both clinically used drugs and of other agents in clinical trials. He is studying platelet function as a predictive biomarker for these clinical agents and studying how the pathway controls Photo platelet functions. As Director of the Medical Scientist Advisory Committee Memberships and Leadership Positions Training Program and the Burroughs Wellcome Fund Fellowship, Dr. • Member, External Advisory Board, MARC Program, Hampton Steinman has a longstanding interest University, 2014-present in the education of physician scientist, • Director, Medical Scientist Training Program, 2019-2020 leading to his nomination in 2019 for the Prize for Research in Medical • Director, Burroughs Wellcome / Pitt Physician Scientist, 2019-2020 Education by the Karolinska Institute.

Department of Medicine 2020 Annual Report Professional Affiliations and Society Memberships • Member, American Society of Hematology, 2000-present Honors and Awards • Institutional Nominee, Prize for Research in Medical Education, Karolinska Institutet, 2019-2020 • Recipient, Academy of Master Educators, 2019-2020

Quanhong Sun, PhD Dr. Sun’s research focus is determining the mechanism by which Measles virus nucleocapsid protein (MVNP) results in aberrant osteoclast differentiation. MVNP has been shown to be able to induce a Pagetic phenotype when transduced into osteoclast precursors—with increasing evidence that it can play a role in the development of Paget’s disease. Dr. Sun’s lab has reported that MVNP signals through the IKK family member TBK1 to increase IL-6, a key player in creating the pagetic microenvironment. Current studies seek to determine the mechanism by which MVNP regulates the competi- tive balance between TBK1 activity and levels of OPTN (a negative regulator) in osteoclasts. Dr. Sun’s group is also using transgenic mouse models to determine whether increased TBK1 expression in OCL precursors will phenocopy MVNP or cooperate with p62P394L to generate the pagetic phenotype in mice. Further, the lab is testing whether TBK1 is required for the formation of pagetic lesions in vivo by crossing TBK1 conditional knockout mice with MVNP/P62KI mice. Dr. Sun is also interested in determining the role and mechanisms of TBK1 and its homolog IKK in other inflammatory bone diseases, such as multiple myeloma (MM) bone disease. Professional Affiliations and Society Memberships • Member, American Society for Bone and Mineral Research, 2011-present Honors and Awards • Plenary Poster Award and Oral Poster Talk, American Society for Bone and Mineral Research, 2019-2020

Darcy L. Thull, MS Dr. Thull’s primary research interest is the use of hereditary cancer registries to facilitate research in cancer prevention, screening, and personalized care for families with hereditary cancer predis- position. Advisory Committee Memberships and Leadership Positions • Member, Advisory Board, University of Pittsburgh GSPH Genetic Counseling Program, 2011-present Professional Affiliations and Society Memberships • Member, National Society of Genetic Counselors, 1990-present

Gijsberta J. van Londen, MD, MS Dr. van Londen performs her own research, but also collaborates on research that is highly relevant to (older) cancer survivors. Her main focus points are the assessment and management of adverse effects of and adherence to self-administered cancer therapies as well as the needs of post-treatment cancer survivors. Professional Affiliations and Society Memberships • Member, American Society for Clinical Oncology, 2004-present • Member, NSABP Foundation, 2011-present Major Lectureships and Seminars • Presenter, UPMC Hillman Cancer Center, San Antonio Breast Cancer Society Review, Pittsburgh, PA, February 2020

Division of Hematology/Oncology RESEARCH

Liza C. Villaruz, MD Dr. Villaruz is a clinical and translational investigator in lung cancer who is actively involved in current clinical trials and who has a strong track record of successful development of institutional clinical trials through NCI-CTEP and industry. Dr. Villaruz actively develops clinical trials in both the HCC Lung Cancer Program (LCP) and the UM1 NCI ET-CTN with Phase I Emphasis at the HCC. She facilitates the interactions between the LCP and the Phase I Program. Among the institutional clinical trials developed by Dr. Villaruz is the NCI-CTEP UM1 sponsored multi-center phase I clinical trial of the ATR inhibitor VX-970 in combination with irinotecan in patients with solid organ tumors (UPCI 15-164/ NCI P9938), which was developed in close collaboration with the translational and basic scientists at the UPCI. Dr. Villaruz is the HCC Principal Investigator for the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), a national consortium of academic institutions that designs and conducts clinical trials in thoracic oncology. Study Sections • Reviewer, U01 Grants, National Cancer Institute, June 2020 Advisory Committee Memberships and Leadership Positions • Member, Protocol Review Committee B, UPMC Hillman Cancer Center, 2009-present • Member, Clinical Disease Pathway Committee, University of Pittsburgh, School of Medicine, 2011-present • Member, The Academic Thoracic Oncology Medical Investigators Consortium, 2014-present • Co-Director, LCSCC, 2015-present • Member, Lung Cancer Mutation Consortium (LCMC), 2016-present • Member, Lung MAP Trial Oversight Committee, SWOG, 2020-present Professional Affiliations and Society Memberships • Member, American Society of Clinical Oncology, 2010-present • Member, International Association for the Study of Lung Cancer, 2014-present • Member, European Society of Medical Oncology, 2019-present Editorships • Reviewer, Multiple journals, 2012-present • Editorial Board, Oncology Research, 2016-present Major Lectureships and Seminars • Invited Speaker, Southwest General Health Center, Middleburg Heights, OH, September 2019 • Invited Speaker, OncLive, State of Science Summit, Pittsburgh, PA, September 2019 • Invited Speaker, University of Pittsburgh, Department of Medicine, DOM Grand Rounds, Hematology/Oncology Year in Review, Pittsburgh, PA, February 2020 • Invited Speaker, IASLC, IASLC 2020 Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA, February 2020

Donald V. Woytowitz, MD Dr. Woytowitz’s research interests are autoimmune hemolytic anemia, ITP, and Lupus anticoagulant. Advisory Committee Memberships and Leadership Positions Member, Quality Collaborative, Pre-surgical Anemia Correction, 2015-present Member, Protocol Review Committee, University of Pittsburgh, 2016-present Professional Affiliations and Society Memberships • Member, American Society of Hematology, 1995-present Editorships • Reviewer, Multiple journals, 2018-present • Editorial Board, Clinical Colorectal Cancer, 2019

Department of Medicine 2020 Annual Report Antoinette Wozniak, MD Dr. Wozniak’s research focuses on lung cancer, including small cell, non-small cell, and mesothelioma, as well as thymus gland cancer. Study Sections • Reviewer, American Lung Association, 2015-present • Reviewer, V Foundation for Cancer Research, 2019-present • Reviewer, Lung Cancer Research Foundation, 2019-present Advisory Committee Memberships and Leadership Positions • Lung Expert, Medical Advisory Panel, American Lung Association, 2015-present • Member, New Member Engagement and Recognition Group, American Society of Clinical Oncology, 2017-present • Member, Scientific Advisory Committee, Lung Cancer Research Foundation, 2017-present • Medical Director, Clinical Research Services (CRS), UPMC Hillman Cancer Center, 2018-present • Member, Clinical Research Oversight Committee (CROC), UPMC Hillman Cancer Center, 2018-present • Member, Research Executive Advisory Committee, UPMC Hillman Cancer Center, 2018-present • Member, Senior Leadership Team, UPMC Hillman Cancer Center, 2018-present • Vice Chair, Women’s Task Force, UPMC Hillman Cancer Center, 2018-present • Member, Board of Directors, Mesothelioma Applied Research Foundation, 2019-present • Member, Education Committee, International Association for the Study of Lung Cancer, 2019-present • Member, Test Materials Development Subcommittee, American Society of Clinical Oncology, 2019-present Professional Affiliations and Society Memberships • Member, SWOG Cancer Research Network, 1984-present • Member, American Association for Cancer Research (AACR), 1985-present • Fellow, American College of Physicians, 1992-present • Member, International Association for the Study of Lung Cancer, 2000-present • Fellow, American Society of Clinical Oncology, 2018-present • Member, Society for Immunotherapy of Cancer, 2018-present Editorships • Editor-in-Chief, Clinical Lung Cancer, 2019-present • Editorial Board Member, Cancer Cells and Therapy, 2019-present Major Lectureships and Seminars • Lecturer, Medical Education Consortium, 14th Annual New Orleans Summer Cancer Meeting, New Orleans, LA, 2019-2020 • Oral Abstract Presenter, International Association for the Study of Lung Cancer, 2019 World Conference on Lung Cancer, Barcelona, Spain, September 2019 • Lecturer, European Prospective Investigation into Cancer, Lung Cancer in 2019 and Beyond, Barcelona, Spain, September 2019 • Lecturer, Xiangya Hospital, Central South University, Xiangya-UPMC Symposium on Cancer Genomics and Immunology, Changsha, Hunan, China, October 2019 • Lecturer, European Prospective Investigation into Cancer, Lung Cancer in 2019 and Beyond, New York City, NY, November 2019 Honors and Awards • Honoree, Best Doctors in America, Pittsburgh Magazine, 2019-2020 • Recipient, Hillman Fellow for Innovative Team Science Cancer Research, UPMC Hillman Cancer Center, 2020 61

Division of Hematology/Oncology RESEARCH

Dan P. Zandberg, MD Dr. Zandberg is a translational and clinical researcher whose primary interest is the development of novel immunotherapy trials to improve outcomes in recurrent/metastatic squamous cell carcinoma of the head and neck. Advisory Committee Memberships and Leadership Positions • Member, Experimental Therapeutics and Rare Tumor Committee, Alliance for Clinical Trials in Oncology, 2016-present • Member, Previously Untreated Locally Advanced Task Force, NCI Head and Neck Steering Committee, 2017-present • Director, Head and Neck and Thyroid Cancer Disease Sections, University of Pittsburgh, Division of Hematology/Oncology, 2018-present • Leader, Clinical Research Services Head and Neck Cancer Clinical Trials Team, UPMC Hillman Cancer Center, 2018-present • Medical Oncology Co-Leader, UPMC Hillman Cancer Center Head and Neck Program, 2018-present • Member, Advances in Cancer Immunotherapy Committee, SITC, 2018-present • Member, Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, 2018-present • Member, Fellowship Selection Committee, University of Pittsburgh, Division of Hematology/Oncology, 2018-present • Member, Head and Neck Cancer Clinical Disease Pathway Committee, Elsevier, 2018-present • Member, Head and Neck Cancer Committee, ECOG-ACRIN, 2018-present • Member, Pharmacy and Therapeutics Committee, UPMC Hillman Cancer Center, 2018-present • Member, Research Executive Advisory Committee (REAC), UPMC Hillman Cancer Center, 2018-present • Member, Translational and Clinical Research Strategic Vision Team, UPMC Hillman Cancer Center, 2018-present • Physician Lead, UPMC Hillman Cancer Center, 2nd Floor, 2020-present Professional Affiliations and Society Memberships • Member, American Society of Clinical Oncology, 2011-present • Member, American Association for Cancer Research (AACR), 2017-present • Member, Society for Immunotherapy in Cancer, 2018-present Editorships • Reviewer, Multiple journals, 2016-present • Editorial Advisory Board, Oncology Research, 2018-present Honors and Awards • Recipient, Cancer Clinical Investigator Team Leadership Award, National Cancer Institute, September 2019

Hassane M. Zarour, MD Dr. Zarour’s research interests include the identification of novel MHC class II epitopes derived from tumor antigens expressed by melanoma. His laboratory has successfully developed the approach to identify T-helper epitopes derived from a number of human tumor antigens and capable of stimulation antigen-specific CD4+ T cells in patients with advanced cancer. A second interest is the development of novel melanoma vaccines trial with T-helper epitopes and adjuvants. His lab has performed clinical trials with MHC class I and MHC class II epitopes derived from the cancer/testis antigen NY-ESO-1 in combination with CPG in patients with advanced melanoma. The lab has also demonstrated the capability of CPG to stimulate potent and ex vivo detectable CD8+ T cell respons-

Department of Medicine 2020 Annual Report es to NY-ESO-1. A third research focus is the study of the mechanisms of melanoma-induced T cell dysfunction, including the role of the PD-1, Tim-3, BTLA and TIGIT pathways. These studies serve as rationale for ongoing clinical trials with dual PD1/Tim-3 and PD-1/TIGIT blockade in cancer patients, including melanoma. Finally, Dr. Zarour studies the role of the gut microbiome in modulating clinical and immune responses to immune checkpoint blockade in the context of a novel clinical trial with fecal microbiota transplant and anti-PD-1 antibodies in patients with PD1 refractory melanoma. Study Sections • External Reviewer, Clinical/Translational Science, Intramural Research Program, Ohio State University Comprehensive Cancer Center, 2019 • Reviewer, Moonshot Initiative, National Cancer Institute, July 2019 • Reviewer, SEP Cancer Diagnostics and Treatments, SBIR/STTR, November 2019 • Reviewer, ZRG-1-OTC-M-08 Immuno-Oncology Research, NCI, March 2020 • Reviewer, Institut National du Cancer (INCA, Frend NCI), 2011-present • Reviewer, Melanoma Research Foundation, 2013-present • Reviewer, SEP-2, Clinical and Translational R21 and Omnibus R03, National Cancer Institute, 2019-2020 Advisory Committee Memberships and Leadership Positions • Member, Cancer Vaccine Collaborative Group, Cancer Research Institute, New York, NY, 2002-present • Co-Leader, Cancer Immunotherapy Trial Network, University of Pittsburgh, 2011-present • Co-Leader, Melanoma Program, UPMC Hillman Cancer Center, 2014-present • Member, Internal Advisory Board, NIBIB Biomedical Technology Resource Center P41, 2015-present • Member, Search Committee, Cancer Biology Program, UPMC Hillman Cancer Center, 2015-present • Member, Shared Facilities Oversight Committee, UPMC Hillman Cancer Center, 2015-present • Internal Advisory Board, Ovarian Cancer SPORE, UPMC Hillman Cancer Center, 2015-present • Co-Leader, Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center, 2018-present • Member, Executive Committee, Cancer Immunology Training Program (CITP), 2018-present • Member, Tenured Faculty Promotions and Appointments Committee, University of Pittsburgh, 2019-present Professional Affiliations and Society Memberships • Member, Société Française de Dermatologie, 1996-present • Member, American Association of Immunology, 2000-present • Member, American Association for Cancer Research, 2000-present • Member, Eastern Cooperative Oncology Group, 2000-present • Member, American Society of Clinical Oncology, 2004-present • Member, International Society for Biological Therapy of Cancer, 2005-present • Member, Society of Immunotherapy of Cancer, 2010-present Editorships • Reviewer, Multiple Journals, 2002-present Major Lectureships and Seminars • Presenter, The Wistar Institute, Annual Skin SPORE Scientific Retreat, Philadelphia, PA, July 2019 • Presenter, FDA, FDA Mini-symposium on Microbiome and Cancer Immunotherapy, White Oak Campus, Silver Spring, MD, July 2019

Division of Hematology/Oncology RESEARCH

• Presenter, National Cancer Institute, Reproductivity of Probiotics and FMT in Cancer Clinical Research and Clinical Trial, NCI Shady Grove Campus, Bethesda, MD, September 2019 • Presenter, Immunotherapy Bridge & Melanoma, Naples, Italy, December 2019 • Presenter, UPMC Children’s Hospital of Pittsburgh, Topics in Pediatric Hematology/ Oncology/BMT/CT Lecture, February 2020 • Presenter, CITP Committee/Trainee Mentor Meeting, Zoom presentation, May 2020 Honors and Awards • James W. and Frances G. McGlothlin Chair, Melanoma Immunotherapy Research, 2019

Department of Medicine 2020 Annual Report GRANTS AND CONTRACTS AWARDED

July 1, 2019 to June 30, 2020

PUBLIC HEALTH SERVICE

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Appleman, Leonard Biomarkers of Sulforaphane/Broccoli Sprout Extract NCI $1,248 $705 in Prostate Cancer Appleman, Leonard Cancer Center Support Grant NCI $64,458 $34,807 Appleman, Leonard (PQ5) Mitochondria are endocellular symbionts that NCI/University of $3,146 $1,777 serve as targets for immune recognition Pennsylvania Bahary, Nathan A mobile sensing system to monitor symptoms NCI $2,518 $1,423 during chemotherapy Bahary, Nathan Validation of biomarkers for early diagnosis and risk NCI $1,552 $877 prediction of pancreatic neoplasms Boyiadzis, Michael University of Pittsburgh Clinical and Translational NCATS $89,989 $50,844 Science Institute Boyiadzis, Michael Peptide vaccine immunotherapy for children with NCI $9,987 $5,393 recurrent low-grade astrocytomas Boyiadzis, Michael Peptide vaccine immunotherapy for children with NCI $9,987 $5,393 recurrent low-grade astrocytomas Boyiadzis, Michael Trial Using Epsilon Aminocaproic Acid Therapy in NHLBI/University $2,420 $1,307 Thrombocytopenia (TREATT)CCC of Washington Brufsky, Adam NCI NCTN-Network Lead Academic Participating Site NCI $497,955 $281,345 at UPMC Hillman Cancer Center Brufsky, Adam A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 NCI/Vanderbilt $48,784 $12,196 Inhibitor) and Erdafitinib (JNJ-42756493, Pan-FGFR University Tyrosine Kinase Inhibitor) in ER+/HER2?/FGFR-Ampli- Medical Center fied Metastatic Breast Cancer Brufsky, Adam The Symptom Experience, Management and NIMHD $6,097 $3,445 Outcomes According to Race and Social Determi- nants of Health (SEMOARS) During Breast Cancer Chemotherapy Chu, Edward A cluster randomized trial of a primary palliative care NCI $2,383 $1,346 intervention (CONNECT) for patients with advanced cancer Chu, Edward Cancer Center Support Grant NCI $267,618 $144,513 Chu, Edward NCI ETCTN Pittsburgh Cancer Consortium (PCC) NCI $73,371 $41,454 Chu, Edward NCI ETCTN Pittsburgh Cancer Consortium (PCC) NCI $129,806 $73,340 Chu, Edward NCI ETCTN Pittsburgh Cancer Consortium (PCC) NCI $15,347 $8,671 Chu, Edward NCI ETCTN Pittsburgh Cancer Consortium (PCC) NCI $2,500 $1,413 Chu, Edward Training in Cancer Therapeutics Research NCI $366,624 $29,330 Coffman, Lan Defining the formation and function of carcino- NCI $153,750 $12,300 ma-associated mesenchymal stem cells in the ovarian cancer microenvironment

Division of Hematology/Oncology GRANTS

PUBLIC HEALTH SERVICE

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Davar, Diwakar Fecal Microbiota Transplant and PD-1 blockade in NCI $24,204 $13,675 Melanoma Donnenberg, Albert Omics, mice and men: Development of precision NHLBI $31,097 $17,570 transfusion medicine Donnenberg, Albert Hemoglobin-based Antidotes for the Treatment of NHLBI/Globin $3,687 $2,083 Carbon Monoxide Poisoning Solutions, Inc Emens, Leisha Predictive experiment-based multiscale models of NCI/Johns $1,322 $747 the tumor immune microenvironment and immuno- Hopkins therapy in breast cancer University Ferguson, Robert Mobile Device CBT for Chemotherapy-Related NCI $322,642 $182,292 Cognitive Dysfunction: A Multi-Center Randomized Controlled Trial Galson, Deborah Viral and Genetic Regulation of Abnormal OCL Activi- NIAMS $243,571 $131,529 ty in Paget’s Disease Galson, Deborah The UPMC Hillman Cancer Center Academy NCI $8,578 $686 Herman, Jim Randomized Clinical Trial of Lung Cancer Chemopre- NCI $9,770 $5,520 vention with Sulforaphane in Former Smokers Herman, Jim Ultrasensitive Detection of Tumor Specific DNA NCI $258,259 $145,916 Methylation Changes for the Early Detection of Lung Cancer Herman, Jim Ultrasensitive Detection of Tumor Specific DNA NCI $79,734 $45,050 Methylation Changes for the Early Detection of Lung Cancer Herman, Jim Validating an integrated biomarker and imaging NCI/Vanderbilt $15,000 $8,475 approach in the evaluation of indeterminate pulmo- University nary nodules Medical Center Herman, Jim Validation of Biomarkers of Risk for the Early Detec- NCI/Vanderbilt $50,000 $28,250 tion of Lung Cancer (Set-Aside Funds) University Medical Center Horn, Charles Multisensory Integration Producing Nausea and NIDCD $24,381 $13,775 Vomiting Horn, Charles Neural mechanisms of nausea, vomiting, and energy NIDDK/ $10,256 $5,795 balance dysregulation in animal models University of Pennsylvania Horn, Charles Therapeutic potential of vagal neurostimulation to NIH $269,131 $152,059 reduce food intake Horn, Charles Infrared Neuromodulation Reveals a New Under- NIH/Case $43,082 $24,342 standing of Ganglion Organization Western Reserve University Horn, Charles Infrared Neuromodulation Reveals a New Under- NIH/Case $182,951 $103,367 standing of Ganglion Organization Western Reserve University Horn, Charles Genomic Underpinnings for Breast Cancer Treat- NINR $5,036 $2,845 ment Induced Nausea and Vomiting Kirkwood, John Harnessing Human Brain and Liver Microphysiolog- NCATS/Vanderbilt $12,105 $6,839 ical Systems for Testing Therapeutics for Metastatic University Melanoma Kirkwood, John Training Program in Skin Biology and Cancer NCI $149,506 $11,960 Kirkwood, John ECOG-ACRIN Operations Center NCI/Ecog-Acrin $12,780 $7,220 Medical Research Foundation, Inc.

Department of Medicine 2020 Annual Report PUBLIC HEALTH SERVICE

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Kirkwood, John ECOG-ACRIN NCORP Research Base - CT NCI/Ecog-Acrin $10,543 $5,957 Medical Research Foundation, Inc. Kiss, Joseph 1/2 Sickle Cell Disease and CardiovAscular Risk - Red NHLBI $96,458 $54,499 cell Exchange Trial (SCD-CARRE Trial) Kiss, Joseph 1/2 Sickle Cell Disease and CardiovAscular Risk - Red NHLBI $96,458 $54,499 cell Exchange Trial (SCD-CARRE Trial) Lokshin, Anna Cancer Center Support Grant NCI $11,759 $6,350 Lokshin, Anna Validation of biomarkers for early diagnosis and risk NCI $39,524 $22,331 prediction of pancreatic neoplasms Lokshin, Anna Breast, Colorectal, and Ovary Cancer Clinical Valida- NCI/Fred $10,992 $6,210 tion Center (CVC) Hutchinson Cancer Research Center Lokshin, Anna Omics Center of Acute to Chronic Pain Signatures NIDA/Pacific $7,703 $4,352 Northwest National Laboratory Low, Carissa Using Smartphone Assessments for Personalized NIAAA $44,661 $25,233 Prediction of Problematic Alcohol Use Low, Carissa The Center for Enhancing Triage and Utilization for NIMH $1,761 $995 Depression and Emergent Suicidality (ETUDES) in Pediatric Primary Care Low, Carissa A mobile sensing system to monitor symptoms NCI $220,083 $124,347 during chemotherapy Low, Carissa Technology-supported sedentary behavior interven- NCI $73,636 $5,891 tion to promote recovery from cancer surgery Low, Carissa A value affirmation intervention for physical symp- NCI/Carnegie $3,710 $2,096 toms and medication adherence in breast cancer Mellon patients taking aromatase inhibitors University Posluszny, Donna Mobile Device CBT for Chemotherapy-Related NCI $6,809 $3,847 Cognitive Dysfunction: A Multi-Center Randomized Controlled Trial Posluszny, Donna Persistent Post-Mastectomy Pain: Randomized NCI/Duke $2,472 $1,397 Clinical Trial of Targeted Pain Coping Skills Training University (T-PCST) with Meditational Analysis Posluszny, Donna Behavioral Health Workforce Education and Training HRSA/Chatham $13,526 $1,082 (BHWET) Program University Ragni, Margaret Training Students in Biomedical Research Hematol- NHLBI $24,372 $1,670 ogy Ragni, Margaret Von Willebrand Disease Minimize Menorrhagia NHLBI $300,332 $129,946 (VWDMin) Trial Ragni, Margaret Comparative Effectiveness in the Diagnosis of VWD NHLBI/Blood $6,050 $3,418 Center of Wisconsin Ragni, Margaret Zimmerman Program on the Biology of VWD NHLBI/Blood $5,463 $3,087 Center of Wisconsin Rastogi, Priya NRG Oncology Network Group Operations Center NCI/NSABP Foun- $130,384 $73,667 dation, Inc. Schmitz, John Cancer Center Support Grant NCI $86,595 $46,761

Division of Hematology/Oncology GRANTS

PUBLIC HEALTH SERVICE

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Schmitz, John Experimental study of stress and DNA damage in NCI $12,164 $6,872 humans: Mediators and moderators Schmitz, John NCI ETCTN Pittsburgh Cancer Consortium (PCC) NCI $8,707 $4,919 Seaman, Craig D. 2/2 Sickle Cell Disease and CardiovAscular Risk – Red NHLBI $3,100 $1,751 cell Exchange Trial (SCD-CARRE Trial) Shlomchik, Warren Prevention of Graft-Versus-Host Disease in the ERA NCI/Fred $15,974 $9,026 of Adoptive Immunotherapy Hutchinson Cancer Research Center Shlomchik, Warren Graft-versus-Host Disease: Local Maintenance in NHLBI $416,167 $235,134 Target Tissue Resident Memory-Type Cells Shlomchik, Warren T Cell Memory in Organ Transplantation NIAID $12,212 $6,900 Shlomchik, Warren Understanding and countering mechanisms under- NIAID $9,684 $5,472 lying IL-33-driven support of graft-vs. host disease Van Londen, Gijsberta A value affirmation intervention for physical symp- NCI/Carnegie $5,243 $2,962 toms and medication adherence in breast cancer Mellon patients taking aromatase inhibitors University Wozniak, Antoinette Cancer Center Support Grant NCI $16,816 $9,081 Wozniak, Antoinette Cancer Center Support Grant NCI $309,015 $166,868 Wozniak, Antoinette Palliative care intervention for socioeconomically NCI $45,078 $25,469 disadvantaged cancer patients Zandberg, Dan Cancer Center Support Grant: Administrative Sup- NCI $38,339 $21,661 plement for CCITLA 2019 Zandberg, Dan Head and Neck Cancer SPORE NCI $944 $510 Zandberg, Dan Head and Neck Cancer SPORE NCI $12,777 $6,900 Zandberg, Dan Palliative care intervention for socioeconomically NCI $1,929 $1,090 disadvantaged cancer patients Zarour, Hassane Fecal Microbiota Transplant and PD-1 blockade in NCI $253,007 $142,949 Melanoma TOTAL PUBLIC HEALTH SERVICE $5,861,077 $2,847,076

OTHER FEDERAL

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Bao, Riyue Genomic and Commensal Variants Associated with U.S. Army $9,425 $5,325 Immunotherapy in Cancer Patients Brufsky, Adam A New Persistence Mechanism for Drug-Tolerant U.S. Army $6,238 $3,524 Breast Cancer Cells Brufsky, Adam Distant inflammation drives emergence from meta- U.S. Army $15,799 $8,926 static dormancy Brufsky, Adam Leveraging Deep Learning and Bayesian Networks U.S. Army $62,725 $35,440 to Identify Risk Factors and Support Personalized Prediction for Metastatic Breast Cancer Donnenberg, Albert Restoration of the Functional Aesthetic Craniofacial U.S. Army/Metis $12,439 $7,028 Envelope and Extremities Foundation

Department of Medicine 2020 Annual Report OTHER FEDERAL

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Emens, Leisha Converting HR+ Breast Cancer into an Individualized DOD/Joan & $25,000 $14,125 Vaccine Sanford I. Weill Medical College of Cornell University Luke, Jason Genomic and Commensal Variants Associated with U.S. Army $193,566 $109,365 Immunotherapy in Cancer Patients Najjar, Yana Metabolic Remodeling of the Tumor Microenviron- U.S. Army $89,045 $50,310 ment to Improve the Efficacy of Immunotherapy Ragni, Margaret Design of Less Immunogenic Factor VIII Proteins DOD/Henry M. $4,271 $2,376 Jackson Foundation TOTAL OTHER FEDERAL $418,508 $236,420

STATE

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Chu, Edward Tobacco Phase 17 Formula Funds Commonwealth $18,485 $3,697 of Pennsylvania Herman, Jim Tobacco Phase 15 Formula Funds Commonwealth $44,146 $8,829 of Pennsylvania

Robertson, Linda Barry Pennsylvania Comprehensive Cancer Control Plan Commonwealth $260,869 $39,130 of Pennsylvania Steinman, Richard Tobacco Phase 17 Formula Funds Commonwealth $10,370 $2,074 of Pennsylvania Zhang, Mei Tobacco Phase 17 Formula Funds Commonwealth $73,426 $14,685 of Pennsylvania TOTAL STATE $407,297 $68,416

SOCIETY AND FOUNDATIONS

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Agha, Mounzer A Phase 2, Multicohort Open-Label Study of JNJ- Janssen Phar- $330,746 $99,224 68284528, a Chimeric Antigen Receptor T cell maceutica, L.P. (CAR-T) Therapy Directed Against BCMA in Subjects Research Foun- with Multiple Myeloma dation Bao, Riyue Integrative Analysis of Prognostic Factors to Neo- Melanoma Re- $9,648 $0 adjuvant Nivolumab/CMP-001 In Stage III B/C/D search Founda- Melanoma tion Brufsky, Adam I-SPY2 TRIAL (Investigation of Serial Studies to Pre- Quantum Leap $1,820,007 $546,002 dict Your Therapeutic Response with Imaging And Healthcare molecular Analysis 2): An Adaptive Breast Cancer Collaborative Trial Design in the Setting of Neoadjuvant Chemo- therapy

Division of Hematology/Oncology GRANTS

SOCIETY AND FOUNDATIONS

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Burgess, Melissa A Phase II Trial of MK-3475 (pembrolizumab) and Fred Hutchinson $43,077 $12,923 Interferon Gamma 1-b Combination Immunother- Cancer Research apy in Patients with Previously Treated Mycosis Center Fungoides and S¿zary Syndrome (Treatment Group 1) and in Patients with Advanced Synovial Sarcoma (Treatment Gro Burns, Timothy Targeting the HGF-TWIST1 Pathway to Overcome American Cancer $148,778 $29,756 MET TKI Resistance in NSCLC Society Coffman, Lan Omics Consortium to Study the Origins of Ovarian Magee-Womens $4,532 $2,560 Cancer Research Institute & Foundation Coffman, Lan Targeting Tumor Desmoplasia to Enhance Immuno- Magee-Womens $23,511 $2,351 therapy Research Institute & Foundation Coffman, Lan Investigating the Role of Carcinoma-Associated Mes- Mary Kay $43,478 $6,522 enchymal Stem Cells in Ovarian Cancer Metastasis Foundation Davar, Diwakar Integrative Analysis of Prognostic Factors to Neo- Melanoma $140,352 $0 adjuvant Nivolumab/CMP-001 In Stage III B/C/D Research Melanoma Foundation Davar, Diwakar CCA TDI Phase 2 (ITTC Project) University of $0 $0 Pittsburgh Medical Center (UPMC) De Castro, Laura Cognitive Behavioral Therapy and Real-time PCORI $22,025 $8,810 pain-management Interventions for Sickle cell via Mobile Applications (CaRISMA) Horn, Charles OncoBioelectrx University of $0 $0 Pittsburgh Medical Center (UPMC) Kirkwood, John Melanoma Tissue Bank Consortium Melanoma Tissue $158,000 $47,400 Bank Consortium Krishnamurthy, Anu- NSABP Subaward Agreement for Industrial Services NSABP $30,696 $7,674 radha Foundation, Inc. Ragni, Margaret A Multicenter Study of Eradication of Hepatitis C American Throm- $7,219 $1,582 Virus (HCV) Infection in People with Hemophilia and bosis and Hemo- Bleeding Disorders (ATHN 6: HCV Eradication Study) stasis Network Ragni, Margaret Hepatitis C Virus (HCV) Outcomes after Treatment American Throm- $5,535 $0 with DAA in Patients with Bleeding Disorders (ATH5: bosis and Hemo- Outcomes Study) stasis Network Ragni, Margaret Hemophilia Inhibitor Response to Eloctate (HIRE Blood Center of $4,376 $1,094 Study) Wisconsin Rastogi, Priya National Surgical Adjuvant Breast and Bowel Project NSABP $58,834 $14,709 - Oncologist (UP-Industrial-01) Foundation, Inc. Shlomchik, Warren Minor Histocompatibility Antigen-Reactive T Cells in University of $667,515 $0 a Mouse Model Pittsburgh Medical Center (UPMC) Shlomchik, Warren Minor Histocompatibility Antigen Vaccination in University of $142,938 $0 Humans Pittsburgh Medical Center (UPMC)

Department of Medicine 2020 Annual Report SOCIETY AND FOUNDATIONS

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Somasundaram, LAG3 on tumor specific CD8+ T International $50,000 $0 Ashwin Association for the Study of Lung Cancer Founda- tion Villaruz, Liza A Single Arm Phase II Study Osimertinib in Patients Duke University $41,529 $12,459 with Stage 4 Advanced Non-small Cell Lung Cancer with Uncommon EGFR Mutations TOTAL SOCIETY AND FOUNDATIONS $3,752,797 $793,065

INDUSTRY

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Agha, Mounzer A Phase 3, Multicenter, Randomized, Open-Label Celgene $897,664 $269,300 Study to Compare the Efficacy and Safety of bb2121 Corporation Verses Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (BarMMa-3) Agha, Mounzer A Phase 1b-2, Open-Label Study of JNJ-68284528, Janssen $810,100 $243,030 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Research & Directed Against BCMA in Subjects with Relapsed or Development, Refractory Multiple Myeloma LLC Brufsky, Adam Clinical Outcomes Analysis of the Oncotype Dx Agendia, Inc. $83,076 $24,924 Breast Cancer test Coffman, Lan Determine the effects of ALKS 4230 vs. recombinant Alkermes, Inc. $57,103 $35,118 human IL-2 on immune cells in the tumor microenvironment in cancer patients Davar, Diwakar An Open-label Phase 1 Study to Assess the Safety, Medimmune, Inc. $1,140,080 $342,024 Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combi- nation with Durvalumab in Subjects with Select Advanced Solid Tumors (HCC 19-024) Davar, Diwakar Randomized Phase 2 Neoadjuvant Study of PD-1 TESARO, Inc. $2,017,156 $605,147 Inhibitor TSR-042 Singly vs. Combination of TIM-3 In- hibitor TSR-022 and PD-1 Inhibtor TSR-042 in Stage IIIB/C/D or Stage IV A/B Resectable Melanoma De Castro, Laura A Phase II Randomized, Double-Blind, Placebo-Con- Bayer $13,229 $3,307 trolled Multi-Center Study to Assess the Safety, Corporation Tolerability, an Donnenberg, Albert Assays to determine optimal dosing and therapeutic METAvivor $7,460 $392 effects of localized immunotherapy for breast cancer Research and metastatic to the pleura Support, Inc. Dorritie, Kathleen A phase I/II Study of lutetium (177Lu)-lilotomab ICON Clinical $149,007 $44,702 satetraxetan (Betalutin(R)) antibodyradionuclide-con- Research jugate for treatment of relapsed non-Hodgkin lymphoma Kirkwood, John Significance of IFNa Adjuvant Therapy Treatment Ventana Medical $15,000 $0 and Clinical Outcomes on BRAF V600E Mutation vs. Systems Inc Wild Type Melanoma Patients in Correlation with Immunoscore Assessmen

Division of Hematology/Oncology GRANTS

INDUSTRY

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Luke, Jason Human Leukocyte Antigen Typing and Tumor Anti- Immatics US, Inc. $255,581 $76,674 gen Expression Profiling (HCC 19-112) Luke, Jason Phase 1 study evaluating genetically modified autol- Immatics US, Inc. $773,274 $231,982 ogous T cells expressing a T-Cell Receptor recog- nizing a cancer/germline antigen in patients having solid tumors including but not limited to NSCLC or HNSCC (ACTengine IMA201-101) (HCC 19-113) Luke, Jason Phase 1 study evaluating genetically modified Immatics US, Inc. $530,876 $159,263 autologous T cells expressing a T-cell receptor rec- ognizing a cancer/germline antigen in patients with recurrent and/or refractory solid tumors (ACTengine IMA202-101) (HCC 19-114) Luke, Jason Phase 1 study evaluating genetically modified Immatics US, Inc. $508,212 $152,464 autologous T cells expressing a T-cell receptor rec- ognizing a cancer/germline antigen in patients with recurrent and or/refractory solid tumors (ACTengine IMA203-101) (HCC 19-115) Luke, Jason A Phase Ib/II study of ARRY-614 plus either nivolum- Pfizer, Inc. $3,265,725 $979,717 ab or ipilimumab in advanced melanoma, renal cell carcinoma, and solid tumors Luke, Jason HCC 20-011 Replimune, Inc. $437,773 $131,332 Ragni, Margaret ALN-AT3SC-002 An Open Label Extension Study Anylan $6,611 $1,983 of Subcutaneously Administered ALN-AT3SC in Pharmaceuticals Subjects with Moderate or Severe Hemophilia A or B who Have Completed a Previous Clinical Study with ALN-AT3SC Ragni, Margaret A Phase 3 Open-Label, Single-Arm Study To Evaluate Biomarin $148,550 $29,542 The Efficacy and Safety of BMN 270, an Adeno-As- Pharmaceuticals sociated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemo- philia A Patients (270-302) Ragni, Margaret A Prospective Non-Interventional Study of Bleeding Biomarin $17,134 $5,140 Episodes, Factor VIII Infusions, and Patient-Reported Pharmaceuticals Outcomes in Individuals with Severe Hemophilia A (BMN 270-902) Ragni, Margaret Natural History Study of Factor IX Treatment and Rho, $104,576 $64,314 Complications (B-Natural) Incorporated Ragni, Margaret A Phase I/II, Open-Label, Adaptive, Dose -Ranging Sangamo $22,036 $5,498 Study to Assess the Safety and Tolerability of SB-525 Therapeutics [AAV2/6 hFactor VIII Gene Therapy] in Adult Subjects with Severe Hemophilia A Ragni, Margaret Genotype and Phenotype Analysis of Adolescents Shire/Baylor $1,453 $0 with Heavy Menstrual Bleeding and Low Von Wille- College of brand Activity Medicine Ragni, Margaret A Long-Term Follow-Up Study in Subjects with Spark $18,802 $4,701 Severe Hemophilia B (Factor IX Deficiency) Who Therapeutics Received a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX (AAV8-hFIX19) Ragni, Margaret Dose-finding study of SPK-8016 gene therapy in Spark $40,806 $5,516 patients with hemophilia A to support future evalua- Therapeutics tions in individuals with FVIII Ragni, Margaret Gene-transfer, Open-Label, Dose-Escalation Study Spark $40,648 $10,162 of SPK-98011 [Adeno-Associated Viral Vector with Therapeutics B-Domain Deleted Human Factor VIII Gene] in Indi- viduals with Hemophilia A

Department of Medicine 2020 Annual Report INDUSTRY

ANNUAL ANNUAL INVESTIGATOR TITLE AGENCY DIRECT INDIRECT COSTS COSTS Ragni, Margaret SPK-8011-LTFU; A Multi-Center Evaluation of the Spark $28,905 $7,226 Long-Term Safety and Efficacy of SPK-8011 (Ade- Therapeutics no-Associated Viral Vector with B-Domain Deleted Human Factor VIII Gene) in Males with Hemophilia A Sehgal, Alison A Global Randomized Multicenter Phase 3 Trial Celgene $500,332 $150,100 to Compare the Efficacy and Safety of JCAR017 to Corporation Standard of Care in Adult Subjects with High-Risk, Transplant Eligible Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM) Villaruz, Liza Phase 2 Trial of Brigatinib after Treatment with Criterium Inc. $113,050 $33,915 Next-Generation ALK inhibitors in Refractory ALK Rearranged NSCLC Zandberg, Dan A phase II trial of personalized immunotherapy in Bristol-Myers $738,100 $221,430 patients with recurrent and/or metastatic squamous Squibb cell carcinoma of the head and neck that have pro- gressed on prior immunotherapy (HCC 18-156) Zarour, Hassane Targeting Multiple Inhibitory Pathways to Reverse m Bristol-Myers $540,000 $0 Tumor-Induced T Cell Dysfunction Squibb Zarour, Hassane Single cell RNAseq studies of therapy with CMP001 Checkmate $368,755 $110,627 and Nivolumab in melanoma patients Pharmaceuticals, Inc. TOTAL INDUSTRY $13,651,074 $3,949,531

PUBLIC HEALTH SERVICE $5,861,077 $2,847,076 OTHER FEDERAL $418,508 $236,420 STATE $407,297 $68,416 SOCIETY AND FOUNDATIONS $3,752,797 $793,065 INDUSTRY $13,651,074 $3,949,531 TOTAL $24,090,752 $7,894,507

Division of Hematology/Oncology TEACHING

TEACHING ACTIVITIES

he Division of Hematology/ Oncology supports training at all levels, from medical school to Tfellowship to continuing medical education. Medical Students Michael Boyiadzis, MD, served as Director of MED 5715, Neoplasia and Neoplastic Diseases course, which is a 4-week elective offered to 4th-year medical students. The overall goal of this course is to expose students to the multidisciplinary approach to cancer diagnosis, patient management and follow up. It involves didactic lectures as well as practical clinic, pathology and radiology experiences. In addition to didactic lectures, there is a series of journal club sessions and one “Great Debate” involving a controversial topic in Medical Oncology. The course also includes an introduction to clinical research by exposing students to the different phases of clinical trials including lectures on biostatistical designs, study endpoints and outcomes. Finally, working in groups with an assigned biostatistician and a mentor (Dr. Boyiadzis), students are required to develop their own design for a research project that could be a clinical trial or a laboratory experiment to be presented on their final day of the course.

Hematology/Oncology Fellowship Our fellowship program has continued to make significant changes and improvements over the past year, which re-affirms our ongoing commitment to the success of this program and its trainees. Dr. Annie Im is the Program Director of our Hematology-Oncology Fellowship Program, and she has served in this role for the past three years since July 1, 2017. Dr. Tim Burns, a long-standing member of the Fellowship Curriculum Committee was appointed Associate Program Director for Research in July 2019. Dr. Vida Passero continues in her role as Associate Program Director, with responsibilities including oversight of the VA and assisting with clinical operations. And, Jen Roethlein was hired as the new program manager. Major changes and other updates during FY20 include: COVID-19 Response All fellowship conferences (fellows’ didactic and case conference, Journal Club, Research in Progress, Morbidity&Mortality/Root Cause Analysis) are now being held virtually through Microsoft Teams. Attendance at conferences has significantly improved with this change. Fellows on outpatient electives during April were pulled from these rotation in anticipation of increasing needs to support the care of COVID-19 patients. They were kept on reserve in case needs arose on the inpatient Oncology services, either from fellows (e.g., 2 pregnant fellows and one with a chronic medical condition) or from faculty. During this time, they developed study guides for the disease area in which they were supposed to have an elective month, and jointly presented at Hematology/Oncology Grand Rounds on “Hematologic complications in COVID-19” and “COVID-19 in Oncology patients.” Because of the COVID-19 situation, two wellness events were canceled. As a result, the Wellness Chairs used the funds to purchase home food kits for the fellows. In addition, weekly fellowship 74

Department of Medicine 2020 Annual Report happy hours through Zoom were held. Fellowship graduation was also held virtually through Microsoft Teams. Didactics/Conferences Based on feedback from the fellows, the Benign Hematology conference was modified such that there were no fellow presentations on the days when there was a concurrent Malignant Hematology conference. Improvements to Journal Club included increased faculty attendance, faculty involvement article selection and discussion, requirement of submitting a question about the articles to enhance fellow engagement, and quarterly off-campus location. The Malignant Hematology conference included more fellow involvement and presentations. Curriculum The disease-specific outpatient rotations were revamped, where schedule templates were reviewed with the disease-specific faculty to ensure the optimal educational experience in terms of clinics and conferences, and disease-specific libraries for each rotation were created and uploaded into MedHub as background reading and as a reference for key articles. The 2nd year schedule structure was split into two 6-month blocks for research and clinical (rather than four 3-month blocks) to enhance continuity in research and continuity clinics. The hematopathology rotations were streamlined and restructured, which allowed for inclusion of the Gynecologic Oncology rotation during the 2nd year (rather than during the 3rd year research months). Teaching Opportunities A library of lectures was created for the Team B (inpatient oncology) fellow to teach the housestaff on various oncology topics during the inpatient rotation. An e-curriculum for the benign hematology rotation was created by one of the outgoing chief fellows, which greatly facilitated teaching by the fellows to the housestaff and created an improved didactic structure. Benign Hematology The Section of Benign Hematology has solidified its role in the trainees' and fellows’ education via multiple initiatives: A new T32 grant that combines cross-departmental strength in laboratory blood research, innovative, well-developed degree programs in clinical research and entrepreneurship, and translationally motivated hematology physician-scientist faculty research mentors. The Section has also developed an extensive core lecture curriculum that is presented primarily during the weekly benign hematology conferences. These conferences include formal lectures and clinical case presentations. Two outpatient (hematology clinic and coagulation service) four-week long rotation of residents and fellows have been redesigned and bolstered to better cater to the needs of trainees interested in pursuing careers in benign hematology. Section Faculty are also actively working at adding one fellowship spot for fellows who wish to receive combined benign hematology and blood banking and transfusion medicine training. Finally, beginning in spring 2021 in collaboration and with support from the American Society of Hematology (ASH), the Benign Hematology Section will host one of three programs nationwide dedicated to providing a 4-week inpatient and outpatient experience managing sickle cell disease to hematology fellows training at an institution that cares for SCD patients but does not have the infrastructure for comprehensive training of their fellows (The other programs will be held through John Hopkins and Duke Universities).

Division of Hematology/Oncology TEACHING

Fellows Scholarly Activity Dr. Tim Burns was appointed Associate Program Director for Research. In this role, Dr. Burns has oversight of the mentoring committees and research progress of all of the fellows, providing better structure, clear expectations, and formal feedback. Over the past year, fellows had multiple poster presentations at national meetings: 2 abstracts at Society for Immunotherapy of Cancer Annual Meeting, 2 abstracts at American Society of Hematology Annual Meeting, 1 abstract at the San Antonio Breast Cancer Symposium, 1 abstract at American Society of Clinical Oncology GI meeting. Other accomplishments included: 2 fellows were on the NCI-funded T32 Cancer Therapeutics training grant, 1 fellow received the Gianni Bonadonna Breast Cancer Research Fellowship grant, 1 fellow was awarded best abstract at the ECOG Young Investigator’s Symposium, 1 fellow completed her Masters of Science degree in Medical Education, 1 fellow continued work towards a PhD in Clinical Translational Science, 1 fellow attended the FDA Fellows Workshop in Silver Spring, Maryland, and 1 fellow attended the Hemophilia Academy in Edinburgh, Scotland. Miscellaneous In addition to continuing the in-service exam action plans (study plan based on ITE results), board review course material was provided to all of the fellows. In addition, the fellow-run board review was restructured to a “Jeopardy” style format, enhancing participation. Our program implemented a “hematology/oncology boot camp” as part of the first-year fellows’ orientation, providing a broad overview and key points for numerous disease-specific oncology topics. Faculty attendance at fellow conferences, journal clubs, research-in-progress presentations was greatly improved this year. There was strong emphasis on the importance of faculty engagement and attendance from the division leadership. Faculty development sessions at division faculty meetings were held, which included fellowship expectations/rotation overview and strategies for verbal feedback.

Continuing Medical Education (CME) The Division of Hematology-Oncology is deeply committed to continuing education of physicians and other oncology professionals. On September 14, 2019, the Division hosted the 8th annual post-American Society of Clinical Oncology (ASCO) conference at the Herberman Conference Center for over 90 oncology physicians, nurses, pharmacists, and APPs throughout the tri-state region. This conference is designed for healthcare providers unable to attend the ASCO meeting held each year in Chicago—and to provide summaries of the most noteworthy presentations. Dr. Edward Chu continued in his role as course director, and several members of the Division, including Drs. Adam Brufsky, Len Appleman, Diwakar Davar, Liza Villaruz, and Nathan Bahary, provided important and timely reviews. On February 1, 2020, the Division hosted a review of the most important and clinically relevant presentations from the 2019 San Antonio Breast Cancer Symposium for nearly 200 oncology professionals. This conference is specifically designed for providers involved in the clinical care of patients with breast cancer. Drs. Adam Brufsky, Shannon Puhalla, and Dhaval Mehta served as course directors. Division faculty were involved in chairing other CME educational events held in Pittsburgh, including: • Robert Redner, MD, continued to serve as Director of the HCC Clinical Grand Rounds Series held each Wednesday throughout the year from Sept. 2019-June 2020. • Franklin Bontempo, MD, served as Course Director and faculty of the Cascade 2020, Advances In Hemostasis & Thrombosis Conference, held on May 4, 2020.

Department of Medicine 2020 Annual Report Clinical Fellows * Indicates departing fellow

Steven Borson, MD Medical School: Temple University School of Medicine Residency: Barnes Jewish Hospital, Washington University School of Medicine

Kristine Gade, MD Medical School: University of Virginia, School of Medicine Residency: University of Virginia

Max Jameson Lee, MD, PhD Medical School: Medical College of Virginia Residency: Virginia Commonwealth University

Lilit Karapetyan, MD, MS Medical School: Yerevan State Medical University Residency: Michigan State University/Sparrow Hospital

Zahra Kelly, DO Medical School: Philadelphia College of Osteopathic Medicine Residency: UPMC

*Charlie Kuang, MD, PhD Medical School: University of Michigan Medical School Residency: UPMC Current Position: T32 Postdoctoral Scholar, University of Pittsburgh

Division of Hematology/Oncology TEACHING

*Konstantinos Lontos, MD Medical School: University of Athens School of Health Sciences Residency: UPMC Current Position: UPMC Academic Faculty Member

Nicoletta Machin, DO Medical School: University of New England College of Osteopathic Medicine Residency: UPMC

William Maguire, MD, PhD Medical School: Weill Cornell Medical College Residency: UPMC

Monica K. Malhotra, MD Medical School: All India Institute of Medical Science, Ansari Nagar Residency: Cleveland Clinic

*Azadeh Nasrazadani, MD, PhD Medical School: Texas Tech University Residency: UPMC Current Position: UPMC Academic Faculty Member

Kevin Quann, MD, PhD Medical School: Sidney Kimmel Medical College, Thomas Jefferson University Residency: UPMC

*Asha Ricciuti, MD Medical School: University of Central Florida, College of Medicine Residency: University of South Florida, Morsani College of Medicine Current Position: VA Western New York Healthcare System, Buffalo, NY

Anjali Rohatgi, MD, PhD Medical School: Washington University in St. Louis School of Medicine Residency: Weill Cornell Medical Center and Barnes Jewish Hospital

Rachel Rosenblum, MD Medical School: Rutgers Robert Wood Johnson Medical School Residency: Icahn School of Medicine at Mount Sinai

Saba Shaikh, MD Medical School: Baylor College of Medicine Residency: McGaw Medical Center of Northwestern University

*Neal Spada, MD Medical School: University of Pittsburgh School of Medicine Residency: UPMC Current Position: UPMC Oncology Hematology Associates

Department of Medicine 2020 Annual Report Clinical Fellow Activities Christine Garcia, MD Presentations and Abstracts • Poster Presentation, ASCO Quality Care Symposium, Phoenix, AZ, September 2019.

Max Jameson Lee, MD, PhD Publications • Jameson-Lee M, Luke JJ. Moving toward multi-dimensional biomarkers in cancer immunotherapy. Chin Clin Oncol. 2020 Jan 2:cco.2019.12.16.

Zahra Kelly, MD Publications • Kelly ZR, Gorantla VC, Davar D. The Role of Neoadjuvant Therapy in Melanoma. Curr Oncol Rep. 2020 Jun 29;22(8):80. Presentations and Abstracts • Poster Presentation, SITC, Washington, DC, November 2019.

Charlie Kuang, MD, PhD As a T32 Postdoctoral Scholar, Dr. Kuang studies epigenetic modifiers and immunotherapy combinations for the treatment of colorectal cancer. Publications • Kuang C, Quann K, Liman AK, Frye R, Alshoubaki N, Ramkumar M, Liman AD. A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab. Clin Case Rep. 2020 Jun 22;8(10):1984-1987. Presentations and Abstracts • Poster Presentation, Association of VA Hematologists and Oncologists, Minneapolis, MN, September 2019. • Poster Presentation, Gastrointestinal Cancer Symposium, San Francisco, CA, January 2020. Honors and Awards • Corrective Studies for UPCI 14-118: A Phase II Study of Pembrolizumab in Combination with Azacitidine in Patients with Refractory Metastatic Colorectal Cancer, ECOG Best Translational Young Investigator Abstract Award, Ft. Lauderdale, FL, October 2019

Konstantinos Lontos, MD Publications • Lutz A, Schelbert EB, Lontos K, Rossetti J, Katz W. Acute Myeloid Leukemia Presenting as Effusive Constrictive Pericarditis. CASE (Phila). 2019 Oct 15;4(2):97-102. • Adamik J, Pulugulla SH, Zhang P, Sun Q, Lontos K, Macar DA, Auron PE, Galson DL. EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets. J Bone Miner Res. 2020 Jan;35(1):181-195. Presentations and Abstracts • Poster Presentation, ASH, Orlando, FL, December 2019. Honors and Awards • Selected, PhD program, Clinical and Translational Science Institute, Pittsburgh, PA, July 2019.

Division of Hematology/Oncology TEACHING

Nicoletta Machin, DO Presentations and Abstracts • Poster Presentation, ASH Annual Meeting, San Diego, CA, December 2019. Honors and Awards • Participant, Hemophilia Academy 2019, Fort Edinburgh, UK, October 2019.

William Maguire, MD, PhD Publications • Maguire WF, Kirkwood JM. Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help? Future Oncol. 2020 Mar;16(9):413-415. Epub 2020 Feb 26.

Monica K. Malhotra, MD Publications • Khunger JM, Kumar N, Punia VPS, Malhotra MK. Study of Prothrombotic Changes in Metabolic Syndrome. Indian J Hematol Blood Transfus. 2020 Oct;36(4):695-699. Epub 2020 May 20. • Malhotra MK, Emens LA. The evolving management of metastatic triple negative breast cancer. Semin Oncol. 2020 Aug;47(4):229-237. Epub 2020 May 28. Honors and Awards • First Place, Recipient, Department of Medicine Fellows Teaching Competition, Pittsburgh, PA, July 2019.

Azadeh Nasrazadani, MD Publications • Nasrazadani A, Brufsky AM. Artificial intelligence-directed prognostication of breast cancer. EBioMedicine. 2019 Aug;46:6-7. Epub 2019 Aug 1. • Nasrazadani A, Brufsky AM. CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019 Oct;20(10):1329-1330. Epub 2019 Sep 4. • Nasrazadani A, Brufsky A. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. Future Oncol. 2020 Mar;16(7):247-254. Epub 2020 Feb 14. • Nasrazadani A, Brufsky AM. Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncol. 2020 Mar;21(3):318-319. Epub 2020 Feb 5. • Brufsky A, Marti JLG, Nasrazadani A, Lotze MT. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. J Transl Med. 2020 Jun 29;18(1):261. Presentations and Abstracts • Poster Presentation, 42nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2019. Honors and Awards • Recipient, Gianni Bondonna Breast Cancer Research Fellowship, Conquer Cancer Foundation of ASCO, August 2019.

Kevin Quann, MD, PhD Publications • Kuang C, Quann K, Liman AK, Frye R, Alshoubaki N, Ramkumar M, Liman AD. A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib,

Department of Medicine 2020 Annual Report dexamethasone, and rituximab. Clin Case Rep. 2020 Jun 22;8(10):1984-1987.

Asha Ricciuti, MD Presentations and Abstracts • Poster Presentation, ASH Annual Meeting, San Diego, CA, December 2019

Anjali Rohatgi, MD Presentations and Abstracts • Poster Presentation, SITC, Washington, DC, November 2019

Saba Shaikh, MD Honors and Awards • Second Place, Department of Medicine Fellows Teaching Competition, Pittsburgh, PA, May 2020

Neal Spada, MD Presentations and Abstracts • Poster Presentation, San Antonio Breast Cancer Symposium, San Antonio, TX, December 2019

Division of Hematology/Oncology TEACHING

Postdoctoral Fellows and Activities Huda Atiya, PhD Mentor: Lan G. Coffman, MD, PhD Dr. Atiya is Investigating the role of direct interaction between mesenchymal stem cells and tumor cells in enhancing ovarian cancer metastasis.

Quanquan Ding, PhD Mentor: Hassane Zarour, MD Dr. Ding is studying the role of CXCL13 releasing CD8+ T cells in melanoma patients.

Vinod Kumar, PhD Dr. Kumar focuses on the development of targeted therapeutic strategies for KRAS and EGFR mutant NSCLC.

Itay Raphael, PhD Dr. Raphael’s work is focused on understanding the mechanisms by which immune-checkpoint blockade drugs promotes development of autoimmune diseases in patient with melanoma.

Faruk Sacirbegovic, PhD Mentor: Warren D. Shlomchik, MD Dr. Sacirbegovic is currently working on understanding the maintenance of GVHD.

Richard C. Wu, PhD Mentor: Dario Vignali, PhD Dr. Wu is investigating the role of inhibitory receptor(s) expression on the function of T regulatory cells in metastatic cancer patients.

Kui Zhao, PhD Dr. Zhou is using two photon intravital microscopy and other approaches to understand how T cells are recruited into the marrow and whether chemokines direct them to leukemia cells after IFN-γ stimulation.

Meng Zhou, PhD Mentor: Warren D. Shlomchik, MD Dr. Zhou is examining how the graft-vs-leukemia effect in allogeneic stem cell transplantation fails due to insufficient alloantigen presentation and due to alloreactive T cells developing exhaustion, both of which can be overcome by targeted interventions.

Bochra Zidi, PhD Dr. Zidi is evaluating tumor antigen-specific immune responses in melanoma patients undergoing novel immunotherapies with 3rd generation immune checkpoint blockade.

Department of Medicine 2020 Annual Report ONE-YEAR BIBLIOGRAPHY

July 1, 2019 to June 30, 2020

Non-original research publications are in italics. Hematology/Oncology faculty are in bold.

Adamik J, Pulugulla SH, Zhang P, Sun Y, Ding F, Puhalla S, Swartz L, Owon- environment. Adv Exp Med Biol. 2020;1234:31- Q, Lontos K, Macar DA, Auron PE, Gal- ikoko TK, Donald Harvey R, Stoller R, 42. son DL. EZH2 Supports Osteoclast Dif- Petro DP, Tawbi HA, Argiris A, Strychor Azad NS, Gray RJ, Overman MJ, Schoen- ferentiation and Bone Resorption Via S, Pouquet M, Kiesel B, Chen AP, Gan- feld JD, Mitchell EP, Zwiebel JA, Sharon Epigenetic and Cytoplasmic Targets. J dara D, Belani CP, Chu E, Ramalingam E, Streicher H, Li S, McShane LM, Ru- Bone Miner Res. 2020 Jan;35(1):181- SS. Phase 1 study of veliparib (ABT- binstein L, Patton DR, Williams PM, 195. Epub 2019 Oct 23. 888), a poly (ADP-ribose) polymerase Coffey B, Hamilton SR,Bahary N, Suga inhibitor, with carboplatin and pacli- Adams S, Diéras V, Barrios CH, Winer JM, Hatoum H, Abrams JS, Conley BA, taxel in advanced solid malignancies. EP, Schneeweiss A, Iwata H, Loi S, Pa- Arteaga CL, Harris L, O’Dwyer PJ, Chen Cancer Chemother Pharmacol. 2019 tel S, Henschel V, Chui SY, Rugo HS, AP, Flaherty KT. Nivolumab Is Effective Dec;84(6):1289-1301. Epub 2019 Sep Emens LA, Schmid P. Patient-report- in Mismatch Repair-Deficient Noncol- 23. ed outcomes from the phase III IM- orectal Cancers: Results From Arm passion130 trial of atezolizumab plus Appleman LJ. Multifactorial, biomark- Z1D-A Subprotocol of the NCI-MATCH nab-paclitaxel in metastatic triple-neg- er-based predictive models for immunother- (EAY131) Study. J Clin Oncol. 2020 Jan ative breast cancer. Ann Oncol. 2020 apy response enter the arena. J Natl Cancer 20;38(3):214-222. Epub 2019 Nov 25. Inst. 2020 Jun 9:djaa077. Online ahead of May;31(5):582-589. Epub 2020 Feb 20. print. Bai S, Zhu W, Coffman , L Vlad A, Schwartz LE, Elishaev E, Drapkin R, Al Abbas AI, Falvello V, Zenati M, Mani Ascierto PA, Agarwala SS, Eggermont A, Ger- . CD105 Is Expressed A, Hogg ME, Zeh HJ 3rd, Singhi A, Ba- shenwald JE, Grob JJ, Hamid O, Michielin O, Buckanovich RJ in Ovarian Cancer Precursor Lesions hary N, Zureikat AH. Impact of adju- Postow M, Puzanov I, Zarour HM, Caracò C, vant chemotherapy regimen on surviv- Testori A. The Great Debate at “Melanoma and Is Required for Metastasis to al outcomes in immunohistochemical Bridge”, Naples, December 7th, 2019. J Transl the Ovary. Cancers (Basel). 2019 Nov subtypes of ampullary carcinoma. J Med. 2020 Apr 16;18(1):171. 2;11(11):1710. Surg Oncol. 2019 Dec 15. Online ahead Ascierto PA, Bifulco C, Buonaguro L, Emens Bakkenist CJ, Czambel RK, Lin Y, Yates of print. LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, NA, Zeng X, Shogan J, Schmitz JC. Amaria RN, Menzies AM, Burton EM, Scolyer Gridelli C, Merlano M, Nathan P, Odunsi K, Quantitative analysis of ATM phos- RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett Okada H, Paulos CM, Pignata S, Schalper KA, phorylation in lymphocytes. DNA Re- Spranger S, Tortora G, Zarour H, Butterfield R, Carter B, Daud A, Faries M, Fecher LA, Fla- pair (Amst). 2019 Aug;80:1-7. Epub LH, Puzanov I. Perspectives in immunothera- herty KT, Gershenwald JE, Hamid O, Hong A, 2019 Jun 4. Kirkwood JM, Lo S, Margolin K, Messina J, Po- py: meeting report from the “Immunotherapy stow MA, Rizos H, Ross MI, Rozeman EA, Saw Bridge 2018” (28-29 November, 2018, Na- Barcenas CH, Hurvitz SA, Di Palma JA, ples, Italy). J Immunother Cancer. 2019 Nov RPM, Sondak V, Sullivan RJ, Taube JM, Thomp- Bose R, Chien AJ, Iannotti N, Marx G, 29;7(1):332. son JF, van de Wiel BA, Eggermont AM, Davies Brufsky A, Litvak A, Ibrahim E, Alvarez MA; International Neoadjuvant Melanoma Ascierto PA, Fox BA, Urba WJ, Anderson AC, RH, Ruiz-Borrego M, Chan N, Manalo Y, Consortium members, Ascierto PA, Spillane Atkins MB, Borden EC, Brahmer JR, Butterfield Kellum A, Trudeau M, Thirlwell M, Gar- AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi LH, Cesano A, Chen DC, de Gruijl TD, Dillman cia Saenz J, Hunt D, Bryce R, McCulloch HA, Long GV. Neoadjuvant systemic therapy in RO, Drake CG, Emens LA, Gajewski TF, Gul- L, Rugo HS, Tripathy D, Chan A; CON- melanoma: recommendations of the Interna- ley JL, Stephen Hodi FJ, Hwu P, Kaufman D, tional Neoadjuvant Melanoma Consortium. Kaufman HL, Lotze MT, McNeel DG, Margolin TROL Study Investigators. Improved Lancet Oncol. 2019 Jul;20(7):e378-e389. KM, Marincola FM, Mastrangelo MJ, Maus MV, tolerability of neratinib in patients with HER2-positive early-stage breast Anastasopoulou A, Ziogas DC, Samarkos M, Parkinson DR, Romero PJ, Sondel PM, Sprang- Kirkwood JM, Gogas H. Reactivation of tu- er S, Sznol M, Weiner GJ, Wigginton JM, We- cancer: the CONTROL trial. Ann Oncol. berculosis in cancer patients following ad- ber JS. Insights from immuno-oncology: the 2020 Sep;31(9):1223-1230. Epub 2020 ministration of immune checkpoint inhibitors: Society for Immunotherapy of Cancer State- May 25. current evidence and clinical practice recom- ment on access to IL-6-targeting therapies mendations. J Immunother Cancer. 2019 Sep for COVID-19. J Immunother Cancer. 2020 Bennewitz MF, Tutuncuoglu E, Gudapa- 4;7(1):239. Apr;8(1):e000878. ti S, Brzoska T, Watkins SC, Monga SP, Atiya H, Frisbie L, Pressimone C, Coffman L. Pradhan-Sundd T, Sundd P. P-selec- Appleman LJ, Beumer JH, Jiang Y, Lin Mesenchymal Stem Cells in the Tumor Micro- tin-deficient mice to study pathophys- 83

Division of Hematology/Oncology BIBLIOGRAPHY

iology of sickle cell disease. Blood Adv. LM, Horn CC, Hayes MR, Doyle RP, De Dekker J, Ferguson RJ, Gielissen MF, 2020 Jan 28;4(2):266-273. Jonghe BC. A second-generation glu- Glimelius B, Goedendorp MM, Graves cagon-like peptide-1 receptor agonist KD, Heiney SP, Horne R, Hunter MS, Jo- Bhargava R, Clark BZ, Carter GJ, Bruf- mitigates vomiting and anorexia while hansson B, Northouse LL, Oldenburg sky AM, Dabbs DJ. The healthcare retaining glucoregulatory potency in HS, Prins JB, Savard J, van Beurden value of the Magee Decision Algo- lean diabetic and emetic mammalian M, van den Berg SW, Brug J, Knoop H, rithm™:use of Magee Equations™ and models. Diabetes Obes Metab. 2020 Verdonck-de Leeuw IM. Effects and mitosis score to safely forgo molecular May 14. Online ahead of print. moderators of coping skills training testing in breast cancer. Mod Pathol. on symptoms of depression and anx- 2020 Aug;33(8):1563-1570. Epub 2020 Brown JR, Chan DK, Shank JJ, Griffith iety in patients with cancer: Aggre- Mar 17. KA, Fan H, Szulawski R, Yang K, Reyn- gate data and individual patient data olds RK, Johnston C, McLean K, Uppal Bialkowski W, Tan S, Mast AE, Kiss JE, meta-analyses. Clin Psychol Rev. 2020 S, Liu JR, Cabrera L, Taylor SE, Orr BC, Kor D, Gottschall J, Wu Y, Roubinian N, Aug;80:101882. Epub 2020 Jun 25. Modugno F, Mehta P, Bregenzer M, Triulzi D, Kleinman S, Choi Y, Brambilla Mehta G, Shen H, Coffman LG, Buck- Caughey MC, Novelli EM. Editorial commen- D, Zimrin A; NHLBI Recipient Epidemi- anovich RJ. Phase II clinical trial of tary: Sickle cell disease: Diagnosing the heart ology and Donor Evaluation (REDS)-III metformin as a cancer stem cell-tar- of the matter. Trends Cardiovasc Med. 2020 Study. Equivalent inpatient mortality Feb 28:S1050-1738(20)30033-5. Online ahead geting agent in ovarian cancer. JCI In- among direct-acting oral anticoagu- of print. sight. 2020 Jun 4;5(11):e133247. lant and warfarin users presenting Chandler C, Liu T, Buckanovich R, Coffman with major hemorrhage. Thromb Res. Brufsky A, Lotze MT. DC/L-SIGNs of hope in LG. The double edge sword of fibrosis in can- 2020 Jan;185:109-118. Epub 2019 Nov the COVID-19 pandemic. J Med Virol. 2020 cer. Transl Res. 2019 Jul;209:55-67. Epub 2019 25. May 6:10.1002/jmv.25980. Online ahead of Feb 21. print. Bibee K, Swartz A, Sridharan S, Kurten CHL, Chang LW, Kazlouskaya V, Bordelon JR, Hughes Wessel CB, Skinner H, Zandberg DP. Cuta- Brufsky A, Lotze MT. Ratcheting down the MA, Najjar YG, Bunimovich Y, Karunamurthy neous squamous cell carcinoma in the or- virulence of SARS-CoV-2 in the COVID-19 pan- A, Ho J. Metastatic Melanoma With Sebo- gan transplant recipient. Oral Oncol. 2020 demic. J Med Virol. 2020 May 27:10.1002/ cyte-Like Melanocytes and Widespread Viscer- Apr;103:104562. Epub 2020 Feb 14. jmv.26067. Online ahead of print. al Involvement. Dermatol Pract Concept. 2020 , Marti JLG, Nasrazadani A, Lotze Apr 20;10(2):e2020045. eCollection 2020. Blohmer M, Zhu L, Atkinson JM, Beri- Brufsky A MT. Boning up: amino-bisphophonates as im- Chang LW, Kazlouskaya V, Kazi R, Davar D, wal S, Rodríguez-López JL, Rosenzweig munostimulants and endosomal disruptors of M, Brufsky AM, Tseng G, Lucas PC, Ferris RL, Ho J, Karunamurthy A, Jedrych JJ, dendritic cell in SARS-CoV-2 infection. J Transl Bunimovich YL. Melanoma Ex Blue Nevus With Lee AV, Oesterreich S, Jankowitz RC. Med. 2020 Jun 29;18(1):261. GNA11 Mutation and BAP1 Loss: Case Report Patient treatment and outcome after , Mathew A. Adjuvant bisphos- and Review of the Literature. Am J Dermatopa- breast cancer orbital and periorbital Brufsky A phonate therapy in early-stage breast can- thol. 2020 Apr 17. Online ahead of print. metastases: a comprehensive case cer-Treating the soil to kill the seed. Breast J. Chauvin JM, Ka M, Pagliano O, Menna series including analysis of lobular 2020 Jan;26(1):65-68. Epub 2019 Dec 26. versus ductal tumor histology. Breast C, Ding Q, DeBlasio R, Sanders C, Hou Cancer Res. 2020 Jun 26;22(1):70. Brufsky A, Mitra D, Davis KL, Nagar J, Li XY, Ferrone S, Davar D, Kirkwood SP, McRoy L, Cotter MJ, Stearns V. JM, Johnston RJ, Korman AJ, Smyth MJ, Boele FW, Terhorst L, Prince J, Dono- Treatment Patterns and Outcomes Zarour HM. IL15 Stimulation with TIG- van HS, Weimer J, Sherwood PR, Lieb- Associated With Palbociclib Plus Letro- IT Blockade Reverses CD155-mediated erman FS, Drappatz J. Psychometric zole for Postmenopausal Women With NK-Cell Dysfunction in Melanoma. Clin Evaluation of the Caregiver Needs HR(+)/HER2(-) Advanced Breast Can- Cancer Res. 2020 Jun 26. Online ahead Screen in Neuro-Oncology Family cer Enrolled in an Expanded Access of print. Caregivers. J Nurs Meas. 2019 Aug Program. Clin Breast Cancer. 2019 Chen C, Huang X, Yin W, Peng M, Wu 1;27(2):162-176. Oct;19(5):317-325.e4. Epub 2019 Apr F, Wu X, Tang J, Chen M, Wang X, Hul- 18. Borhani AA, Dewan R, Furlan A, Seiser bert A, Brock MV, Liu W, Herman JG, N, Zureikat AH, Singhi AD, Boone B, Brufsky A. Distinct viral clades of SARS-CoV-2: Yu F. Ultrasensitive DNA hypermethyl- Bahary N, Hogg ME, Lotze M, Zeh HJ Implications for modeling of viral spread. J ation detection using plasma for early III, Tublin ME. Assessment of Response Med Virol. 2020 Apr 20:10.1002/jmv.25902. detection of NSCLC: a study in Chinese Online ahead of print. to Neoadjuvant Therapy Using CT Tex- patients with very small nodules. Clin ture Analysis in Patients With Resect- Brufsky A. Hyperglycemia, hydroxychloro- Epigenetics. 2020 Mar 5;12(1):39. able and Borderline Resectable Pan- quine, and the COVID-19 pandemic. J Med Vi- creatic Ductal Adenocarcinoma. AJR rol. 2020 Jul;92(7):770-775. Epub 2020 Apr 27. Christner SM, Parise RA, Ivy PS, Taw- Am J Roentgenol. 2020 Feb;214(2):362- bi H, Chu E, Beumer JH. Quantitation Buckanovich RJ, Rustin G, Uppal S, Olawaiye of paclitaxel, and its 6-alpha-OH and 369. Epub 2019 Dec 4. AB, Kelley JL, Berger JL, Landen CN. No Role for 3-para-OH metabolites in human plas- Borner T, Shaulson ED, Ghidewon MY, Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer. J Clin Oncol. 2019 Oct ma by LC-MS/MS. J Pharm Biomed Barnett AB, Horn CC, Doyle RP, Grill HJ, 10;37(29):2707-2708. Epub 2019 Aug 26. Anal. 2019 Aug 5;172:26-32. Epub 2019 Hayes MR, De Jonghe BC. GDF15 Induc- Apr 15. es Anorexia through Nausea and Eme- Buffart LM, Schreurs MAC, Abrahams sis. Cell Metab. 2020 Feb 4;31(2):351- HJG, Kalter J, Aaronson NK, Jacobsen Cobleigh M, Yardley DA, Brufsky AM, 362.e5. Epub 2020 Jan 9. PB, Newton RU, Courneya KS, Armes Rugo HS, Swain SM, Kaufman PA, Trip- J, Arving C, Braamse AM, Brandberg Y, athy D, Hurvitz SA, O’Shaughnessy Borner T, Shaulson ED, Tinsley IC, Stein 84

Department of Medicine 2020 Annual Report J, Mason G, Antao V, Li H, Chu L, Jah- Smith RE. Clinical outcomes with un- DJ, Dennis CJ, Meyer EM, Gladwin anzeb M. Baseline Characteristics, fractionated heparin monitored by an- M. Improved quantitative detection Treatment Patterns, and Outcomes in ti-factor Xa vs. activated partial Throm- of biotin-labeled red blood cells by Patients with HER2-Positive Metastatic boplastin time. Am J Hematol. 2019 flow cytometry. Transfusion. 2019 Breast Cancer by Hormone Receptor Sep;94(9):1015-1019. Epub 2019 Jul 16. Aug;59(8):2691-2698. Epub 2019 Jun 6. Status from SystHERs. Clin Cancer Res. Davar D, Kirkwood JM. PD-1 Immune Check- Donnenberg AD, Kanias T, Triulzi DJ, 2020 Mar 1;26(5):1105-1113. Epub point Inhibitors and Immune-Related Adverse Dennis CJ, Moore LR, Meyer EM, Sin- 2019 Nov 26. Events: Understanding the Upside of the char D, Kiss JE, Normolle DP, Gladwin Downside of Checkpoint Blockade. JAMA On- Cohen EEW, Bell RB, Bifulco CB, Burtness B, MT. Current good manufacturing prac- col. 2019 Jul 1;5(7):942-943. Gillison ML, Harrington KJ, Le QT, Lee NY, Leid- tices-compliant manufacture and mea- ner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Davar D, Zarour HM. Immunological Targets surement of biotin-labeled red blood Raben A, Sikora AG, Uppaluri R, Whitworth for Immunotherapy: Inhibitory T Cell Recep- cells. Cytotherapy. 2019 Jul;21(7):793- F, Zandberg DP, Ferris RL. The Society for tors. Methods Mol Biol. 2020;2055:23-60. Immunotherapy of Cancer consensus state- 800. Epub 2019 May 14. ment on immunotherapy for the treatment de Azambuja E, Ponde N, Procter M, Donnenberg AD, Luketich JD, Don- of squamous cell carcinoma of the head and Rastogi P, Cecchini RS, Lambertini M, nenberg VS. Secretome of pleural neck (HNSCC). J Immunother Cancer. 2019 Jul Ballman K, Aspitia AM, Zardavas D, 15;7(1):184. effusions associated with non-small Roca L, Gelber RD, Piccart-Gebhart M, cell lung cancer (NSCLC) and ma- Cohen JB, Comer DM, Yabes JG, Rag- Suter T. A pooled analysis of the cardi- lignant mesothelioma: therapeutic ni MV. Inflammatory Bowel Disease ac events in the trastuzumab adjuvant implications. Oncotarget. 2019 Nov and Thrombosis: A National Inpatient trials. Breast Cancer Res Treat. 2020 5;10(60):6456-6465. eCollection 2019 Sample Study. TH Open. 2020 May Jan;179(1):161-171. Epub 2019 Oct 11. Nov 5. 18;4(1):e51-e58. eCollection 2020 Jan. Dekanek EW, Thull DL, Massart M, Dosunmu-Ogunbi AM, Wood KC, Novelli Cohen MG, Althouse AD, Arnold RM, Grubs RE, Rajkovic A, Mai PL. Knowl- EM, Straub AC. Decoding the role of SOD2 Bulls HW, White D, Chu E, Rosenzweig edge and opinions regarding BRCA1 in sickle cell disease. Blood Adv. 2019 Sep M, Smith K, Schenker Y. Is Advance Care and BRCA2 genetic testing among pri- 10;3(17):2679-2687. mary care physicians. J Genet Couns. Planning Associated With Decreased Drilon A, Clark JW, Weiss J, Ou SI, 2020 Feb;29(1):122-130. Epub 2019 Hope in Advanced Cancer? JCO Oncol Camidge DR, Solomon BJ, Otterson GA, Nov 14. Pract. 2020 Jun 12:OP2000039. Online Villaruz LC, Riely GJ, Heist RS, Awad ahead of print. Dharmarajan H, Anderson JL, Kim S, Sridha- MM, Shapiro GI, Satouchi M, Hida T, Cole AJ, Fayomi AP, Anyaeche VI, Bai S, Buck- ran S, Duvvuri U, Ferris RL, Solari MG, Clump Hayashi H, Murphy DA, Wang SC, Li S, anovich RJ. An evolving paradigm of cancer DA 2nd, Skinner HD, Ohr JP, Zandberg DP, Usari T, Wilner KD, Paik PK. Antitumor stem cell hierarchies: therapeutic implica- Branstetter B 4th, Hughes MA, Traylor KS, activity of crizotinib in lung cancers Seethala R, Chiosea SI, Nilsen ML, Johnson JT, tions. Theranostics. 2020 Feb 10;10(7):3083- harboring a MET exon 14 alteration. 3098. eCollection 2020. Kubik MW. Transition to a virtual multidisciplinary tumor board during the COVID-19 Nat Med. 2020 Jan;26(1):47-51. Epub Cole AJ, Iyengar M, Panesso-Gómez pandemic: University of Pittsburgh experi- 2020 Jan 13. ence. Head Neck. 2020 Jun;42(6):1310-1316. S, O’Hayer P, Chan D, Delgoffe GM, Dummer R, Brase JC, Garrett J, Camp- Epub 2020 Apr 27. Aird KM, Yoon E, Bai S, Buckanovich bell CD, Gasal E, Squires M, Gusen- RJ. NFATC4 promotes quiescence Dietrich J, Versmee L, Drappatz J, leitner D, Santinami M, Atkinson V, and chemotherapy resistance in Eichler AF, Nayak L, Norden A, Wong Mandalà M, Chiarion-Sileni V, Flaherty ovarian cancer. JCI Insight. 2020 Apr E, Pisapia MR, Jones SS, Gordon AB, K, Larkin J, Robert C, Kefford R, Kirk- 9;5(7):e131486. Chabner BA, Hochberg F, Batchelor TT. wood JM, Hauschild A, Schadendorf Conte P, Schneeweiss A, Loibl S, Ma- Pemetrexed in Recurrent or Progres- D, Long GV. Adjuvant dabrafenib plus mounas EP, von Minckwitz G, Mano sive Central Nervous System Lympho- trametinib versus placebo in patients V600 MS, Untch M, Huang CS, Wolmark N, ma: A Phase I Multicenter Clinical Trial. with resected, BRAF -mutant, stage Rastogi P, D’Hondt V, Redondo A, Sta- Oncologist. 2020 Jun 10. Online ahead III melanoma (COMBI-AD): explorato- matovic L, Bonnefoi H, Castro-Salguero of print. ry biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. H, Fischer HH, Wahl T, Song C, Boulet T, Dizier B, Callegaro A, Debois M, Dre- 2020 Mar;21(3):358-372. Epub 2020 Trask P, Geyer CE Jr. Patient-reported no B, Hersey P, Gogas HJ, Kirkwood Jan 30. outcomes from KATHERINE: A phase 3 JM, Vansteenkiste JF, Sequist LV, study of adjuvant trastuzumab emtan- Atanackovic D, Goeman J, van Hou- Dyer MR, Plautz WE, Ragni MV, Alexan- sine versus trastuzumab in patients welingen H, Salceda S, Wang F, Ther- der W, Haldeman S, Sperry JL, Guyette with residual invasive disease after asse P, Debruyne C, Spiessens B, Brich- FX, Zuckerbraun BS, Rollins-Raval MA, neoadjuvant therapy for human epi- ard VG, Louahed J, Ulloa-Montoya F. A Raval JS, Neal MD; A TACTIC Publica- dermal growth factor receptor 2-pos- Th1/IFNγ Gene Signature Is Prognostic tion. Traumatic injury results in pro- itive breast cancer. Cancer. 2020 Jul in the Adjuvant Setting of Resectable longed circulation of ultralarge von 1;126(13):3132-3139. Epub 2020 Apr High-Risk Melanoma but Not in Non- Willebrand factor and a reduction in 14. Small Cell Lung Cancer. Clin Cancer ADAMTS13 activity. Transfusion. 2020 Coons JC, Iasella CJ, Thornberg M, Fitz- Res. 2020 Apr 1;26(7):1725-1735. Epub Jun;60(6):1308-1318. Epub 2020 May maurice MG, Goehring K, Jablonski L, 2019 Nov 15. 22. Leader D, Meyer A, Seo H, Benedict NJ, Donnenberg AD, Kanias T, Triulzi Ebbert PT, Xavier F, Seaman CD, Rag-

Division of Hematology/Oncology BIBLIOGRAPHY

ni MV. Emicizumab prophylaxis in M, Jager A, Jakimovska M, Jakubowska Genet. 2020 Jan;52(1):56-73. 2020 Jan patients with haemophilia A with and A, James PA, Janavicius R, Jankowitz RC, 7. without inhibitors. Haemophilia. 2020 John EM, Johnson N, Jones ME, Jukko- Farrell AT, Panepinto J, Desai AA, Kas- Jan;26(1):41-46. Epub 2019 Nov 20. la-Vuorinen A, Jung A, Kaaks R, Kang D, sim AA, Lebensburger J, Walters MC, Kapoor PM, Karlan BY, Keeman R, Ker- Emens LA. The dawn of immunotherapy for Bauer DE, Blaylark RM, DiMichele DM, in MJ, Khusnutdinova E, Kiiski JI, Kirk J, breast cancer. Clin Adv Hematol Oncol. 2019 Gladwin MT, Green NS, Hassell K, Kato Kitahara CM, Ko YD, Konstantopoulou Jun;17(6):332-335. GJ, Klings ES, Kohn DB, Krishnamurti L, I, Kosma VM, Koutros S, Kubelka-Sabit Little J, Makani J, Malik P, McGann PT, Eom KY, Jarlenski M, Schoen RE, Rob- K, Kwong A, Kyriacou K, Laitman Y, Minniti C, Morris CR, Odame I, Oneal ertson L, Sabik LM. Sex differences Lambrechts D, Lee E, Leslie G, Lester PA, Setse R, Sharma P, Shenoy S. End in the impact of Affordable Care Act J, Lesueur F, Lindblom A, Lo WY, Long points for sickle cell disease clinical tri- Medicaid expansion on colorectal J, Lophatananon A, Loud JT, Lubiński als: renal and cardiopulmonary, cure, cancer screening. Prev Med. 2020 J, MacInnis RJ, Maishman T, Makalic E, and low-resource settings. Blood Adv. Sep;138:106171. Epub 2020 Jun 24. Mannermaa A, Manoochehri M, Ma- 2019 Dec 10;3(23):4002-4020. Fachal L, Aschard H, Beesley J, Barnes noukian S, Margolin S, Martinez ME, DR, Allen J, Kar S, Pooley KA, Dennis Matsuo K, Maurer T, Mavroudis D, Favazza LA, Parseghian CM, Kaya C, J, Michailidou K, Turman C, Soucy P, Mayes R, McGuffog L, McLean C,- Me Nikiforova MN, Roy S, Wald AI, Landau Lemaçon A, Lush M, Tyrer JP, Ghous- birouk N, Meindl A, Miller A, Miller N, MS, Proksell SS, Dueker JM, Johnston saini M, Moradi Marjaneh M, Jiang X, Montagna M, Moreno F, Muir K, Mulli- ER, Brand RE, Bahary N, Gorantla VC, Agata S, Aittomäki K, Alonso MR, An- gan AM, Muñoz-Garzon VM, Muranen Rhee JC, Pingpank JF, Choudry HA, Lee drulis IL, Anton-Culver H, Antonenko- TA, Narod SA, Nassir R, Nathanson KL, K, Paniccia A, Ongchin MC, Zureikat va NN, Arason A, Arndt V, Aronson KJ, Neuhausen SL, Nevanlinna H, Neven AH, Bartlett DL, Singhi AD. KRAS am- Arun BK, Auber B, Auer PL, Azzollini J, P, Nielsen FC, Nikitina-Zake L, Nor- plification in metastatic colon cancer Balmaña J, Barkardottir RB, Barrow- man A, Offit K, Olah E, Olopade OI, is associated with a history of inflam- dale D, Beeghly-Fadiel A, Benitez J, Olsson H, Orr N, Osorio A, Pankratz matory bowel disease and may confer Bermisheva M, Białkowska K, Blanco VS, Papp J, Park SK, Park-Simon TW, resistance to anti-EGFR therapy. Mod AM, Blomqvist C, Blot W, Bogdanova Parsons MT, Paul J, Pedersen IS, Peis- Pathol. 2020 Sep;33(9):1832-1843. NV, Bojesen SE, Bolla MK, Bonanni B, sel B, Peshkin B, Peterlongo P, Peto J, Epub 2020 May 6. Borg A, Bosse K, Brauch H, Brenner H, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Presneau N, Prokofyeva Fehrenbacher L, Cecchini RS, Geyer Briceno I, Brock IW, Brooks-Wilson A, CE Jr, Rastogi P, Costantino JP, At- Brüning T, Burwinkel B, Buys SS, Cai Q, D, Pujana MA, Pylkäs K, Radice P, Ra- mus SJ, Rantala J, Rau-Murthy R, Ren- kins JN, Crown JP, Polikoff J, Boileau Caldés T, Caligo MA, Camp NJ, Camp- JF, Provencher L, Stokoe C, Moore TD, bell I, Canzian F, Carroll JS, Carter BD, nert G, Risch HA, Robson M, Romero A, Rossing M, Saloustros E, Sánchez-Her- Robidoux A, Flynn PJ, Borges VF, Albain Castelao JE, Chiquette J, Christiansen KS, Swain SM, Paik S, Mamounas EP, H, Chung WK, Claes KBM, Clarke CL; rero E, Sandler DP, Santamariña M, Saunders C, Sawyer EJ, Scheuner MT, Wolmark N. NSABP B-47/NRG Oncol- GEMO Study Collaborators; EMBRACE ogy Phase III Randomized Trial Com- Collaborators, Collée JM, Cornelissen Schmidt DF, Schmutzler RK, Schnee- weiss A, Schoemaker MJ, Schöttker B, paring Adjuvant Chemotherapy With S, Couch FJ, Cox A, Cross SS, Cybuls- or Without Trastuzumab in High-Risk ki C, Czene K, Daly MB, de la Hoya M, Schürmann P, Scott C, Scott RJ, Senter L, Seynaeve CM, Shah M, Sharma P, Invasive Breast Cancer Negative for Devilee P, Diez O, Ding YC, Dite GS, HER2 by FISH and With IHC 1+ or 2. J Domchek SM, Dörk T, Dos-Santos-Silva Shen CY, Shu XO, Singer CF, Slavin TP, Smichkoska S, Southey MC, Spinelli JJ, Clin Oncol. 2020 Feb 10;38(5):444-453. I, Droit A, Dubois S, Dumont M, Duran Epub 2019 Dec 10. M, Durcan L, Dwek M, Eccles DM, Engel Spurdle AB, Stone J, Stoppa-Lyonnet C, Eriksson M, Evans DG, Fasching PA, D, Sutter C, Swerdlow AJ, Tamimi RM, Feng H, Gusev A, Pasaniuc B, Wu L, Fletcher O, Floris G, Flyger H, Foretova Tan YY, Tapper WJ, Taylor JA, Teixeira Long J, Abu-Full Z, Aittomäki K, Andru- L, Foulkes WD, Friedman E, Fritschi L, MR, Tengström M, Teo SH, Terry MB, lis IL, Anton-Culver H, Antoniou AC, Frost D, Gabrielson M, Gago-Domin- Teulé A, Thomassen M, Thull DL, Tisc- Arason A, Arndt V, Aronson KJ, Arun guez M, Gambino G, Ganz PA, Gapstur hkowitz M, Toland AE, Tollenaar RAEM, BK, Asseryanis E, Auer PL, Azzollini J, SM, Garber J, García-Sáenz JA, Gaudet Tomlinson I, Torres D, Torres-Mejía G, Balmaña J, Barkardottir RB, Barnes MM, Georgoulias V, Giles GG, Glendon Troester MA, Truong T, Tung N, Tzardi DR, Barrowdale D, Beckmann MW, G, Godwin AK, Goldberg MS, Goldgar M, Ulmer HU, Vachon CM, van Asperen Behrens S, Benitez J, Bermisheva M, DE, González-Neira A, Tibiletti MG, CJ, van der Kolk LE, van Rensburg EJ, Białkowska K, Blanco A, Blomqvist C, Greene MH, Grip M, Gronwald J, Grun- Vega A, Viel A, Vijai J, Vogel MJ, Wang Q, Boeckx B, Bogdanova NV, Bojesen SE, dy A, Guénel P, Hahnen E, Haiman CA, Wappenschmidt B, Weinberg CR, Weit- Bolla MK, Bonanni B, Borg A, Brauch H, Håkansson N, Hall P, Hamann U, Har- zel JN, Wendt C, Wildiers H, Winqvist Brenner H, Briceno I, Broeks A, Brüning rington PA, Hartikainen JM, Hartman R, Wolk A, Wu AH, Yannoukakos D, T, Burwinkel B, Cai Q, Caldés T, Caligo M, He W, Healey CS, Heemskerk-Ger- Zhang Y, Zheng W, Hunter D, Pharoah MA, Campbell I, Canisius S, Campa D, ritsen BAM, Heyworth J, Hillemanns P, PDP, Chang-Claude J, García-Closas M, Carter BD, Carter J, Castelao JE, Chang- Hogervorst FBL, Hollestelle A, Hoon- Schmidt MK, Milne RL, Kristensen VN, Claude J, Chanock SJ, Christiansen ing MJ, Hopper JL, Howell A, Huang French JD, Edwards SL, Antoniou AC, H, Chung WK, Claes KBM, Clarke CL; G, Hulick PJ, Imyanitov EN; KConFab Chenevix-Trench G, Simard J, Easton GEMO Study Collaborators; EMBRACE Investigators; HEBON Investigators; DF, Kraft P, Dunning AM. Fine-map- Collaborators; GC-HBOC study Collab- ABCTB Investigators, Isaacs C, Iwasaki ping of 150 breast cancer risk regions orators, Couch FJ, Cox A, Cross SS, Cy- identifies 191 likely target genes. Nat 86

Department of Medicine 2020 Annual Report bulski C, Czene K, Daly MB, de la Hoya Transcriptome-wide association study JT, Lu KH, Luben RN, Lubinski J, Man- M, De Leeneer K, Dennis J, Devilee P, of breast cancer risk by estrogen-re- nermaa A, Manoochehri M, Manouki- Diez O, Domchek SM, Dörk T, Dos-San- ceptor status. Genet Epidemiol. 2020 an S, Margolin S, Martens JWM, Maur- tos-Silva I, Dunning AM, Dwek M, Ec- Jul;44(5):442-468. Epub 2020 Mar 1. er T, Mavroudis D, Mebirouk N, Meindl cles DM, Ejlertsen B, Ellberg C, Engel A, Menon U, Miller A, Montagna M, Feng X, Bao R, Li L, Deisenhammer F, C, Eriksson M, Fasching PA, Fletcher O, Nathanson KL, Neuhausen SL, New- Arnason BGW, Reder AT. Interferon-β Flyger H, Fostira F, Friedman E, Frits- man WG, Nguyen-Dumont T, Nielsen corrects massive gene dysregulation chi L, Frost D, Gabrielson M, Ganz PA, FC, Nielsen S, Nikitina-Zake L, Offit K, in multiple sclerosis: Short-term and Gapstur SM, Garber J, García-Closas M, Olah E, Olopade OI, Olshan AF, Olson long-term effects on immune regula- García-Sáenz JA, Gaudet MM, Giles GG, JE, Olsson H, Osorio A, Ottini L, Peissel tion and neuroprotection. EBioMedi- Glendon G, Godwin AK, Goldberg MS, B, Peixoto A, Peto J, Plaseska-Karanfils- cine. 2019 Nov;49:269-283. Epub 2019 Goldgar DE, González-Neira A, Greene ka D, Pocza T, Presneau N, Pujana MA, Oct 21. MH, Gronwald J, Guénel P, Haiman CA, Punie K, Rack B, Rantala J, Rashid MU, Hall P, Hamann U, Hake C, He W, Hey- Figlioli G, Bogliolo M, Catucci I, Caleca L, Rau-Murthy R, Rennert G, Lejbkowicz worth J, Hogervorst FBL, Hollestelle Lasheras SV, Pujol R, Kiiski JI, Muranen F, Rhenius V, Romero A, Rookus MA, A, Hooning MJ, Hoover RN, Hopper TA, Barnes DR, Dennis J, Michailidou K, Ross EA, Rossing M, Rudaitis V, Rueb- JL, Huang G, Hulick PJ, Humphreys K, Bolla MK, Leslie G, Aalfs CM; ABCTB In- ner M, Saloustros E, Sanden K, Santam- Imyanitov EN; ABCTB Investigators; vestigators, Adank MA, Adlard J, Agata ariña M, Scheuner MT, Schmutzler RK, HEBON Investigators; BCFR Investi- S, Cadoo K, Agnarsson BA, Ahearn T, Schneider M, Scott C, Senter L, Shah M, gators; OCGN Investigators, Isaacs C, Aittomäki K, Ambrosone CB, Andrews Sharma P, Shu XO, Simard J, Singer CF, Jakimovska M, Jakubowska A, James L, Anton-Culver H, Antonenkova NN, Sohn C, Soucy P, Southey MC, Spinelli P, Janavicius R, Jankowitz RC, John EM, Arndt V, Arnold N, Aronson KJ, Arun JJ, Steele L, Stoppa-Lyonnet D, Tapper Johnson N, Joseph V, Jung A, Karlan BY, BK, Asseryanis E, Auber B, Auvinen P, WJ, Teixeira MR, Terry MB, Thomassen Khusnutdinova E, Kiiski JI, Konstan- Azzollini J, Balmaña J, Barkardottir RB, M, Thompson J, Thull DL, Tischkow- topoulou I, Kristensen VN, Laitman Barrowdale D, Barwell J, Beane Free- itz M, Tollenaar RAEM, Torres D, Tro- Y, Lambrechts D, Lazaro C, Leroux D, man LE, Beauparlant CJ, Beckmann ester MA, Truong T, Tung N, Untch M, Leslie G, Lester J, Lesueur F, Lindor N, MW, Behrens S, Benitez J, Berger R, Vachon CM, van Rensburg EJ, van Veen Lindström S, Lo WY, Loud JT, Lubiński J, Bermisheva M, Blanco AM, Blomqvist EM, Vega A, Viel A, Wappenschmidt B, Makalic E, Mannermaa A, Manoocheh- C, Bogdanova NV, Bojesen A, Bojesen Weitzel JN, Wendt C, Wieme G, Wolk A, ri M, Manoukian S, Margolin S, Martens SE, Bonanni B, Borg A, Brady AF, Yang XR, Zheng W, Ziogas A, Zorn KK, JWM, Martinez ME, Matricardi L, Maur- Brauch H, Brenner H, Brüning T, Bur- Dunning AM, Lush M, Wang Q, McGuf- er T, Mavroudis D, McGuffog L, Meindl winkel B, Buys SS, Caldés T, Caliebe fog L, Parsons MT, Pharoah PDP, Fosti- A, Menon U, Michailidou K, Kapoor A, Caligo MA, Campa D, Campbell IG, ra F, Toland AE, Andrulis IL, Ramus SJ, PM, Miller A, Montagna M, Moreno F, Canzian F, Castelao JE, Chang-Claude Swerdlow AJ, Greene MH, Chung WK, Moserle L, Mulligan AM, Muranen TA, J, Chanock SJ, Claes KBM, Clarke CL, Milne RL, Chenevix-Trench G, Dörk Nathanson KL, Neuhausen SL, Nevan- Collavoli A, Conner TA, Cox DG, Cy- T, Schmidt MK, Easton DF, Radice P, linna H, Nevelsteen I, Nielsen FC, Nikiti- bulski C, Czene K, Daly MB, de la Hoya Hahnen E, Antoniou AC, Couch FJ, na-Zake L, Offit K, Olah E, Olopade OI, M, Devilee P, Diez O, Ding YC, Dite GS, Nevanlinna H, Surrallés J, Peterlongo Olsson H, Osorio A, Papp J, Park-Simon Ditsch N, Domchek SM, Dorfling CM, P. The FANCM:p.Arg658* truncating TW, Parsons MT, Pedersen IS, Peixo- Dos-Santos-Silva I, Durda K, Dwek M, variant is associated with risk of tri- to A, Peterlongo P, Peto J, Pharoah Eccles DM, Ekici AB, Eliassen AH, Ell- ple-negative breast cancer. NPJ Breast PDP, Phillips KA, Plaseska-Karanfils- berg C, Eriksson M, Evans DG, Fasching Cancer. 2019 Nov 1;5:38. ka D, Poppe B, Pradhan N, Prajzen- PA, Figueroa J, Flyger H, Foulkes WD, Fong L, Hotson A, Powderly JD, Sznol danc K, Presneau N, Punie K, Pylkäs K, Friebel TM, Friedman E, Gabrielson M, M, Heist RS, Choueiri TK, George S, Radice P, Rantala J, Rashid MU, Ren- Gaddam P, Gago-Dominguez M, Gao Hughes BGM, Hellmann MD, Shep- nert G, Risch HA, Robson M, Romero C, Gapstur SM, Garber J, García-Closas ard DR, Rini BI, Kummar S, Weise AM, A, Saloustros E, Sandler DP, Santos C, M, García-Sáenz JA, Gaudet MM, Gay- Riese MJ, Markman B, Emens LA, Ma- Sawyer EJ, Schmidt MK, Schmidt DF, ther SA; GEMO Study Collaborators, hadevan D, Luke JJ, Laport G, Brody JD, Schmutzler RK, Schoemaker MJ, Scott Giles GG, Glendon G, Godwin AK, Gold- Hernandez-Aya L, Bonomi P, Goldman RJ, Sharma P, Shu XO, Simard J, Sing- berg MS, Goldgar DE, Guénel P, Guti- JW, Berim L, Renouf DJ, Goodwin RA, er CF, Skytte AB, Soucy P, Southey MC, errez-Barrera AM, Haeberle L, Haiman Munneke B, Ho PY, Hsieh J, McCaffery Spinelli JJ, Spurdle AB, Stone J, Swerd- CA, Håkansson N, Hall P, Hamann U, I, Kwei L, Willingham SB, Miller RA. Ad- low AJ, Tapper WJ, Taylor JA, Teixeira Harrington PA, Hein A, Heyworth J, enosine 2A Receptor Blockade as an MR, Terry MB, Teulé A, Thomassen Hillemanns P, Hollestelle A, Hopper JL, Immunotherapy for Treatment-Re- M, Thöne K, Thull DL, Tischkowitz M, Hosgood HD 3rd, Howell A, Hu C, Hulick fractory Renal Cell Cancer. Cancer Dis- Toland AE, Tollenaar RAEM, Torres PJ, Hunter DJ, Imyanitov EN; KConFab, cov. 2020 Jan;10(1):40-53. Epub 2019 D, Truong T, Tung N, Vachon CM, van Isaacs C, Jakimovska M, Jakubowska Nov 15. Asperen CJ, van den Ouweland AMW, A, James P, Janavicius R, Janni W, John van Rensburg EJ, Vega A, Viel A, Vie- EM, Jones ME, Jung A, Kaaks R, Karlan Foote JB, Sarvesh S, Emens LA. Cytokine profil- iro-Balo P, Wang Q, Wappenschmidt BY, Khusnutdinova E, Kitahara CM, ing of tumor-infiltrating T lymphocytes by flow B, Weinberg CR, Weitzel JN, Wendt C, Konstantopoulou I, Koutros S, Kraft P, cytometry. Methods Enzymol. 2020;631:1-20. Epub 2019 Oct 18. Winqvist R, Yang XR, Yannoukakos D, Lambrechts D, Lazaro C, Le Marchand Ziogas A, Milne RL, Easton DF, Chene- L, Lester J, Lesueur F, Lilyquist J, Loud Forde PM, Bonomi P, Shaw A, Blumen- vix-Trench G, Zheng W, Kraft P, Jiang X. 87

Division of Hematology/Oncology BIBLIOGRAPHY

thal GM, Ferris A, Patel C, Melemed A, George LA, Ragni MV, Rasko JEJ, Raf- Moss ML, Garlin MA, Miller MA, Her- Basu Roy U, Ramamoorthy A, Liu Q, fini LJ, Samelson-Jones BJ, Ozelo M, man J, Stabile LP, Vujanovic NL. Devel- Burns T, Gainor JF, Lovly C, Piotrowska Hazbon M, Runowski AR, Wellman JA, opment of flow cytometry assays for Z, Lehman J, Selig W. Expanding Access Wachtel K, Chen Y, Anguela XM, Ku- measuring cell-membrane enzyme ac- to Lung Cancer Clinical Trials by Re- randa K, Mingozzi F, High KA. Long- tivity on individual cells. J Cancer. 2020 ducing the Use of Restrictive Exclusion Term Follow-Up of the First in Hu- Jan 1;11(3):702-715. eCollection 2020. Criteria: Perspectives of a Multistake- man Intravascular Delivery of AAV Gouraud E, Charrin E, Dubé JJ, holder Working Group. Clin Lung Can- for Gene Transfer: AAV2-hFIX16 for Ofori-Acquah SF, Martin C, Skinner cer. 2020 Jul;21(4):295-307. Epub 2020 Severe Hemophilia B. Mol Ther. 2020 S, Chatel B, Boreau A, Messonnier LA, Feb 26. Jun 10:S1525-0016(20)30291-4. Online Connes P, Pialoux V, Hautier C, Faes C. ahead of print. Fournier MV, Goodwin EC, Chen J, Effects of Individualized Treadmill En- Obenauer JC, Tannenbaum SH, Bruf- Geramita EM, DeVito Dabbs AJ, durance Training on Oxidative Stress sky AM. A Predictor of Pathological DiMartini AF, Pilewski JM, Switzer GE, in Skeletal Muscles of Transgenic Sick- Complete Response to Neoadjuvant Posluszny DM, Myaskovsky L, Dew le Mice. Oxid Med Cell Longev. 2019 Jul Chemotherapy Stratifies Triple Nega- MA. Impact of a Mobile Health Inter- 24;2019:3765643. eCollection 2019. tive Breast Cancer Patients with High vention on Long-term Nonadherence Guo M, Peng Y, Gao A, Du C, Herman JG. Epi- Risk of Recurrence. Sci Rep. 2019 Oct After Lung Transplantation: Follow-up genetic heterogeneity in cancer. Biomark Res. 16;9(1):14863. After a Randomized Controlled Trial. 2019 Oct 31;7:23. eCollection 2019. Transplantation. 2020 Mar;104(3):640- Gao C, Chen G, Zhang DH, Zhang J, 651. Gutkin DW, Shurin MR, El Azher MA, Kuan SF, Hu W, Esni F, Gao X, Guan JL, Shurin GV, Velikokhatnaya L, Pross- Chu E, Hu J. PYK2 Is Involved in Pre- Geramita EM, Parker IR, Brufsky JW, er D, Shin N, Modugno F, Stemmer P, malignant Acinar Cell Reprogramming Diergaarde B, van Londen GJ. Primary Elishaev E, Lokshin A. Novel protein and Pancreatic Ductal Adenocarcino- Care Providers’ Knowledge, Attitudes, and immune response markers of hu- ma Maintenance by Phosphorylating Beliefs, and Practices Regarding Their man serous tubal intraepithelial carci- Y654 β-Catenin . Cell Mol Gastroenterol Preparedness to Provide Cancer Survi- noma of the ovary. Cancer Biomark. Hepatol. 2019;8(4):561-578. Epub 2019 vorship Care. J Cancer Educ. 2019 Aug 2019;26(4):471-479. Jul 19. 6. Online ahead of print. Heng YJ, Hankinson SE, Wang J, Alexan- Garcia CA, Bhatnagar M, Rodenbach Gerber DE, Camidge DR, Morgensztern drov LB, Ambrosone CB, de Andrade R, Chu E, Marks S, Graham-Pardus A, D, Cetnar J, Kelly RJ, Ramalingam SS, VP, Brufsky AM, Couch FJ, King TA, Kriner J, Winfield M, Minnier C, Leahy Spigel DR, Jeong W, Scaglioni PP, Zhang Modugno F, Vachon CM, Eliassen AH, J, Hanchett S, Baird E, Arnold RM, Lev- S, Li M, Weaver DT, Vaikus L, Keegan M, Tamimi RM, Kraft P. The Association of enson JE. Standardization of Inpatient Horobin JC, Burns TF. Phase 2 study of Modifiable Breast Cancer Risk Factors CPR Status Discussions and Documen- the focal adhesion kinase inhibitor de- and Somatic Genomic Alterations in tation Within the Division of Hematol- factinib (VS-6063) in previously treat- Breast Tumors: The Cancer Genome ogy-Oncology at UPMC Shadyside: Re- ed advanced KRAS mutant non-small Atlas Network. Cancer Epidemiol Bio- sults From PDSA Cycles 1 and 2. J Oncol cell lung cancer. Lung Cancer. 2020 markers Prev. 2020 Mar;29(3):599- Pract. 2019 Aug;15(8):e746-e754. Epub Jan;139:60-67. Epub 2019 Nov 4. 605. Epub 2020 Jan 13. 2019 Jun 17. Ghosh S, Flage B, Weidert F, Ofori-Ac- Hong CS, Danet-Desnoyers G, Shan Garris CS, Luke JJ. Dendritic Cells, the T-cell-in- quah SF. P-selectin plays a role in X, Sharma P, Whiteside TL, Boyiadzis flamed Tumor Microenvironment, and Immu- haem-induced acute lung injury in M. Human acute myeloid leukemia notherapy Treatment Response. Clin Cancer sickle mice. Br J Haematol. 2019 Res. 2020 Aug 1;26(15):3901-3907. Epub 2020 blast-derived exosomes in patient-de- Jul;186(2):329-333. Epub 2019 Feb 27. Apr 24. rived xenograft mice mediate immune Goklemez S, Im AP, Cao L, Pirsl F, suppression. Exp Hematol. 2019 Gbotosho OT, Ghosh S, Kapetana- Steinberg SM, Curtis LM, Mitchell SA, Aug;76:60-66.e2. Epub 2019 Jul 29. ki MG, Lin Y, Weidert F, Bullock GC, Cowen EW, Baruffaldi J, Rose J, Mays Ofori-Acquah SF, Kato GJ. Cardiac ex- Hughes AD, Zhao D, Dai H, Abou-Daya J, Ostojic A, Holtzman NG, Hakim FT, pression of HMOX1 and PGF in sickle KI, Tieu R, Rammal R, Williams AL, Pavletic SZ. Clinical characteristics and cell mice and haem-treated wild type Landsittel DP, Shlomchik WD, Morel- cytokine biomarkers in patients with mice dominates organ expression pro- li AE, Oberbarnscheidt MH, Lakkis FG. chronic graft-vs-host disease persist- files via Nrf2 (Nfe2l2). Br J Haematol. Cross-dressed dendritic cells sustain ing seven or more years after diagno- 2019 Dec;187(5):666-675. Epub 2019 effector T cell responses in islet and sis. Am J Hematol. 2020 Jan 5. Online Aug 6. kidney allografts. J Clin Invest. 2020 Jan ahead of print. 2;130(1):287-294. Gbotosho OT, Kapetanaki MG, Ross Goldmacher GV, Khilnani AD, Andtbacka RHI, Im A, Rashidi A, Wang T, Hemmer M, Ghosh S, Weidert F, Bullock GC, , Hodi FS, Marabelle A, Harrington K, Luke JJ M, MacMillan ML, Pidala J, Jagasia M, Watkins S, Ofori-Acquah SF, Kato Perrone A, Tse A, Madoff DC, Schwartz LH. GJ. Nrf2 deficiency in mice attenuates Response Criteria for Intratumoral Immuno- Pavletic S, Majhail NS, Weisdorf D, Ab- erythropoietic stress-related macro- therapy in Solid Tumors: itRECIST. J Clin Oncol. del-Azim H, Agrawal V, Al-Homsi AS, phage hypercellularity. Exp Hematol. 2020 Aug 10;38(23):2667-2676. Epub 2020 Aljurf M, Askar M, Auletta JJ, Bashey A, 2020 Apr;84:19-28.e4. Epub 2020 Mar Jun 18. Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhab- 6. Gorry M, Yoneyama T, Vujanovic L, ra S, Choe H, Ciurea S, Daly A, Perez

Department of Medicine 2020 Annual Report MAD, Farhadfar N, Gadalla SM, Gale R, ra ER, Rodrigues-Canales J, Bolejack ease: cardiopulmonary and kidney disease. Ganguly S, Gergis U, Hanna R, Hemat- V, Van Tine BA, Schuetze SM, Attia S, Blood Adv. 2019 Dec 10;3(23):3867-3897. ti P, Herzig R, Hildebrandt GC, Lad DP, Riedel RF, Hu J, Okuno SH, Priebat DA, Ling DC, Moppins BL, Champ CE, Lee C, Lehmann L, Lekakis L, Kamble Movva S, Davis LE, Reed DR, Reuben Gorantla VC, Beriwal S. Quality of RT, Kharfan-Dabaja MA, Khandelwal A, Roland CL, Reinke D, Lazar AJ, Wang Regional Nodal Irradiation Plans in P, Martino R, Murthy HS, Nishihori T, WL, Wargo JA, Tawbi HA. Correlative Breast Cancer Patients Across a Large O’Brien TA, Olsson RF, Patel SS, Pera- Analyses of the SARC028 Trial Reveal Network-Can We Translate Results les MA, Prestidge T, Qayed M, Romee an Association Between Sarcoma-As- From Randomized Trials Into the R, Schoemans H, Seo S, Sharma A, Solh sociated Immune Infiltrate and Re- Clinic?. Pract Radiat Oncol. 2020 Jun M, Strair R, Teshima T, Urbano-Ispizua sponse to Pembrolizumab. Clin Can- 29:S1879-8500(20)30164-8. Online A, Van der Poel M, Vij R, Wagner JL, cer Res. 2020 Mar 15;26(6):1258-1266. ahead of print. William B, Wirk B, Yared JA, Spellman Epub 2020 Jan 3. SR, Arora M, Hamilton BK. Risk Factors Liu B, Ricarte Filho J, Mallisetty A, Villani Klar N, Rosenzweig M, Diergaarde B, for Graft-versus-Host Disease in Hap- C, Kottorou A, Rodgers K, Chen C, Ito Brufsky A. Features Associated With loidentical Hematopoietic Cell Trans- T, Holmes K, Gastala N, Valyi-Nagy K, Long-Term Survival in Patients With plantation Using Post-Transplant Cy- David O, Gaba RC, Ascoli C, Pasquinelli Metastatic Breast Cancer. Clin Breast clophosphamide. Biol Blood Marrow M, Feldman LE, Massad MG, Wang TH, Cancer. 2019 Aug;19(4):304-310. Epub Transplant. 2020 Aug;26(8):1459-1468. Jusue-Torres I, Benedetti E, Winn RA, 2019 Feb 6. Epub 2020 May 17. Brock MV, Herman JG, Hulbert A. De- tection of Promoter DNA Methylation Jameson-Lee M, Luke JJ. Moving toward Korpics MC, Polley MY, Bhave SR, in Urine and Plasma Aids the Detection multi-dimensional biomarkers in cancer Redler G, Pitroda SP, Luke JJ, Chmura immunotherapy. Chin Clin Oncol. 2020 Jan SJ. A Validated T Cell Radiomics Score of Non-Small Cell Lung Cancer. Clin 2:cco.2019.12.16. Online ahead of print. Is Associated With Clinical Outcomes Cancer Res. 2020 Aug 15;26(16):4339- Following Multisite SBRT and Pem- 4348. Epub 2020 May 19. Jonassaint CR, Kang C, Prussien KV, brolizumab. Int J Radiat Oncol Biol Yarboi J, Sanger MS, Wilson JD, De Liu H, Zenati MS, Rieser CJ, Al-Abbas Phys. 2020 Sep 1;108(1):189-195. Epub Castro L, Shah N, Sarkar U. Feasibili- A, Lee KK, Singhi AD, Bahary N, Hogg 2020 Jun 20. ty of implementing mobile technolo- ME, Zeh HJ 3rd, Zureikat AH. CA19-9 gy-delivered mental health treatment Kubik MW, Sridharan S, Varvares MA, Zand- Change During Neoadjuvant Therapy in routine adult sickle cell disease berg DP, Skinner HD, Seethala RR, Chiosea May Guide the Need for Additional care. Transl Behav Med. 2020 Feb SI. Intraoperative Margin Assessment in Head Adjuvant Therapy Following Resected and Neck Cancer: A Case of Misuse and Abuse?. 3;10(1):58-67. Pancreatic Cancer. Ann Surg Oncol. Head Neck Pathol. 2020 Jun;14(2):291-302. 2020 Apr 22. Online ahead of print. Jonna S, Feldman RA, Swensen J, Ga- Epub 2020 Mar 2. Liu JF, Gordon M, Veneris J, Braiteh talica Z, Korn WM, Borghaei H, Ma Labadie BW, Liu P, Bao R, Crist M, F, Balmanoukian A, Eder JP, Oaknin PC, Nieva JJ, Spira AI, Vanderwalde Fernandes R, Ferreira L, Graupner S, A, Hamilton E, Wang Y, Sarkar I, Mo- AM, Wozniak AJ, Kim ES, Liu SV. De- Poklepovic AS, Duran I, Maleki Vare- linero L, Fassò M, O’Hear C, Lin YG, tection of NRG1 Gene Fusions in Sol- ki S, Balar AV, Luke JJ. BMI, irAE, and Emens LA. Safety, clinical activity and id Tumors. Clin Cancer Res. 2019 Aug gene expression signatures associate biomarker assessments of atezolizum- 15;25(16):4966-4972. Epub 2019 Apr with resistance to immune-checkpoint ab from a Phase I study in advanced/ 15. inhibition and outcomes in renal cell recurrent ovarian and uterine cancers. carcinoma. J Transl Med. 2019 Nov Kalpatthi R, Kiss JE. Thrombotic Throm- Gynecol Oncol. 2019 Aug;154(2):314- bocytopenic Purpura, Heparin-Induced 25;17(1):386. 322. Epub 2019 Jun 14. Thrombocytopenia, and Disseminated Intra- Lapinski J, Maurer LM, Ragni MV, McShea vascular Coagulation. Crit Care Clin. 2020 Lopez LV, Yatsenko SA, Burgess M, Schoedel C, Cooper JD, Xavier F. Unsuspected Lyme Apr;36(2):357-377. Epub 2020 Feb 6. K, Rao UNM. Dermatofibrosarcoma protuber- disease presenting in refractory haemo- ans with fibrosarcomatous transformation: philic haemarthrosis. Haemophilia. 2019 Kapetanaki MG, Gbotosho OT, Shar- our experience, molecular evaluation of se- Sep;25(5):e331-e333. Epub 2019 Jul 29. ma D, Weidert F, Ofori-Acquah SF, lected cases, and short literature review. Int J Kato GJ. Free heme regulates placenta Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam Dermatol. 2019 Nov;58(11):1246-1252. Epub growth factor through NRF2-antiox- S, van den Bent M, Ahluwalia M, Campian 2019 Apr 10. idant response signaling. Free Radic JL, Galanis E, Gilbert MR, Holdhoff M, Lesser Biol Med. 2019 Nov 1;143:300-308. GJ, Lieberman FS, Mehta MP, Penas-Prado Lu T, Wang S, Xu L, Zhou Q, Singla N, Epub 2019 Aug 10. M, Schreck KC, Strowd RE, Vogelbaum MA, Gao J, Manna S, Pop L, Xie Z, Chen M, Walbert T, Chang SM, Nabors LB, Grossman Luke JJ, Brugarolas J, Hannan R, Wang Kelly ZR, Gorantla VC, Davar D. The Role of S, Reardon DA, Wen PY. Optimizing eligibility T. Tumor neoantigenicity assessment Neoadjuvant Therapy in Melanoma. Curr On- criteria and clinical trial conduct to enhance with CSiN score incorporates clonality col Rep. 2020 Jun 29;22(8):80. clinical trial participation for primary brain and immunogenicity to predict immu- tumor patients. Neuro Oncol. 2020 May Kesselheim JC, Clayton CP, Fritz J, Smith RE, notherapy outcomes. Sci Immunol. 15;22(5):601-612. Gitlin SD, Reid E, Zuckerman KS, Kahn MJ. The 2020 Feb 21;5(44):eaaz3199. American Society of Hematology (ASH) Medi- Liem RI, Lanzkron S, D Coates T, DeCastro cal Educators Institute: a Pilot Faculty Devel- L, Desai AA, Ataga KI, Cohen RT, Haynes J, Luke JJ, Ascierto PA, Carlino MS, Ger- opment Project for Hematology Educators. J Osunkwo I, Lebensburger JD, Lash JP, Wun T, shenwald JE, Grob JJ, Hauschild A, Kirk- Cancer Educ. 2019 Aug;34(4):719-724. Verhovsek M, Ontala E, Blaylark R, Alahdab wood JM, Long GV, Mohr P, Robert C, F, Katabi A, Mustafa RA. American Society of Ross M, Scolyer RA, Yoon CH, Pokle- Keung EZ, Burgess M, Salazar R, Par- Hematology 2019 guidelines for sickle cell dis- povic A, Rutkowski P, Anderson JR, 89

Division of Hematology/Oncology BIBLIOGRAPHY

Ahsan S, Ibrahim N, M Eggermont AM. ly career plans. Blood Adv. 2019 Nov Jul 23;3(14):2082-2092. KEYNOTE-716: Phase III study of adju- 12;3(21):3278-3286. Murthy P, Zenati MS, Al Abbas AI, Ries- vant pembrolizumab versus placebo Mast AE, Langer JC, Guo Y, Bialkowski er CJ, Bahary N, Lotze MT, Zeh HJ 3rd, in resected high-risk stage II melano- W, Spencer BR, Lee TH, Kiss J, Cable Zureikat AH, Boone BA. Prognostic ma. Future Oncol. 2020 Jan;16(3):4429- RG, Brambilla D, Busch MP, Page GP; Value of the Systemic Immune-Inflam- 4438. Epub 2019 Dec 24. NHLBI Recipient Epidemiology Donor mation Index (SII) After Neoadjuvant Luke JJ, Ascierto PA. Biology confirmed Evaluation Study (REDS)-III. Genetic Therapy for Patients with Resected but biomarkers elusive in melanoma im- and behavioral modification of - he Pancreatic Cancer. Ann Surg Oncol. munotherapy. Nat Rev Clin Oncol. 2020 moglobin and iron status among first- 2020 Mar;27(3):898-906. Epub 2019 Apr;17(4):198-199. time and high-intensity blood donors. Dec 2. Luke JJ, Olson DJ, Allred JB, Strand CA, Transfusion. 2020 Apr;60(4):747-758. Nagasaka M, Abdallah N, Crosby M, Bao R, Zha Y, Carll T, Labadie BW, Bas- Epub 2020 Mar 12. Thummala N, Patel D, Wozniak AJ, tos BR, Butler MO, Hogg D, Munster Mast AE, Szabo A, Stone M, Cable RG, Gadgeel S, Abrams J, Sukari A. A retro- PN, Schwartz GK. Randomized Phase Spencer BR, Kiss JE; NHLBI Recipient spective study evaluating the pretreat- II Trial and Tumor Mutational Spec- Epidemiology Donor Evaluation Study ment tumor volume (PTV) in non-small trum Analysis from Cabozantinib ver- (REDS)-III. The benefits of iron supple- cell lung cancer (NSCLC) as a predictor sus Chemotherapy in Metastatic Uveal mentation following blood donation of response to program death-1 (PD-1) Melanoma (Alliance A091201). Clin vary with baseline iron status. Am J inhibitors. Lung Cancer (Auckl). 2019 Cancer Res. 2020 Feb 15;26(4):804- Hematol. 2020 Jul;95(7):784-791. Epub Sep 12;10:95-105. eCollection 2019. 811. Epub 2019 Sep 26. 2020 Apr 15. Najjar YG, Navrazhina K, Ding F, Bha- Luke JJ. The newest treatments for uveal melanoma. Clin Adv Hematol Oncol. 2019 McCormick M, Richardson T, Warady tia R, Tsai K, Abbate K, Durden B, Ero- Sep;17(9):490-493. BA, Novelli EM, Kalpatthi R. Acute glu Z, Bhatia S, Park S, Chowdhary A, kidney injury in paediatric patients Chandra S, Kennedy J, Ernstoff M, Luu T, Frankel P, Beumer JH, Lim D, with sickle cell disease is associat- Vachhani P, Drabick J, Singh A, Xu T, Cristea M, Appleman LJ, Lenz HJ, Gan- ed with increased morbidity and re- Yang J, Carvajal R, Manson D, M Kirk- dara DR, Kiesel BF, Piekarz RL, New- source utilization. Br J Haematol. 2020 wood J, Cohen J, Sullivan R, Johnson D, man EM. Phase I trial of belinostat in May;189(3):559-565. Epub 2020 Feb 6. Funchain P, Shoushtari A. Ipilimumab combination with 13-cis-retinoic acid plus nivolumab for patients with met- Mehta KD, Siddappa Malleshappa SK, in advanced solid tumor malignancies: astatic uveal melanoma: a multicenter, Patel S, Giri S, Wang H, Smith R, Parikh a California Cancer Consortium NCI/ retrospective study. J Immunother RA. Trends of Inpatient Venous Throm- CTEP sponsored trial. Cancer Chemo- Cancer. 2020 Jun;8(1):e000331. ther Pharmacol. 2019 Dec;84(6):1201- boembolism in United States Before 1208. Epub 2019 Sep 14. and After the Surgeon General’s Call Najjar YG, Puligandla M, Lee SJ, Kirk- to Action. Am J Cardiol. 2019 Sep wood JM. An updated analysis of 4 Machin N, Ragni MV. Hormones and throm- 15;124(6):960-965. Epub 2019 Jun 26. randomized ECOG trials of high-dose bosis: risk across the reproductive years interferon in the adjuvant treatment and beyond. Transl Res. 2020 Jun 26:S1931- Mohr P, Kiecker F, Soriano V, Dereure of melanoma. Cancer. 2019 Sep 5244(20)30150-X. Online ahead of print. O, Mujika K, Saiag P, Utikal J, Koneru 1;125(17):3013-3024. Epub 2019 May R, Robert C, Cuadros F, Chacón M, Vil- Maguire WF, Kirkwood JM. Developing agents 8. for the therapeutic prevention of melano- larroel RU, Najjar YG, Kottschade L, ma: can the assessment of cutaneous pre- Couselo EM, Koruth R, Guérin A, Burne Nanivadekar AC, Miller DM, Fulton cursor lesions help?. Future Oncol. 2020 R, Ionescu-Ittu R, Perrinjaquet M, Zager S, Wong L, Ogren J, Chitnis G, Mc- Mar;16(9):413-415. Epub 2020 Feb 26. JS. Adjuvant therapy versus watch- Laughlin B, Zhai S, Fisher LE, Yates Makani J, Sangeda RZ, Nnodu O, Nem- and-wait post surgery for stage III mel- BJ, Horn CC. Machine learning pre- baware V, Osei-Akoto A, Paintsil V, Bal- anoma: a multicountry retrospective diction of emesis and gastrointestinal andya E, Kent J, Luzzatto L, Ofori-Ac- chart review. Melanoma Manag. 2019 state in ferrets. PLoS One. 2019 Oct quah S, Olopade OI, Pallangyo K, Minja Oct 4;6(4):MMT33. 18;14(10):e0223279. eCollection 2019. IK, Jonas M, Mazandu GK, Mulder N, Molinero L, Li Y, Chang CW, Maund S, Berg Nasrazadani A, Brufsky A. Neratinib: the Ohene-Frempong K, Wonkam A. Sick- M, Harrison J, Fassò M, O’Hear C, Hegde P, emergence of a new player in the manage- leInAfrica. Lancet Haematol. 2020 Emens LA. Tumor immune microenvironment ment of HER2+ breast cancer brain metas- Feb;7(2):e98-e99. and genomic evolution in a patient with meta- tasis. Future Oncol. 2020 Mar;16(7):247-254. static triple negative breast cancer and a com- Epub 2020 Feb 14. Malhotra MK, Emens LA. The evolving man- plete response to atezolizumab. J Immunother Nasrazadani A, Brufsky AM. Artificial intel- agement of metastatic triple negative breast Cancer. 2019 Oct 23;7(1):274. cancer. Semin Oncol. 2020 Aug;47(4):229-237. ligence-directed prognostication of breast Epub 2020 May 28. Morin-Zorman S, Wysocki C, Zhu J, cancer. EBioMedicine. 2019 Aug;46:6-7. Epub Li H, Zorman S, Matte-Martone C, Ki- 2019 Aug 1. Masselink LE, Erikson CE, Connell NT, sanga E, McNiff J, Jain D, Gonzalez D, Nasrazadani A, Brufsky AM. Capivasertib in- De Castro LM, Dent GA, Marshall AL, Rothstein DM, Lakkis FG, Haberman A, hibits a key pathway in metastatic breast can- Naik RP, Nelson M, O’Connell CL, Ra- Shlomchik WD. In vivo dynamics of T cer. Lancet Oncol. 2020 Mar;21(3):318-319. jasekhar A, Sharma D, Smith M, Lee cells and their interactions with den- Epub 2020 Feb 5. AI. Associations between hematology/ dritic cells in mouse cutaneous graft- oncology fellows’ training and mentor- Nasrazadani A, Brufsky AM. CDK4/6 inhibi- versus-host disease. Blood Adv. 2019 tors: taking the place of chemotherapy?. Lan- ship experiences and hematology-on-

Department of Medicine 2020 Annual Report cet Oncol. 2019 Oct;20(10):1329-1330. Epub Lenhart D, Tan RJ, Vitturi DA, Pain- Valuable Imaging Biomarker of Inflammation 2019 Sep 4. tsil V, Owusu-Dabo E, Ghosh S; Sick- in Cardiovascular Disease. J Nucl Med. 2019 Dec;60(12):1691-1697. Epub 2019 Oct 10. Nastoupil LJ, Jain MD, Feng L, Spiegel leGenAfrica Network. Hemopexin de- JY, Ghobadi A, Lin Y, Dahiya S, Lun- ficiency promotes acute kidney injury Petitprez F, de Reyniès A, Keung EZ, ning M, Lekakis L, Reagan P, Oluwole in sickle cell disease. Blood. 2020 Mar Chen TW, Sun CM, Calderaro J, Jeng O, McGuirk J, Deol A, Sehgal AR, Goy 26;135(13):1044-1048. YM, Hsiao LP, Lacroix L, Bougoüin A, A, Hill BT, Vu K, Andreadis C, Munoz Ofori-Acquah SF. Sickle cell disease as a Moreira M, Lacroix G, Natario I, Adam J, Westin J, Chavez JC, Cashen A, Ben- vascular disorder. Expert Rev Hematol. 2020 J, Lucchesi C, Laizet YH, Toulmonde nani NN, Rapoport AP, Vose JM, Miklos Jun;13(6):645-653. Epub 2020 May 3. M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland DB, Neelapu SS, Locke FL. Standard- Olson DJ, Luke JJ. Improving therapy in meta- of-Care Axicabtagene Ciloleucel for static uveal melanoma by understanding pri- CL, Wargo JA, Italiano A, Sautès-Frid- Relapsed or Refractory Large B-Cell or failures. Oncoscience. 2020 Jun 1;7(5-6):40- man C, Tawbi HA, Fridman WH. B cells Lymphoma: Results From the US Lym- 43. eCollection 2020 May. are associated with survival and im- phoma CAR T Consortium. J Clin On- munotherapy response in sarcoma. Olson DJ, Rajagopal P, Tjota MY, Venkatara- Nature. 2020 Jan;577(7791):556-560. col. 2020 May 13:JCO1902104. Online man G, Luke JJ, Gajewski TF. A case of du- ahead of print. al-mechanism immune-related anaemia in Epub 2020 Jan 15. a patient with metastatic melanoma treated Nelson BW, Low CA, Jacobson N, Areán P, Petrylak DP, Vogelzang NJ, Chatta K, with nivolumab and ipilimumab. J Immunoth- Torous J, Allen NB. Guidelines for wrist-worn Fleming MT, Smith DC, er Cancer. 2020 Mar;8(1):e000380. Appleman consumer wearable assessment of heart rate LJ, Hussain A, Modiano M, Singh P, in biobehavioral research. NPJ Digit Med. Onwuemene OA, Zantek ND, Roll- Tagawa ST, Gore I, McClay EF, Mega AE, 2020 Jun 26;3:90. eCollection 2020. ins-Raval MA, Raval JS, Kiss JE, Ipe TS, Sartor AO, Somer B, Wadlow R, Shore Nilsen ML, Clump DA 2nd, Kubik M, Losego K, Kuchibhatla M, Pagano MB, Wong ND, Olson WC, Stambler N, DiPippo Mrozek A, Pawlowicz E, Pickford D, Sridharan ECC. Therapeutic plasma exchange VA, Israel RJ. PSMA ADC monotherapy S, Traylor K, Wasserman-Wincko T, Young K, for management of heparin-induced in patients with progressive metastat- Zandberg D, Johnson JT. Prevision of multidis- thrombocytopenia: Results of an inter- ic castration-resistant prostate cancer ciplinary head and neck cancer survivorship national practice survey. J Clin Apher. following abiraterone and/or enzalut- care during the 2019 novel coronavirus pan- 2019 Oct;34(5):545-554. Epub 2019 amide: Efficacy and safety in open-la- demic. Head Neck. 2020 Jul;42(7):1668-1673. Epub 2020 May 18. May 22. bel single-arm phase 2 study. Prostate. 2020 Jan;80(1):99-108. Epub 2019 Nov Paniccia A, Gleisner AL, Zenati MS, Al Nilsen ML, Lyu L, Belsky MA, Mady LJ, 19. Zandberg DP, Clump DA 2nd, Skinner Abbas AI, Jung JP, Bahary N, Lee KKW, HD, Peddada SD, George S, Johnson JT. Bartlett D, Hogg ME, Zeh HJ, Zureikat Pidala J, Jaglowski S, Im A, Chen G, Impact of Neck Disability on Health-Re- AH. Predictors of Disease Progression Onstad L, Storer B, Kurukulasuriya C, lated Quality of Life among Head and or Performance Status Decline in Pa- Lee SJ. Carfilzomib for Treatment of Neck Cancer Survivors. Otolaryngol tients Undergoing Neoadjuvant Ther- Refractory Chronic Graft-versus-Host Head Neck Surg. 2020 Jan;162(1):64- apy for Localized Pancreatic Head Ad- Disease: A Chronic GVHD Consortium 72. Epub 2019 Oct 15. enocarcinoma. Ann Surg Oncol. 2020 Pilot Phase II Trial. Biol Blood Marrow Aug;27(8):2961-2971. Epub 2020 Mar Transplant. 2020 Feb;26(2):278-284. Nouraie M, Darbari DS, Rana S, Minniti 28. Epub 2019 Sep 6. CP, Castro OL, Luchtman-Jones L, Sa- ble C, Dham N, Kato GJ, Gladwin MT, Pasi KJ, Fischer K, Ragni M, Kulkarni Pimentel I, Chen BE, Lohmann AE, En- Ensing G, Arteta M, Campbell A, Taylor R, Ozelo MC, Mahlangu J, Shapiro A, nis M, Ligibel J, Shepherd L, Hershman JG 6th, Nekhai S, Gordeuk VR. Tricus- P’Ng S, Chambost H, Nolan B, Bennett DL, Whelan T, Stambolic V, Mayer I, pid regurgitation velocity and other C, Matsushita T, Winding B, Fruebis J, Hobday T, Lemieux J, Thompson A, biomarkers of mortality in children, Yuan H, Rudin D, Oldenburg J. Long- Rastogi P, Gelmon K, Rea D, Rabaglio adolescents and young adults with term safety and sustained efficacy M, Ellard S, Mates M, Bedard P, Pitre L, sickle cell disease in the United States: for up to 5 years of treatment with Vandenberg T, Jo Dowling R, Parulekar The PUSH study. Am J Hematol. 2020 recombinant factor IX Fc fusion pro- W, Goodwin PJ. The effect of met- Jul;95(7):766-774. Epub 2020 Apr 21. tein in subjects with haemophilia B: formin vs placebo on sex hormones in Results from the B-YOND extension CCTG MA.32. J Natl Cancer Inst. 2020 Nouraie M, Little JA, Hildesheim M, study. Haemophilia. 2020 Jun 4. Online Jun 4:djaa082. Online ahead of print. Gibbs JSR, Morris CR, Machado RF, ahead of print. Poklepovic AS, Luke JJ. Considering adjuvant Kato GJ, Gordeuk VR, Gladwin MT. Perez MC, Zager JS, Amatruda T, Con- therapy for stage II melanoma. Cancer. 2020 Validation of a composite vascular Mar 15;126(6):1166-1174. Epub 2019 Dec 23. high-risk profile for adult patients with ry R, Ariyan C, Desai A, Kirkwood JM, sickle cell disease. Am J Hematol. 2019 Treichel S, Cohan D, Raskin L. Obser- Pollack SM, Somaiah N, Araujo DM, Dec;94(12):E312-E314. Epub 2019 Sep vational study of talimogene laher- Druta M, Van Tine BA, Burgess MA, 17. parepvec use for melanoma in clinical Chawla SP, Seetharam M, Okuno SH, practice in the United States (COS- Bohac C, Chen M, Yurasov S, Attia S. . COVID-19 and SCA: an old Novelli EM MUS-1). Melanoma Manag. 2019 Jul Clinical outcomes of patients with ad- friend comes to the rescue. Blood. 2020 May 3;6(2):MMT19. 28;135(22):1925-1926. vanced synovial sarcoma or myxoid/ Perkins LA, Anderson CJ, Novelli EM. Tar- round cell liposarcoma treated at ma- Ofori-Acquah SF, Hazra R, Orikog- geting P-Selectin Adhesion Molecule in Mo- jor cancer centers in the United States. bo OO, Crosby D, Flage B, Ackah EB, lecular Imaging: P-Selectin Expression as a Cancer Med. 2020 Jul;9(13):4593-4602. 91

Division of Hematology/Oncology BIBLIOGRAPHY

Epub 2020 May 6. myelosuppression toxicities: a cor- breast cancer (IMpassion130): updat- relative analysis of NRG oncology ed efficacy results from a randomised, Pore SK, Hahm ER, Kim SH, Singh KB, RTOG 0525. Neurooncol Pract. 2019 double-blind, placebo-controlled, Nyiranshuti L, Latoche JD, Anderson CJ, Dec;6(6):473-478. Epub 2019 Apr 6. phase 3 trial. Lancet Oncol. 2020 Adamik J, Galson DL, Weiss KR, Wat- Jan;21(1):44-59. Epub 2019 Nov 27. ters RJ, Lee B, Kumta PN, Singh SV. A Rodeghiero F, Pabinger I, Ragni M, Ab- Novel Sulforaphane-Regulated Gene dul-Kadir R, Berntorp E, Blanchette V, Bodó I, Sen M, Kindsfather A, Danilova L, Network in Suppression of Breast Casini A, Gresele P, Lassila R, Leebeek F, Lilli- Zhang F, Colombo R, LaPorte MG, Cancer-Induced Osteolytic Bone Re- crap D, Mezzano D, Noris P, Srivastava A, To- Kurland BF, Huryn DM, Wipf P, Her- setto A, Windyga J, Zieger B, Makris M, Key N. sorption. Mol Cancer Ther. 2020 man JG. PTPRT epigenetic silencing Fundamentals for a Systematic Approach to Feb;19(2):420-431. Epub 2019 Nov 29. Mild and Moderate Inherited Bleeding Disor- defines lung cancer with STAT3 activation and can direct STAT3 target- Pradhan-Sundd T, Kosar K, Saggi ders: An EHA Consensus Report. Hemasphere. 2019 Sep 17;3(5):e286. eCollection 2019 Oct. ed therapies. Epigenetics. 2020 Jun- H, Zhang R, Vats R, Cornuet P, Green Jul;15(6-7):604-617. Epub 2019 Oct 13. S, Singh S, Zeng G, Sundd P, Ne- Sabik LM, Eom KY, Dahman B, Li J, Yao jak-Bowen K. Wnt/β-Catenin Signaling N, van Londen GJ, Bradley CJ. The Seth R, Messersmith H, Kaur V, Kirkwood Plays a Protective Role in the Mdr2 Impact of Massachusetts Health Re- JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Knockout Murine Model of Choles- form on Colorectal and Breast Cancer Ascierto PA, Atkins MB, Davis N, Ernstoff MS, tatic Liver Disease. Hepatology. 2020 Stage at Diagnosis. Med Care. 2020 Faries MB, Gold JS, Guild S, Gyorki DE, Khu- May;71(5):1732-1749. Epub 2019 Dec Feb;58(2):183-191. shalani NI, Meyers MO, Robert C, Santinami 31. M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, Saha AK, Mourad M, Kaplan MH, Pradhan-Sundd T. Sirtuin-6 in Hepatic Fibro- van Akkooi A, Funchain P. Systemic Therapy Chefetz I, Malek SN, Buckanovich for Melanoma: ASCO Guideline. J Clin Oncol. sis: Does Cell Type Matter? Cell Mol Gastroen- R, Markovitz DM, Contreras-Galindo terol Hepatol. 2020;10(2):420-421. Epub 2020 2020 Mar 31:JCO2000198. Online ahead of R. The Genomic Landscape of Cen- May 29. print. tromeres in Cancers. Sci Rep. 2019 Aug Ragni MV, George LA; Members of Working 2;9(1):11259. Shao L, Hou W, Scharping NE, Vendet- Group 1, the NHLBI State of the Science Work- ti FP, Srivastava R, Roy CN, Menk AV, shop on factor VIII inhibitors: Generating a Samanta S, Tamura S, Dubeau L, Wang Y, Chauvin JM, Karukonda P, national blueprint for future research. The Mhawech-Fauceglia P, Miyagi Y, Kato Thorne SH, Hornung V, Zarour HM, national blueprint for future factor VIII inhib- H, Lieberman R, Buckanovich RJ, Lin Bakkenist CJ, Delgoffe GM, Sarkar itor clinical trials: NHLBI State of the Science YG, Neamati N. Clinicopathological SN. IRF1 Inhibits Antitumor Immunity (SOS) Workshop on factor VIII inhibitors. Hae- significance of endoplasmic reticulum through the Upregulation of PD-L1 in mophilia. 2019 Jul;25(4):581-589. stress proteins in ovarian carcinoma. the Tumor Cell. Cancer Immunol Res. Ragni MV. Case-based discussion on the im- Sci Rep. 2020 Feb 7;10(1):2160. 2019 Aug;7(8):1258-1266. Epub 2019 plications of exogenous estrogens in hemosta- Jun 25. sis and thrombosis: the hematologist’s view. Sambade MJ, Prince G, Deal AM, Trem- Hematology Am Soc Hematol Educ Program. bath D, McKee M, Garrett A, Keith K, Sharma P, Diergaarde B, Ferrone S, 2019 Dec 6;2019(1):152-157. Ramirez J, Midkiff B, Blackwell K, Sam- Kirkwood JM, Whiteside TL. Melano- mons S, Leone JP, Brufsky A, Morika- ma cell-derived exosomes in plasma Raghu VK, Zhao W, Pu J, Leader JK, wa A, Brogi E, Seidman A, Ewend M, of melanoma patients suppress func- Wang R, Herman J, Yuan JM, Benos PV, Carey LA, Moschos SJ, Hamilton RL, tions of immune effector cells. Sci Rep. Wilson DO. Feasibility of lung cancer Vincent B, Anders C. Examination and 2020 Jan 9;10(1):92. prediction from low-dose CT scan and prognostic implications of the unique smoking factors using causal models. microenvironment of breast cancer Shore ND, Morrow MP, McMullan Thorax. 2019 Jul;74(7):643-649. Epub brain metastases. Breast Cancer Res T, Kraynyak KA, Sylvester A, Bhatt K, 2019 Mar 12. Treat. 2019 Jul;176(2):321-328. Epub Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Regan MM, Werner L, Rao S, Gupte- 2019 Apr 23. Cheng HH, Tagawa ST, Appleman LJ, Singh K, Hodi FS, Kirkwood JM, Kluger Samuel CA, Mbah O, Schaal J, Eng E, Tutrone R, Garcia JA, Whang YE, Kelly HM, Larkin J, Postow MA, Ritchings C, Black KZ, Baker S, Ellis KR, Guerrab WK, Weiner DB, Bagarazzi ML, Skolnik Sznol M, Tarhini AA, Wolchok JD, Atkins F, Jordan L, Lightfoot AF, Robertson JM. CD8(+) T Cells Impact Rising PSA MB, McDermott DF. Treatment-Free LB, Yongue CM, Cykert S. The role in Biochemically Relapsed Cancer Pa- Survival: A Novel Outcome Measure of of patient-physician relationship on tients Using Immunotherapy Target- the Effects of Immune Checkpoint In- health-related quality of life and pain ing Tumor-Associated Antigens. Mol hibition-A Pooled Analysis of Patients in cancer patients. Support Care Can- Ther. 2020 May 6;28(5):1238-1250. With Advanced Melanoma. J Clin On- cer. 2020 Jun;28(6):2615-2626. Epub Epub 2020 Mar 3. col. 2019 Dec 10;37(35):3350-3358. 2019 Oct 16. Epub 2019 Sep 9. Shoushtari AN, Bao R, Luke JJ. PD-1 Block- Schmid P, Rugo HS, Adams S, Schnee- ade in Chinese versus Western Patients Robins HI, Eickhoff J, Gilbert MR, Arm- weiss A, Barrios CH, Iwata H, Diéras V, with Melanoma. Clin Cancer Res. 2020 Aug strong TS, Shi W, De Groot JF, Schultz Henschel V, Molinero L, Chui SY, Maiya 15;26(16):4171-4173. Epub 2020 Jun 2. CJ, Hunter GK, Valeinis E, Roach M 3rd, V, Husain A, Winer EP, Loi S, Emens LA; Youssef EF, Souhami L, Howard SP, Siddappa Malleshappa SK, Valecha IMpassion130 Investigators. Atezoli- Lieberman FS, Herman JG, Zhang P, GK, Mehta T, Patel S, Giri S, Smith zumab plus nab-paclitaxel as first-line Mehta MP. The association between RE, Parikh RA, Mehta K. Thirty-day treatment for unresectable, locally ad- BMI and BSA-temozolomide-induced readmissions due to Venous throm- vanced or metastatic triple-negative 92

Department of Medicine 2020 Annual Report boembolism in patients discharged donor population. Transfusion. 2019 man JA, Kluger HM, Eroglu Z, Koon with syncope. PLoS One. 2020 Apr Oct;59(10):3146-3156. Epub 2019 Jul HB, Lawrence DP, Kendra KL, Minor 13;15(4):e0230859. eCollection 2020. 18. DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Singhi AD, Nikiforova MN, Chennat J, Stacy SL, Buchanich JM, Ma ZQ, Mair Kirkwood JM. Phase III Study of Adju- Papachristou GI, Khalid A, Rabinovitz C, Robertson L, Sharma RK, Talbott vant Ipilimumab (3 or 10 mg/kg) Ver- M, Das R, Sarkaria S, Ayasso MS, Wald EO, Yuan JM. Maternal Obesity, Birth sus High-Dose Interferon Alfa-2b for AI, Monaco SE, Nalesnik M, Ohori NP, Size, and Risk of Childhood Cancer De- Resected High-Risk Melanoma: North Geller D, Tsung A, Zureikat AH, Zeh velopment. Am J Epidemiol. 2019 Aug American Intergroup E1609. J Clin On- H, Marsh JW, Hogg M, Lee K, Bartlett 1;188(8):1503-1511. col. 2020 Feb 20;38(6):567-575. Epub DL, Pingpank JF, Humar A, Bahary N, Stopeck A, Brufsky A, Kennedy L, 2019 Dec 27. Dasyam AK, Brand R, Fasanella KE, Mc- Bhatta S, Bhowmik D, Buchanan J, De- Grath K, Slivka A. Integrating next-gen- Tarney CM, Wang G, Bateman NW, spiegel N, Hechmati G. Cost-effective- eration sequencing to endoscopic ret- Conrads KA, Zhou M, Hood BL, Loffre- ness of denosumab for the prevention rograde cholangiopancreatography do J, Tian C, Darcy KM, Hamilton CA, of skeletal-related events in patients (ERCP)-obtained biliary specimens Casablanca Y, Lokshin A, Conrads TP, with solid tumors and bone metasta- improves the detection and manage- Maxwell GL. Biomarker panel for early ses in the United States. J Med Econ. ment of patients with malignant bile detection of endometrial cancer in the 2020 Jan;23(1):37-47. Epub 2019 Aug duct strictures. Gut. 2020 Jan;69(1):52- Prostate, Lung, Colorectal, and Ovari- 26. 61. Epub 2019 Apr 10. an cancer screening trial. Am J Obstet Stratton P, Battiwalla M, Tian X, Ab- Gynecol. 2019 Nov;221(5):472.e1-472. Smith SM, Boppana A, Traupman JA, delazim S, Baird K, Barrett AJ, Cantile- e10. Epub 2019 Jul 4. Unson E, Maddock DA, Chao K, Do- na CR, Childs RW, DeJesus J, Fitzhugh besh DP, Brufsky A, Connor RI. Im- Tian N, Wu H, Zhang H, Yang D, Lv L, C, Fowler D, Gea-Banacloche J, Gress paired glucose metabolism in patients Yang Z, Zhang T, Quan D, Zhou L, Xie Y, RE, Hickstein D, Hsieh M, Ito S, Kemp with diabetes, prediabetes, and obesi- Xu Y, Wei N, Zhang J, Chen M, Schmitz TJ, Khachikyan I, Merideth MA, Pavlet- ty is associated with severe COVID-19. JC, Tian Y, Wu S. Discovery of [1,2,4] ic SZ, Quint W, Schiffman M, Scrivani J Med Virol. 2020 Jun 26:10.1002/ triazolo[4,3-a]pyridines as potent C, Shanis D, Shenoy AG, Struijk L, Tis- jmv.26227. Online ahead of print. Smoothened inhibitors targeting the dale JF, Wagner S, Williams KM, Yu Q, Hedgehog pathway with improved Solinas C, Aiello M, Migliori E, Willard-Gallo K, Wood LV, Pinto LA. Immune Response antitumor activity in vivo. Bioorg Med Emens LA. Breast cancer vaccines: Heeding Following Quadrivalent Human Papil- Chem. 2020 Aug 15;28(16):115584. the lessons of the past to guide a path for- lomavirus Vaccination in Women After ward. Cancer Treat Rev. 2020 Mar;84:101947. Epub 2020 Jun 15. Hematopoietic Allogeneic Stem Cell Epub 2019 Nov 29. Transplant: A Nonrandomized Clinical Tripathy D, Brufsky A, Cobleigh M, Somasundaram A, Socinski MA, Villaruz Trial. JAMA Oncol. 2020 Feb 27;6(5):1- Jahanzeb M, Kaufman PA, Mason G, LC. Immune Checkpoint Blockade in Onco- 10. Online ahead of print. O’Shaughnessy J, Rugo HS, Swain gene-Driven Non-Small-Cell Lung Cancer. SM, Yardley DA, Chu L, Li H, Antao Drugs. 2020 Jun;80(9):883-892. Subbiah V, Baik C, Kirkwood JM. Clinical De- velopment of BRAF plus MEK Inhibitor Com- V, Hurvitz SA. De Novo Versus Re- Sparano JA, Gray RJ, Makower DF, Al- binations. Trends Cancer. 2020 Sep;6(9):797- current HER2-Positive Metastatic bain KS, Saphner TJ, Badve SS, Wagner 810. Epub 2020 Jun 13. Breast Cancer: Patient Characteris- LI, Kaklamani VG, Keane MM, Gomez tics, Treatment, and Survival from the Swain SM, Tang G, Brauer HA, Goerlitz HL, Reddy PS, Goggins TF, Mayer IA, SystHERs Registry. Oncologist. 2020 DS, Lucas PC, Robidoux A, Harris BT, Toppmeyer DL, Brufsky AM, Goetz Feb;25(2):e214-e222. Epub 2019 Oct Bandos H, Ren Y, Geyer CE Jr, Rastogi MP, Berenberg JL, Mahalcioiu C, Desbi- 14. P, Mamounas EP, Wolmark N. NSABP ens C, Hayes DF, Dees EC, Geyer CE Jr, B-41, a Randomized Neoadjuvant Trial: Valle BL, Rodriguez-Torres S, Kuhn Olson JA Jr, Wood WC, Lively T, Paik S, Genes and Signatures Associated with E, Díaz-Montes T, Parrilla-Castellar E, Ellis MJ, Abrams J, Sledge GW Jr. Clinical Pathologic Complete Response. Clin Lawson FP, Folawiyo O, Ili-Gangas C, Outcomes in Early Breast Cancer With Cancer Res. 2020 Aug 15;26(16):4233- Brebi-Mieville P, Eshleman JR, Her- a High 21-Gene Recurrence Score of 4241. Epub 2020 May 5. man J, Shih IM, Sidransky D, Guerre- 26 to 100 Assigned to Adjuvant Che- ro-Preston R. HIST1H2BB and MAGI2 motherapy Plus Endocrine Therapy: Swain SM, Tang G, Lucas PC, Robi- Methylation and Somatic Mutations A Secondary Analysis of the TAILORx doux A, Goerlitz D, Harris BT, Bandos as Precision Medicine Biomarkers for Randomized Clinical Trial. JAMA Oncol. H, Geyer CE Jr, Rastogi P, Mamounas Diagnosis and Prognosis of High-grade 2019 Sep 30;6(3):367-74. Online ahead EP, Wolmark N. Pathologic complete Serous Ovarian Cancer. Cancer Prev of print. response and outcomes by intrinsic Res (Phila). 2020 Jun 24. Online ahead subtypes in NSABP B-41, a random- Spencer BR, Guo Y, Cable RG, Kiss JE, of print. ized neoadjuvant trial of chemothera- Busch MP, Page GP, Endres-Dighe SM, py with trastuzumab, lapatinib, or the Vats R, Brzoska T, Bennewitz MF, Kleinman S, Glynn SA, Mast AE; Na- combination. Breast Cancer Res Treat. Jimenez MA, Pradhan-Sundd T, Tu- tional Heart, Lung, and Blood Institute 2019 Nov;178(2):389-399. Epub 2019 tuncuoglu E, Jonassaint J, Gutierrez E, Recipient Epidemiology and Donor Aug 19. Watkins SC, Shiva S, Scott MJ, Morelli Evaluation Study-III (REDS-III). Iron sta- AE, Neal MD, Kato GJ, Gladwin MT, tus and risk factors for iron depletion Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Sundd P. Platelet Extracellular Vesicles in a racially/ethnically diverse blood Cohen GI, Hamid O, Hutchins LF, Sos- Drive Inflammasome-IL-1β-Depen- 93

Division of Hematology/Oncology BIBLIOGRAPHY

dent Lung Injury in Sickle Cell Disease. gensztern D, Bradford DS, Crane J, DM, Ekici AB, Evans DG, Fasching PA, Am J Respir Crit Care Med. 2020 Jan West HJ, Lee C, Pecot C, Stevenson JP, Figueroa J, Foretova L, Fostira F, Fried- 1;201(1):33-46. Irvin W, Socinski M, Stinchcombe T, Vil- man E, Frost D, Gago-Dominguez M, laruz LC, Muss HB. Nab-paclitaxel in Gapstur SM, Garber J, García-Sáenz Vats R, Liu S, Zhu J, Mukhi D, Tutuncuo- older patients with non-small cell lung JA, Gaudet MM, Gayther SA, Giles GG, glu E, Cardenes N, Singh S, Brzoska T, cancer who have developed disease Godwin AK, Goldberg MS, Goldgar DE, Kosar K, Bamne M, Jonassaint J, Ade- progression after platinum-based González-Neira A, Greene MH, Gron- bayo Michael A, Watkins SC, Hillery C, doublet chemotherapy. Cancer. 2020 wald J, Guénel P, Häberle L, Hahnen E, Ma X, Nejak-Bowen K, Rojas M, Glad- Mar 1;126(5):1060-1067. Epub 2020 Haiman CA, Hake CR, Hall P, Hamann win MT, Kato GJ, Ramakrishnan S, Jan 14. U, Harkness EF, Heemskerk-Gerritsen Sundd P, Monga SP, Pradhan-Sundd BAM, Hillemanns P, Hogervorst FBL, T. Impaired bile secretion promotes Wood KC, Durgin BG, Schmidt HM, Holleczek B, Hollestelle A, Hooning hepatobiliary injury in Sickle Cell Dis- Hahn SA, Baust JJ, Bachman T, Vitturi MJ, Hoover RN, Hopper JL, Howell A, ease. Hepatology. 2020 Mar 19. Online DA, Ghosh S, Ofori-Acquah SF, Mora Huebner H, Hulick PJ, Imyanitov EN; ahead of print. AL, Gladwin MT, Straub AC. Smooth kConFab Investigators; ABCTB Inves- muscle cytochrome b5 reductase 3 Vats R, Tutuncuoglu E, Pradhan-Sundd tigators, Isaacs C, Izatt L, Jager A, Jaki- deficiency accelerates pulmonary T, Tejero J, Shaw GD, Sundd P. Tandem movska M, Jakubowska A, James P, Ja- hypertension development in sick- P-selectin glycoprotein ligand immu- navicius R, Janni W, John EM, Jones ME, le cell mice. Blood Adv. 2019 Dec noglobulin prevents lung vaso-occlu- Jung A, Kaaks R, Kapoor PM, Karlan BY, 10;3(23):4104-4116. sion in sickle cell disease mice. Exp He- Keeman R, Khan S, Khusnutdinova E, matol. 2020 Apr;84:1-6.e1. Epub 2020 Zandberg DP, Tallon LJ, Nagaraj S, Kitahara CM, Ko YD, Konstantopoulou Mar 31. Sadzewicz LK, Zhang Y, Strome MB, I, Koppert LB, Koutros S, Kristensen Zhao XE, Vavikolanu K, Zhang X, Pa- VN, Laenkholm AV, Lambrechts D, Velez MA, , Stabile LP. The estro- Burns TF Larsson SC, Laurent-Puig P, Lazaro C, gen pathway as a modulator of response padimitriou JC, Hubbard FA, Bentzen to immunotherapy. Immunotherapy. 2019 SM, Strome SE, Fraser CM. Intratumor Lazarova E, Lejbkowicz F, Leslie G, Le- Sep;11(13):1161-1176. Epub 2019 Jul 30. genetic heterogeneity in squamous sueur F, Lindblom A, Lissowska J, Lo cell carcinoma of the oral cavity. Head WY, Loud JT, Lubinski J, Lukomska A, Velez MA, . Is the game over for PD-1 Burns TF Neck. 2019 Aug;41(8):2514-2524. Epub MacInnis RJ, Mannermaa A, Manoo- inhibitors in EGFR mutant non-small cell lung chehri M, Manoukian S, Margolin S, cancer?. Transl Lung Cancer Res. 2019 Dec;8(- 2019 Mar 14. Suppl 4):S339-S342. Martinez ME, Matricardi L, McGuffog L, Zeh HJ, Bahary N, Boone BA, Singhi McLean C, Mebirouk N, Meindl A, Me- Vidula N, Rich TA, Sartor O, Yen J, Har- AD, Miller-Ocuin JL, Normolle DP, Zu- non U, Miller A, Mingazheva E, Montag- din A, Nance T, Lilly MB, Nezami MA, reikat AH, Hogg ME, Bartlett DL, Lee KK, na M, Mulligan AM, Mulot C, Muranen Patel SP, Carneiro BA, Fan AC, Brufsky Tsung A, Marsh JW, Murthy P, Tang D, TA, Nathanson KL, Neuhausen SL, AM, Parker BA, Bridges BB, Agarwal N, Seiser N, Amaravadi RK, Espina V, Liot- Nevanlinna H, Neven P, Newman WG, Maughan BL, Raymond VM, Fairclough ta L, Lotze MT. A Randomized Phase II Nielsen FC, Nikitina-Zake L, Nodora J, SR, Lanman RB, Bardia A, Cristofanilli Preoperative Study of Autophagy Inhi- Offit K, Olah E, Olopade OI, Olsson H, M. Routine Plasma-Based Genotyping bition with High-Dose Hydroxychloro- Orr N, Papi L, Papp J, Park-Simon TW, to Comprehensively Detect Germline, quine and Gemcitabine/Nab-Paclitaxel Parsons MT, Peissel B, Peixoto A, Pesh- Somatic, and Reversion BRCA Muta- in Pancreatic Cancer Patients. Clin kin B, Peterlongo P, Peto J, Phillips KA, tions among Patients with Advanced Cancer Res. 2020 Jul 1;26(13):3126- Piedmonte M, Plaseska-Karanfilska D, Solid Tumors. Clin Cancer Res. 2020 3134. Epub 2020 Mar 10. Prajzendanc K, Prentice R, Prokofyeva Jun 1;26(11):2546-2555. Epub 2020 Zhang H, Ahearn TU, Lecarpentier D, Rack B, Radice P, Ramus SJ, Rantala Feb 7. J, Barnes D, Beesley J, Qi G, Jiang X, J, Rashid MU, Rennert G, Rennert HS, Risch HA, Romero A, Rookus MA, Rüb- Villaruz LC, Cobo M, Syrigos K, Mav- O’Mara TA, Zhao N, Bolla MK, Dun- ner M, Rüdiger T, Saloustros E, Samp- roudis D, Zhang W, Kim JS, Socinski ning AM, Dennis J, Wang Q, Ful ZA, son S, Sandler DP, Sawyer EJ, Scheuner MA. A phase II study of nab-paclitaxel Aittomäki K, Andrulis IL, Anton-Culver MT, Schmutzler RK, Schneeweiss A, and carboplatin chemotherapy plus H, Arndt V, Aronson KJ, Arun BK, Auer Schoemaker MJ, Schöttker B, Schür- necitumumab in the first-line treat- PL, Azzollini J, Barrowdale D, Becher mann P, Senter L, Sharma P, Sherman ment of patients with stage IV squa- H, Beckmann MW, Behrens S, Beni- ME, Shu XO, Singer CF, Smichkoska S, mous non-small cell lung cancer. Lung tez J, Bermisheva M, Bialkowska K, Soucy P, Southey MC, Spinelli JJ, Stone Cancer. 2019 Oct;136:52-56. Epub Blanco A, Blomqvist C, Bogdanova NV, J, Stoppa-Lyonnet D; EMBRACE Study; 2019 Aug 14. Bojesen SE, Bonanni B, Bondavalli D, Borg A, Brauch H, Brenner H, Brice- GEMO Study Collaborators, Swerd- Ward Rashidi MR, Mehta P, Bregenzer no I, Broeks A, Brucker SY, Brüning T, low AJ, Szabo CI, Tamimi RM, Tapper M, Raghavan S, Fleck EM, Horst EN, Ha- Burwinkel B, Buys SS, Byers H, Caldés WJ, Taylor JA, Teixeira MR, Terry M, rissa Z, Ravikumar V, Brady S, Bild A, T, Caligo MA, Calvello M, Campa D, Thomassen M, Thull DL, Tischkowitz Rao A, Buckanovich RJ, Mehta G. Engi- Castelao JE, Chang-Claude J, Chano- M, Toland AE, Tollenaar RAEM, Tom- neered 3D Model of Cancer Stem Cell ck SJ, Christiaens M, Christiansen H, linson I, Torres D, Troester MA, Truong Enrichment and Chemoresistance. Chung WK, Claes KBM, Clarke CL, Cor- T, Tung N, Untch M, Vachon CM, van Neoplasia. 2019 Aug;21(8):822-836. nelissen S, Couch FJ, Cox A, Cross SS, den Ouweland AMW, van der Kolk LE, Epub 2019 Jul 9. Czene K, Daly MB, Devilee P, Diez O, van Veen EM, vanRensburg EJ, Vega A, Wappenschmidt B, Weinberg CR, Weit- Weiss JM, Pennell N, Deal AM, Mor- Domchek SM, Dörk T, Dwek M, Eccles zel JN, Wildiers H, Winqvist R, Wolk A, 94

Department of Medicine 2020 Annual Report Yang XR, Yannoukakos D, Zheng W, Zorn KK, Milne RL, Kraft P, Simard J, Pharoah PDP, Michailidou K, Antoniou AC, Schmidt MK, Chenevix-Trench G, Easton DF, Chatterjee N, García-Closas M. Genome-wide association study identifies 32 novel breast cancer sus- ceptibility loci from overall and sub- type-specific analyses. Nat Genet. 2020 Jun;52(6):572-581. Epub 2020 May 18. Zhang SH, Liu R, Siripong N, Kirkwood JM, Holtzman MP, Davar D, Najjar Y, Marshall K, Jackson Cullison SR, Hous- ton NA, Switzer G, Ferris LK. Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. J Am Acad Dermatol. 2020 Aug;83(2):587-590. Epub 2019 May 29. Zhu L, Narloch JL, Onkar S, Joy M, Broadwater G, Luedke C, Hall A, Kim R, Pogue-Geile K, Sammons S, Nayyar N, Chukwueke U, Brastianos PK, An- ders CK, Soloff AC, Vignali DAA, Tseng GC, Emens LA, Lucas PC, Blackwell KL, Oesterreich S, Lee AV. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. J Immunother Can- cer. 2019 Oct 18;7(1):265. Ziogas DC, Diamantopoulos P, Ben- opoulou O, Anastasopoulou A, Bafa- loukos D, Stratigos AJ, Kirkwood JM, Gogas H. Prognosis and Management of BRAF V600E-Mutated Pregnancy-As- sociated Melanoma. Oncologist. 2020 Apr 9;25(8):e1209-20. Online ahead of print.

Division of Hematology/Oncology CREDITS

ACKNOWLEDGMENTS AND PHOTO CREDITS

EXECUTIVE EDITORS Christopher O'Donnell, PhD Assistant Vice Chancellor for Special Projects in the Health Sciences Executive Vice Chair for Academic Affairs, Department of Medicine Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine Nichole Radulovich, MEd, CRA Executive Administrator

SENIOR EDITOR AND GRAPHIC DESIGN Katie Nauman

PROJECT COORDINATOR Kristen Bagwell

DATABASE DEVELOPMENT Nemanja Tomic

GRANTS AND RESEARCH EXPENDITURES Jim Jarvis and Ed Hughes

HEMATOLOGY/ONCOLOGY CONTENT MANAGERS Lois Malehorn and Dorothy Mann

Photo credits: All photos courtesy of Department of Medicine/University of Pittsburgh faculty and staff except cover: Open- Stax College, Anatomy & Physiology, Connexions Web site, http://cnx.org/content/col11496/1.6/; page 13: Amornrat Phuchom, iStock photo ID: 1188880201; page 17: Schistra, Dreamstime photo ID: 142772076. Google maps, accessed October 2020 (pages 14-15).

Department of Medicine 2020 Annual Report

1218 Scaife Hall Phone 412.648.9636 3550 Terrace Street Website www.dom.pitt.edu Pittsburgh, PA 15261